var title_f21_36_22080="Wing block 2";
var content_f21_36_22080=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85733&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85733&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Anesthesia of the nail apparatus by wing block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_36_22080=[""].join("\n");
var outline_f21_36_22080=null;
var title_f21_36_22081="Leak and stricture after sleeve gastrectomy";
var content_f21_36_22081=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F60609&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F60609&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Leak and stricture after sleeve gastrectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 461px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The upper arrow shows a leak and the lower arrow shows a stricture in a sleeve gastrectomy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_36_22081=[""].join("\n");
var outline_f21_36_22081=null;
var title_f21_36_22082="Exocervical incision cone bx";
var content_f21_36_22082=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65918&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65918&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Start of cervical (uterine cervix) cone biopsy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 317px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An exocervical circumferential incision is initiated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_36_22082=[""].join("\n");
var outline_f21_36_22082=null;
var title_f21_36_22083="Lentigo maligna melanoma dermoscopy 1";
var content_f21_36_22083=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F63812&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F63812&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Dermoscopy of lentigo maligna melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 370px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 69-year-old woman was evaluated for an enlarging pigmented lesion of her right cheek.&nbsp;Two biopsies were performed with the help of dermoscopy to outline the borders of the lesion. Pathology revealed a lentigo maligna melanoma. On this dermoscopic image (x50), one can see slate-gray dots and globules leading to annular-granular pattern which is typical of lentigo maligna melanoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Eric Ehrsam, MD, Dermatlas;",
"     <a href=\"file://www.dermatlas.org\" target=\"_blank\">",
"      file://www.dermatlas.org",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_36_22083=[""].join("\n");
var outline_f21_36_22083=null;
var title_f21_36_22084="Ulipristal: Patient drug information";
var content_f21_36_22084=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ulipristal: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39412?source=see_link\">",
"     see \"Ulipristal: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10519685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      ella&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10584264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700605",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug does not protect you from diseases caused by having sex.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10584464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691546",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop pregnancy.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10584265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2879220",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ulipristal or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10584267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697710",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will not end a pregnancy.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697680",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is not for regular use to stop pregnancy.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To protect from diseases caused by having sex, use a latex condom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2770240",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696708",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Birth control pills and other hormone-based birth control may not work to stop pregnancy. Use 2 kinds of birth control while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10584467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698017",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals and good mouth care may help. Older children may suck hard, sugar-free candy.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2879299",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Period (menstrual) pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698231",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Period (menstrual) changes. These include lots of bleeding, spotting, or bleeding between cycles.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10584269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2879340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your period is delayed for more than 7 days.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698666",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2879359",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you throw up within 3 hours of taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10584466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2879280",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug within 5 days after unprotected sex.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2879279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you throw up within 3 hours of taking this drug, call your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10584266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10584468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10584270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16074 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-199.231.185.123-23AA9155C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_36_22084=[""].join("\n");
var outline_f21_36_22084=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10519685\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10584264\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10584464\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10584265\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10584267\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10584467\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10584269\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10584466\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10584266\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10584468\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10584270\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39412?source=related_link\">",
"      Ulipristal: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_36_22085="Epidermolysis bullosa acquisita";
var content_f21_36_22085=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F62505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F62505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Epidermolysis bullosa acquisita",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF7AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDy8nCADp2oAO75hgHjdTZG5559QKblQeT16DPSvsT5q485JJIwBSFu5AJHemZycjqRijGB7igVx4PzNk80oIB689iaZF1P0pz9RkA4ouNLQCcjOfmPFRHhj3+tPPGOBnrSMAQO1Ahw54JPPpTXA7nnuKOe3FNbls45oHcYx4GKa3BAFO4ABApjk7iaDNjs4Gec96ej5GR36561H1BpQMMd3XFDKTJoyVAU/MR/FSoDnjoeT6UzsvYU5AAR19hUlrckBODuxn2pW5AwcGm89uPegDORzuoKHrnORzTsnuOO9IvPXIp4Qnv+dZznGOrZrCnKWiQgIPTinqrsQByKswwAffAI9ewqWPDHbH2NeZWzSMdKauz06GWylrUZXNr8h3OR7jtT0iTafLG3AzkVaFvuBBJIyDgVZEO0Z8snsFz2rx6+JqVnebPYo4aFFWgipGjgcZUEZzjrTxEFcFuF7nrmr3lgYUZ5Xp2qNIW3Akbl6ZPQGuVu50JWKyoHOMYcHJPpUkUTGJkAz3z61LFH5R3MCw7n1qVVAb5DyTjFRY1RFHFtwoXdIexqWRSjnKhT6jmpljV5fmO0/qakjjZGLMRgHgsKBkQRWTO4liOakgiBjbBCqBnA705sYBjUYqKZ1SNZCCoHYUWtqUhSoOGU89MVZMAZgXPJGSe2KSJFcBh0I7dqsuQ6iPHCjr680yncbbptB3YOTwMcAVchnkkx5bbgvAHc1ARsG1eWBxn0pznyUymQxODn+lGwNXLd5ckxD98VbHIrM8xnk2OpUHkg07e7syFyT29qrsxMrGXIIGKVxpWViwGiHG0lhTLjJhAUoW/lUcKkqzuykj0qSEJLEQQQx7Z4pWArbSvzcHPqKcRtAwM5GTU7Q7OGYFc5HsaWS3beu1Ts4IxQkBUg+ZeFIIbIOandQjmRsFsdzUkcILNuB5OMDimtGVYovP17U0yWhuMYx9zqRUbYGPLcD144ApS2zcoI5HU9DS4AZtpKhgML7073BIbs4BULnqMVYjV22sTkZ5BOaZDHtYl+/vQ4fbhMhe59KNh2uaE7hIwFQE9OR2qvIyIC5A6fdBoJxFhGJGM80m/5BlSCe4pvUViAzMzjar56Yz0rQhhaaFmRlXPXcOlQvtRS4Ukt0NLv+QHJVe+4fyoWgSV0ExKtsUAHOQe9RSIx+ZiTnnOKsAJJgxDJ/wBo9fxpJDF5o27l2jp6UXM9ik5cPhsnuM9RSMkivggEKcDPIIq+Cr7RMu4DlvWnuiSW/wC4JIGcZppj59LFUqY4i0eWycbahdFkYr5YRuOavRyyIpCRqSp6HqaZcKpBLLsIOQ2OKLkGfmSNijc88n1+tTxj92fs52jOWwevsRSxsWmIKKwz97tSzpmTdCVHbC9Km9gHW84ZCJF8k/3gP6VbjuI/MywxGSMSKfvVWXbPiO7RS+NoLDAP40tvE8E5II2dAvXH+NIdjRgOAyErz0Yd/wDGimwzhCXhjCn6cH8Oxoqhankjn14pGJC8Y+tMkb5uPunpRkDnr7V96fnxIxHIPHHakJx09KaDk4paQyWLkdOaVlJPUVGpKgj17U/OQdowPSkylsDYOcY44phUg96OcjtxTlY4LDjFACbS3J4FI467gQOxzS5LD0zSOCAcgmkHQZkMM88UwE4J608klemDUZZuRjgU2SIOoB69xT1Xk+lAwQTxzR/CKQIeW6Ljp3qROfvZNLBbyS7WUHb9KvwWSA/Od39K5a2LpUviZ20MHVq6paFONC2QAefWrEdu7sOMVpQ243gogxip4oyxIGADXlVs0k9Keh69HK4x1nqUfs6x7cDJNTLBuX5gc54AFXRAFJ2rkjvViK3ZkBK4J7V5lStOq7ydz0qdGMFaKKYtt6YdsgdvSpYLYKFG0Ad6viIKnK7R6etOSJEUuzDzD+lZ3RvHQreVHECRweo96aCjAl+GJ4FTS7X+4u4d81BwXJH3ycAGpcikh4VssxwCBx70bMEBiB7A0187/LbOVOTTREvmksSGzgc9ahsEKEfIjP3Sc/SpVbDNs+Zj1psMe8gbtnH50sIaKVjjaRw3pmkWlckhjQuC2duMnPUn2qSQYUZwUBp4BSMFl+8e3an7gwI5GDjdjGKCiDy2O5VAORnA7Uoj81kXIKqM4xVxWKldhVuOD6UjKFCMDyTj60FJ9wijV40ViVbPPtWnBEhBjf5QBkAdTVAlWwc4ya0l8szRlpMYxnA5JqloKTEawLp5m0+XnhfSqlzCEYEjeByAD0roo1WVJFLjBGFOcY+tZ0kCwyOZAN3VGAp8vYiNXWzMqRUcDqjf0qu37pTkbl7MOa0HjWeQ5HPrSx25SQKApGOo4qbG6tbUy1jA+XPXuafxESkoCY+4QK0ZUQHyJO/PTn86d9jR1wTuZT+lK3YCnEjXABOGcdR0wauRW3nOoPybBhm561Y+ykNmHCYHbqferEaFEZcZPQjv9aYmQ3OntFH5isGQjO33rGmjyARuTPU1sXDl0jVXOc854qo8DtKm1iAeACe9KxcY6amVJA8i4yCF/lTY4sSMzHIx1xwPwre+xXLBs4B9MZ/WoLi1kgI86Mx+55BoRPkZbbWVcMQg7460oBMYIwGzx/8AqqzJAzANG6/NzgdDUbITKhQbOe3c0xWsNtmDSeWSCW7etWZRgBFIAJ6n+VQ+QVUNjB68cc05YzLGSeo5Pc/lTE3cdLEwUEDiPkgHmq04DMzElmGOP61YEmxCpCsTxkdTSxrltg4ye/ekwTsR25bBG3lenP8AOpY4jJj5S284P/66RrYoylDviPQA9KuWYKgqflVuDk5oSCUFbmI2Ty0bbnBO3jmiJE8pmZSD93JODV9bcLExdlCDgYGM0+OCM7Vw3HOO/wCVFjnuVY4xPkAqncEio5Yy8bqw+boB1B960vJZYyGIO44G01C6DzOQOB1xjFVbQLmQkAhYRtwxGQcZBqNImjDbcHHcdK0rmDzMODnHGf8A61Z83mxuTjcg6HpmpY0yOUMxCOqjdjHcZqa3iaKZgX3A87SOR9DSyhHCSbTk9QTjFSMjBgoIZGwCQcEf/WotYd7kW1mlIj4cHiMnn86Kn8qOQ/OqMU6FThwfpRQOyPJJAAcH5R6Cmq2DnqO1K+CxJHNNGAcAcV98nc/OmhwIJBwaXf8AN603AHI5pQQRnFA4oUEg5PXtT8kDpTRjA4pQScCpZQ9VJPPAHNC7QSD17UE88H8KBycEYzSKsPGFGGFRsTUhJI47CmsOMdaRTREWyB2I60gBAyOnU+9TJC8h4BI9cVpWmmgEGQEgdKwrYqnQ+J69jehg6lfbRGXBbyzt8q/L3J4xWtbabGiBpPmOOMitKK1wGXaQBxUqQsQAT9319K8OvmNSrpHRHuYfLadLV6srCJ0QOFAU8YqaK34Ygd+9Wgg6cnPAFWjAEUAHJP4Zrzm7npJWIIrfMZyMHoMU4W4Q42YwPxNW1j2AFscdADU20sDuPNJosorCrZLFvYepq4w8kJtTLGgmNcjI3dPWo5wfLK5JNRcuwjMHbA4YcsajK5bYhGP7x704AowVlI9adKN6fIM/TrU6vcHoVXZ03BTnscVF5e5lK5yBmppHEZK7cdqYx2MCOB1Hfml1GMVyZCXXLHgg8UwjfMFxtUnP0qUod+2Yhk/hIHP41BK2SyqCwB4agESBiGAUFscZFTqwGVcfMRyTVZYZBhtwxjscYqzbEYbdn2JGcUblrQmQySbljYEL61IkjQ/INhBPzLSAqB5m4ZHYDrSqyOG3gcjJwaBjZ1G9mU4VeRj19DSx4kZfmwSd2R2qNxhm2MCrelELK6tjKOMDcOhpILWJxKFwSSXB2gEZ5q1bTHdvZQT0IJ7VWRyHLDkd1Ip0gDggAoG5GetPYV9TcspVx1xycgngfWlcCPJJZ42549fastZAIwqtznJUDg1NaSq7uJCwPQelFxcmpYk2qgCDJP3veolfaoCnqcfMOaWRJCQwKlFHcZB/Gnpkpv2ewJ5NF7mqVkFq6PhJHUtydwqw8aFN0JKLnOV71TADEBRsIHJ6Z96tq4EIQ8nHOKLg9CKS6LSKXAKkEA+tPklkVUxhcc4z/WmNArorL97ByM8Cq7SeWNrjIFJtmisy0pWchZRiTOfbH1pIneCc4YPH39cVWS7CRuF4B7E81RnuxGssoZYoU+9Ix4FUW/M1Jb/y5mYE7xg7M8Gqs+qpeSOpfYR/Cc1x+qeLbRZVhs7aWWVW2tcs2Fx6BavW/izSp7bdfWDxRIwjS4Xhifp6VfI+plzxXS50EEL7d8ZDIeu3rViIbwwbDp3GPmBrM0d0nM32a7VmUbkjb5S4PTFa9rMLmEhTtkXjLDB+lZ26A3fYie2L/vFJODnaPSo5kIciJfnAyxHBIq7tk8seYAPmwCP60yRVPOf3hHUUyShabQucuT1PA/KpYY3E5fYTkYJ61Klu8jMCNyYyATg1ZgizGV3bjjPHXGaBjJIGcK6AnHQelTwQnDiYnB5AxnNWETaAGGwDhR60xpXQ5OMjjGOtGm5GrVkSKu9SS4CdsDio2RHXeqYf1z0pryM0P3WVAwzgdasJGQnA3Z+YsOD9Kepm4tbleB2RSCqiRj1PIx609PMeQfODHjHA6+9WI7Qsqk4K9jnkU7y9iN1DHqeuaQrIz5EQqXUkHOCarXcLF1ZWXO7IHTFbFzbLLHuYbZD3T7v41UuY1FpuZTIwwq57UErcy2hLXXAyAudueM1KQMb1CkAZMePercLRJtWVCygc7fX0p8ccLAbG2qc4VsZNNLqMpbVlmJAKMozhuM0VZmh4JY4KjkN0/CikB4o45NRn8Kk2jJINNb5R0zX3qPz5iEH1pST0FAOevFJjj9TTEOJJxx0p2aYcHHb096TJHPbNIq49jnnvUmetMVj/AAjJ9DVyC1aXlgMVjVqwprmk7I3o0p1ZcsURKC5IUE1ct7EtgsRx2FXrWz2qGAP41qRW4QZPBPUAV4uIzGUtKasj3cPlsYa1NWUrWAJGcDHvV6GMAh85Hp61IkQwQTtUdKdGoc4HYd68qTbd2enFJKyGnOOMqe5FSLDucbQccfjUiop+UgrnvV6FMYDDjsak0RXSEhvmBU08KoJ38HtmrUnKgbWK54aqrB3Q/KCaVykrixpkjI/A01mkLFFGfQ4qWPIBV1yAOaVPlXcoyPQ1N+hSuiukRUKxAPPIqUAO45OB3qUfMu3rmiICPcCjAevrSsVchbLg5J3Ad6jc+VFlAd3XA5qUM0j7scYGKju97kkfI3fNJ+YWuUbnE3J+8fTvUSErDtYEAHg46VetBGTL9oUZPAJHBqtdqY4WKHdgZX2+tSwsRSExtHsIOTz7GpoIUllZXYIx4xniq8eGtyxZlc8/MOM+1SxxMyAhOincfWncew5VMTHeuQT0HSnygbgF4TPPalRZDEVVgcdc9abwmEfjd1JGcUgW5LGiNGQxHTqKqXMuyPCY5ODirmxXQBG5PODVa5TzRhgFIOCyD+lDRpCSTEReUIbAzg/WhVkXcBn5jwaSG3aJh85YDoQfWrNxIHQqoIdR8uBSZcpJ7D/MkJO9dg7nHWpFY8ndkDiooG/d7ckqBlgxyKlRsgArtzyCBkUbkXJsKXXy2B29AKsyNH5yqAVIPJPeqKlTuOCW6A9M1NuMuC/HO0U7AjTCshXaTgjI5ojjZS+G49/Wq8EzoSknIHRqtxyBSGc7jjBx0osguyvjzec4A9eCT7VJEFWERSgBt2S+eSaklKScn5do44pjwAqGKkPgEY6UWKvfclbd8zKAUBqpezrGjEj5jV0tiIjkFueOlY+osxJxwD604pLc0jG7M+a5G1mZsHGcYzwKxNRvI1vIZLk77MqG8lgcL6Eina7cpZxyF2DZTA2jJHv9K5G6maW3kdZFSHoSWzkdlAPPXmtaUU2Z4rm2Rb1xLVn32kjNcykmRGUKFGOuahWRriGC3kjVYUIIUHBJ9DVLUo54La1lkuY3Eo2hQcsAPUV0NrDbXOjRtDALORANwzu3f7QzzXU721OSLUS1pQ8yVIJZNrs3DAY2gdcV2UpWPUJBbu8kSEIrNwWGOv1rN8OWohM7tb+cViLI3BB45/xrSt43kHmYyW+Yk8VytHZBrV9C/FdkKUDb19B96lhk8wHyn8zb/CwwRUflblXKjIPXvQWWE4dRIp9uRWTQNouQgyM247WHI4zVq3hUMS7BmXjJ4z9Kjs5sAMnKkcrjJH1pTOHLHCkHoBz/APqoRm23oWy6BMqQB0x1quVDyKdoGOob/GkjYMB86/THSmrK6PhRvZu3rQ3cFFosx/vYTsJJ7qKngLyxmMxpuXHPQ1BBGA5ZMq+OcdKktQ6TB5DuyeTTtcbV7mjCwyVJTYvcdjU/kK7MUUEkcn1qtEodsYX5yfmHb8KvxABQzMAw4GO9J6HNNNFea0GVzlDjjHT8aqTxB3KIuV24OOhrYb95kk9BwB3qMxo23I2kDselIhOxgi3Ijbaq44GCKguLZGjCvkSDoAOldEYo2O1jjnrVSaDLkg9OPrTtcpSMdEdIP3pDDHG3kGirskLR5YHK8cL/AA0UWKufPvbJ49qa+dvuaGLA9M0vUn2r74+AvcbkcDjNGecc0gXpwBS7u1ILCnvjnHWlRCzAKMinRx7mAztLHp61s2VtsYAqCemRXBisdCjotZHo4TL51nzS0RBZWZBLONx6Y9K2ra3G0IBtz7dacqBWVAhO3jip3xFEu3PmMcD2rwKtedR80mfQ0aMaS5IKxYigCoR1P8qsbcDKnr1yKitY28vMhOasqu5CM5bsMVhc1asV5wowCDmolU+YCASCelWgjBcbeehzU8K7VCsBkc59am5aQ+2gAbc/TtVhvkIOzchOAfSo3bhMEEnt6VFdTmNcsSxzgbaTeg1FtluI/K6l8Y6A0z93s3hsEHFRwneArNgn86sQohLZALCpNErECyIvHXcORSwRBlzjcAc4JwRUrBRIWXGT60yEM7MAuCOQcUrFpXQK/kKwAABPQjpVeVnZyGBUHGasSxFyC3KjnBpnDSbW4XsKe4rWGoqKfLVMZ75qTywGJIyBxzUs0KIqMpycfM470kW11wWIHTd60DKksRV2GRtY8D2qneCMwjGVlDcn2rQdSgCFtwJxim3EQDjcQ0gHSp6CuY0iJsXBIGcH0FTQr5cILMAvTHrVyUxuVj2qBxyehqjMvlMQAcAknJ4FTsG4jlgxCjCnkgdDT9qHaxOUbtnOBUamNzhQcHoc4xUc6Kk6rwPm4KnrRvqUi7C21gWjwW+7n0qIpvdgoKkdBTJptkZjZSRnkk8imR5LqASAD96h72KSe5OBIQuFyq5xjvUojDxuXzlfmDf0qNG2bg+cg+vWkZyZMRA7iMY7Um+41FvYF3RvkkKPpwaVXZ1DKfm/2T/SpEtGYYkkOOpFTCCJHwnGe4FZuZ0Ki2VPN2r8wwR3FTLcgDa+BkZVu1TfZomJKqRxzSfZIsAKMA9s5zT5w9j3H/aVDKg5GBk56UpnMMox9wnOW/pTDZZZsqOgPBwarywzxoC/zKOgPaq5ieSxuJIskIYkM4GSPX8KlEzkBWyFHUY6CsyFXeMSxlFZeCp4zUtvJI0hZsuhPJqrgomhG0bEg9unNZmqxuI33cAjgirtwYwyuDgAYH1rH1G62oQzblzgY6/lVJXLpp7nLX0kweVPJjIiPmEucZHTB9qw4ZpLxxFKYVaR9zB0+724PYYrqJvtK/aZLiOMggvK7jhcD5R9fashNOtU0ZryW4dbmUrtB5DZPJ9sVvBaaGVSeln1ZLB4dgj1iMhnnBIIWPBUY/2j/KtmCONLu5gghleSeMopAwF9Tz/Ss2yW3jLxxO7xJ0kU4Kt64710+lK9zbPPcpuEB+Rs7dxP60uaVrdDKSUXdkuheRZ3kQMrSQRkrtI25OMHj1rTgQbmIXbknHpWVCJSYIXIHl7iOPXknPet2zPmgL97ccZ6VN+pqqfKubuKY9qDAwevPWnvErnLKJQB24IqwqMrAzgFV6Hpn2qvdzfZombAB65PYVm3pqQk3sLaBY8hwWXnocGolESS5XOWPr/Km28m6P7RgmMnb5g5XNPic7gFA465HakOxMwjV9yOSccjHWpbVVGcAAgbsk4NVyu+6xCfmH4DHpQS6vyM46HGce1JgX02ht5PDDn+tVl3cOrbhjrmnRlPLbHzvngqcY/ClkchduCQTjB9aPUIuzNCJ8FTIxHHDYq7bRqyklyCvr0NZcCtGi715P8ADu4PvWzZsjBvm/AmmZ1fIfAqbWDE7O1POBgY+Xo3rQQGB+UgA9ewpXiIAMIHI5/xNBz2uQSQjAEbHAOTjpSCMkMPTpSxRloiykqp4IP8NOkQbNq5Rs/eFA7WK0iNETkO+OeD1oq8kbBQd4HYn3oou+gHy+ThyOnsKMdccUpU8AKfrilQF/lUHg9TX3kpJK7PhIwbdhoBzjPNWraDe2ccj16VSurhYJPKX/Wt+OK6GwhZbUb8jjJ4rxMZmP2KX3nv4LKrL2lb7hbe0jUlimT2PXFalvCqplQF+vWoYFB2hcgk1fgRVYtnJ968fmb3PXatoEKbATn5upqwqq3Kp8w7ntSLleXXK+1TJG0iF+Rjt60MkWLdIcBgpHB96nljMagbtrDnilhByGUKeOc0hDOwK9B0BqGUojS7Lnf1amBwEJXJJ6VIPmb5ssR69BTVXL7lAXngdqVzdRSHxLkhWJyTkYqSSMEdTx7U+OM+YGI4HGat4BcjcAMckDNTfTUa0ZXmRSVwedufpQGEbqu8FyMnaacsbbCQ6kgdDQIwGV1HI4PFK5SsOnTewcjBB7dDSFmWYK2MdQelK8m47CQCep7Zpxgk6MuR9eR9KGCSsQ3rMqnAbnsf4vpSAJLHG0ZySMFTU8pxCVlJwDwSP84rO8gqSAcOGyGzwanYI6ouXBaKNSN2fQ05huiBJQbvQ1G7eapErAOB27iq7u0UeWXggHgZGKe2oWvoiWdNsBZgSc4BqKRNiBnYkHrnt9KYl4+W8tGaEH14FMnkdlGRjPIzyKV+th8rRHfKscbSbwwxkCqQdGsGY5VSN2R/KrG5ZpFThM/LyOKZ9nLu0Lcp90EdKQJpbkNpJ5tsx2hUUcE9qiuLHzZI33gFeeeBV1SkMSq6bQpxx0NLc7lUEDfG3Qk80mHNroVPLZEAYZU8VZjERgwNyse9RCIvFuQtjPftT23O6bAd33QR0+tJuyNI+87BtEj7Ufp1+XFXIkIAwMn+VNghKdDnI61YA2DB644rmcnI74U1FWEA5wGJHpSBlz93H9KQHgDP1qWNN2OnPahamrshd7ZIA28dB3qaJAOMYHUVPbWrNyoBOe5q3DGhJR8LIDna3861jFs55zSK6R/MAyfMeh9KlkshIoBwyk9fQ1ppZDYhzg5x83TPv7U42m2TO1gQeWBz/kVuodzllUuYLWLqilCEbPfofaooiNuUYgg4ZD2roGgLeYHxyeT61laxp2yIzQttlXgjHyuvr9aHFpBCp0ZlTTF2aMgHHfHf2qtPbSRI9w+NiDg989gPfNTTRhFXIdZexqrcTTO0DMHJRgSqdGYHjimnY6akmoe6ZFy7RabMJVkle5ZiwAPzE8c060hgtdNVrkxtIq4EZyPwFdcvkQ6NILmPddF8xlj8qg8nIrBuLCe/k/dxBbMDqv3SfrWqkl6nFFua1RV0iwigtZQksQBy5I6FqXTJ7l9SBkldbVYwpB65rP192tZVtLDLW0iZJA6NWx4LsXOo2azOW+fdJxkEY4qt9OxTgox527m6qpJK2xmKhio7Vr28YWPevCjHGKZdxQxXssMUOza5yB3Pr9KtRA4w2FXuKiTVjVyvFBcTNNFsI68fL2rPv4kkt8SA49W7/WtGZRGAUA54GOaq3qJJGNv0znoai12RBpOyIYb22tbaS3t0MbSABxncifQe9EbCc/JsHHX1rl/L1OzFw9w0SIXJXa4JYZ4NbGiTSYUzLlCMnHXFTfWx0exioOUTViUxSY3FiBn2qUfOu0nazcgjoKmmjQxZUYyBwaSGPcpXlOeKEjnImijRFGdzn0WiPfGjENu57Dlf8asJB82ZMl+xpkXlF23g7sA89R9KGkTdIZG5fYOpX5sg8gVrWUhl5Drkcc8GqKW6lmUgbfbrj61PAGDlF5XtupKwparQ1kfO5cnIOMH+lWgx2ldpK+oNUbcrG+S3ysOBWg+fLBDAr7CmcsiuuFJ2/e/WowsiyHPK9cg81LI2OwDe47U0OQCqr8xPQf8A16BhKzxoDEgY55I7UUxcqzMg3dsZwc0U7MR87qgYAJkn1PelELCQAABR973q2FwCcDNPiTHJGTXZKrJqzZzwpRTvYhttPjE3nBMuRgkjmtXy0VFBJxnkUR7tmDj8atKq7l2rlumTyKy3Nm2NiUIdwUE9s1eARoxuC4qKOJsdRx2NTw4wQwytBO4vlqw3ZG3tnvVm2AyeCf8AZHSopISoGMAHoKtxqI4iSRu6dKQyONQHJUHnt6UqLh/vZIzT85OEOWAzmmFipIUYPXApFIRNyqeDz147Usa7ZT3VhwfSnIdybidpPGKmhAixxux2pMLixPswOx/KnKh3eZ0QmpGVXIUjhvTtTZkCYXdlB6VDLTIJmBmBX7melVLiSVJBtbAOehq+HQspIwfQjGap3duZZQx4A/hBwal7GsGr6kcMxcheXA68ZNa1tKuDvJGBgHv+VZtpC2/gHPc960n/AHUSt5ZZc8gDn6mnEdSwkrPvyMMpypqNk8pWAC4frkVZgSPyiyHcCc4NQvIF+Y4KelDI66FKRRHA5Y8KOGIx+FUGWTaOSYyOctjj2q9cN5jMYvu9wR1qlPK32bywhx6+lS9hxui3CiQxANgoOWyOaqXDeZzFu2HjOMioVlZYN8cmQezc4FECCZHTfskjJPysfm96V9Cne92LIiNHvGGTGBjqKLVkB8uRNwYHawPOaiVHinB8stt7qeTUsfkvcRPMVMWcs2cde1C7k2GzFfkGDjdhhjGKbEjox2fMgzlSecVYvPLUhoVz175BqrMDHPhiVY9OaL6jjdjxJsZkcEMO/Yj0xTrb5nJbAC9AKiZmjQPKAwz8rHvU+nukltuUYyc81lVdlY6sNC8tS0h5x2NJy7HDD2zUqDJAzkUkluyruwQM5zWNmehdLQSGPJK5wR1NWAwGDjkdRTLNwGRjgydweQRWg0Ee09SD1B7VrGPUxqOzFtLlQ2/ABzzx/St6WK0u7b+HeRlXU8iua8vBByVIOcH+Kte0kWOQvKsZhIw4Uk/p/WtYy0szlqpbohdrmMlSSwUY6ckVsaNdq6lZBvjIw5HVfw70OYQh8l2uISucH7yj2PpWcIfIkM1tIQOuccj6itFeLujF2mrWNbUIE3mS1YMuORnqP6Gsxx5uIs/u8Hg1ch3ShtgUEjPl54PqRUU6BXQgjAOB6g+9avUzXu6M5e8RkMicSxA8hRgr9Paueu5sXEQCKyq+4B+57Z9q7W7K7mxFlQeTjB+oqldaXFcQMwCvGeR6g+lY3udSmranL6jeRyWIgCszg4fucHuD6VPatPpSGGxunkjZM+U/KfiPWk/sqWG4AmjaaH36kegNaFnNaQOjSCaaUfN5bLtDHsCapWbuzRSUY8sSo0LtGt00KxzAkmPI5BFW9FmaCzkFvC8k0yESMz4Cjv8AT0q3HK93eSTzxRAuuxk5GB9ap2+ni1ZiYiYzkEsCSR6Zq72M1CLfvGxbtvlO1QmTgDOcD0zWiIWIZV4PYE1mW8kY/wBWcAfwkVNPeFRt+U+xOKmWpM7t6FvYAmxiM9irVTnjcb8Esf7wqxbgsmQTvPQHpSpLEjfvHHXHHr3FSttSNUVWsheLt2o7rzjHNW7SxSFf7qDse1SxOpZTGNrBuW68VMZQVcuV+uOBRcbqytYZgrtUICDyMdaJVJwXbHORt/lTjOQobKnbxz3/ABqnJchWbzODntyKm5EeaTL0EgZRGDyD3pGJ3gpz0zUFtKCrEggg8Ed6njDMS4PX86B2dywHQjhsE8mnwMF6jHpnnNVvLXB7t2BPSrSRKx+Zju7c0yWkiYOFYNw/bAFaFrKNmJNo9umKy1wZEEQOM4bmrhQqVGPfnrigxnEtyKCM8k4xinRorAYB9ORSI6ryee24U/cx+6MY5FUiCncsN53fcHHFFWJFXdkj5zziik43Fc8D8tgp4yx4wO1TQwnaAQCelTxxgybm+76VYUggkgAL0xXTymfMRRqGbgZHSrMYyTgYPrVYN7AYqxCxZl9+wpbBqTb9ygEEdyatRSGQHaBwMU6MLIMBBxj8akIESgRYyTz34qXcqNgXbkD8MmgEK2ZRlcZJpJBuHyjBHamZJjK8hyOT2xUu+5fLcb5uMiJufX0pYpm34xlwKiRVEfBPmfxehqSFA7EZ59O9S5WNowRbhxMucjPuKkYlcA8KMcimQJ5akEkY5IIzmnTnI3KMpjJ9qOa61Ia1JiCgJB+U+lV3Cl+M89VPeliJMG4MCDwPagzE7RwcHmpBaCCUE7VU5HApDlRmUA45AbrRcYVgSNoPNIGU5OSy+9A0WraHzYhMPu5455FSPKwULn5ScnPSoI3ZYwI+VxkrT94kZSBtfGCD/Smg6jhI00hEZC4/DNU7x1Em0YVz2B4oaQxzM6NsYcEepqO5dXkHmDDMuSpH60nqVcZNC6AspDHGQFNJHLGyFJwMqDk9qqmVrNxs/eRDt35p1y0TQ71kxj5SMc5pJ6g7siXZb58xSYmXh1prRkoZFwUPJI4Kj3qRZDFCY54zImc7h0pbdFMTm3l3qRloz60WQWIWklQiSOTKuPXIP41NFJBIY3nxFJnsePxqCQRSFSQ8LEYz2HvinTiWNUjlUShvlDLzSsMnKNuYW7KwxgnGTk1XmRluBBIrNCMfgfWiCJSCYm2EcjnOKLcyEebId+DyD39KLDWhJqbqUREaPYEx05zRpmBZRA9xuP1NJdKLmNthBfGSGGGHtmodBRxZojEMykgewz0rGtrqdeGkk9dzWjzwR0FSyzt5YRqhwM/MxZh36Yqy9sphDRNn1HpURR0Ta0bKUa/OehGc+9akR8xAXbOBgH1qrChPBxnvxV+2h2Y2nK/rVxVjKrJdS1bosgIlAIJBww7Vox6YQry2rEovJUnp+NVonVGUyRkqPzH+NatrO7oWjYhR/D3xW8EupwzlJbFYRYLmH91IeTF03fSm2syu5G7ZxhgRg/jU7+a8mGUyIeQRwf8A69WY4VNsQwimB6c4Yf1rVLUnmsigytAxDgOpORIh6fgKjchVMkhBz0Pc1YuLqR3KBBtPy5KgGswK0rvECVT1bu3+FKclHQqKctWJKI7g71Rsd1x92onhSQqFY+WepHUfWpLfa0zKj7XH3iDkE1JG8SvlgQzcM3YmsdWaNWFWF44yq7ZEAwcDLflWfeW8GM7OWOCAOM/StaMyRcD7p545qGeLzWzvZTgjIGQPqO1UStHqYUlvsnIiYSDg7WBH4Cp1uNsexZWQd1k6UrxSLkSKSCSAVOcVjX88rSlVjZlXg56fWmpGyXNoaZuoY2/eKAMZJFV7i4y4aNklUjOCKxlJAcJlR0OeTTxGUXG7H49aL33NHBXN5L8GI4Kq2MFCeMVPbSRSSfvCpYdQeuK54JgFgwOeCQeRSxuRt5YNnBPemkmg5InXWyuFO1lVT2PcVJKBsOQdvXI7VhWV/P8AdKBwOrL6VpWt8rqVXkZ+73FDiZum2WmyFzwY8YOB1qKeL51xgg/Nj/CrEYTBGNrd+ePypk+Cq5I2AZxmp5TNSs9BtrEFw4Ug55z61M2ZGOxh6k4psM8ZXEbEEDlWqaParbQSGIyQORQDld6iwspJ3DeOmR0+vtWkgTaGjPIHAaqVvEpkLLxnkg1dDRsxR/vj8qRExFcJKJAGODtGBVuykS5LBSu8cYxjiqzr8qmMjgcgdKnsnhD8r07kUbkTs0XHXyMLgBm6cd6SCdcc8jOMU6dmkkHzEr0quiIhOck54x2FU3qYpaalt0BGQeP1oqL/AGQQV96KdxWZ4opG0YHbFJK4AwpyO9RknkkYxxilcYKgYyeoFbtkRQkTYTJHDdqdE4DhySPakj/hG3Hp7UrHEvA47Vlc1aRoW8uFAxkHv6VaQKqg8lwe1ZsBcEg889a07fau1mOCeM+tO5ahpcsyAHYwbOR6UxBw6N1boaFdnXkDap7UZRlbD4ZfapDlKmxjJ+5429T6mrEOwSAkEMOtIu0S4LbT6nvSEsAX/lWbRr01NAybU3KAVPANQRu28hSG9vSqi3JIYk7R/u0wXA35xzjqOop81nqSoE7g73KE7fTtTFuFdNspCyDpSszEbgRg9T/jVWfdOG2AlwMEEdfpVRJsMmvG81g2SuOfUfSo3vFt3G19xcYIPeqMqySzKyhzInG0DBrPDu2qICCy579RUXNlBM7S1lXywwwGx0z2qQudpRhsfGR/9asaKYKf3hC5OCx6A1YluN2UQ7woyMHv7Vr8Jz26l1nV2w2PNHQ5xkVTkkLlkwHdDubPWk82O8jVR8syHGBx17/Sq7Borgdd4OC2ev1pdA20JJRG8AKMAc4Y+lVy6JH5brtboH9RUmQjkyruQjPy8ioyUM6xh8wsM5bsT2qX3KWg5BNBDu4eInoecChoVkLtAfLYHdgHn2pjK0LfLukjQ84OaVmRp98D4k64PB+lS9ik9BxmYxsLtOcY3dCPwpFM0UeYZTKi8jH8P4U66lE5yw6D+E8g1VCmOJ3hfOf4QDmkOxcglhvSzbQkin72eR+FNeKaN2bBLZzxVaNFlOQRHKOGZRjn3q5azT26HzVEsTDHmJ1z6073HsTXJR7ZkbJY4JUjBFZdpdjT9SFtcNiKfGyUngN6GtqOaO5Q4ZGGNu3OG+tZeoWpljZY1LqB8yEUpRTRUJNSubjjcCMZPXgVYtYi3Vm2nriuR0fW3spPsmqM3kg7FlYHKegPqPeushfCb1bcjc8NkYrJHW3zR0J4oiqDvzwT3q5HuwQvyv0bI4qOxMciEKuQPTtWnBYT4LoVdDxg1vGm2cs52dmPW3jkgR9u2U9Sp4Iq3aRyLGYxh4wM4HWqkflw7y+VcZAR/lz9D61AmprAyNGxkiBAZiMcHrz6irTSMbN7GsxCxfI5Rhj5W/zxVfU4yAPNKRDBzIrfzrnfEXiIR6RqMkQnlaGNmjRQPmPbPtUPgjUUu9FY3tvHIrQl2cLnLf3ck9Kq99UyWuV+8bL3LuiyKUlCnHHUe5rPcvLPks4kbsT96izSNEL5IJGNvUCiVhIP3gDoOABwwrCbudG2xIqxxHNwhTH8SdRU6j5G3EbW9VzxUSs6lU4aMfjTWIMoSMZA5O1TigXUmk81AoR/LA4XB7Ust0CoXBQt8pOPvVCxEbhnYGLquedpprTiRRl0YY5brgf40XsDV9R0yDyXmLIRjnsfauZeR5AQCSCc5FXtVmkFptViVPUr1ArMhd2VQjnOcBXGM1UdTelG0blpAhXAYH0z/Wqk6Kbh1TGF4bvTnEkasC2RjGF9e9FvHyrAMfXA61EpX0NlDW5HHCCQBkkng1qWdnH5ZLSqJC33GGPxFMgTZNh1/d9QPWtGGNJYiQh64O3rSiZ1dNiOS0m02ZFdSkj8oAMgg9xVcQXH2u4ZoWhlt8Fs8HHY+/0rUhhlkli3TjEDblLAnp2xTtZkWf8AdSAu7HcXHc+/tW+r2OeDkpJEdrdvPHlsbh/EOv5VQ1uSdrGdrVtsu04zz+VSW8TIRJGdwxhx3yKvyWsckSyAESfXvRLY2laLuZ/hkXMmlJNIXlUPsYyd/wAPaukhVQmcAKD3PSqMSeWgjJKspyV6AH1qWGfdJ5bkAtxkVndGEk2Xjtde2T602MEy/M3I/hz1pI5I4yUdtzHpupYwCu7aev4ijdk7FuGU7AeCucFT/Sp87QfJXK+h6isp96ygrnYO4HIrWspQ+0OB0+8eKexLTSuXbcLNGFyQ3rU0tuuck4+nFVnH2cSTMxVEBY4HYUJfXM+ii6WyHmkblgZxlkPfPqR2pmEnroLGA/8Aq8Oh5BU5z9DRTdO8h7KCW0UR2jqCiAY2e2Prmii6HdHiM7Ej5NueuaijYll6bz3HanTIowB0I6ZqazTfIFQAHHHtWkhQHlG3qVzgimyoyynkFccHvVuQbEBJ+pFV2wz7mIBPTNIq5ZtAGTk8HuKnJVVwFJIOSBzk1Wgf/Rx0BJxntT48iMknB7VDNosnhlwxUcE8kGnN8vJxgc8dTUQyyhjgN3Jp+N+dzcqOMClzBbUdK4I6YHuOlLGCmQCWJH4U4hAgDq2H9ahEgG9N2cf5zSuNkcgdrmOFz949u9aD27SxHCBcDHK4NYjvPNOpTa6r0GfmArXtpQ6lJJvnA/iPJpqW5cr2QGPykcnkeh71FhGYSHeVx/3zTmdlnZVIBAxTVlUfK4Kg8ErTRHK2QzQkgyRybz1DDrn0qufKkk3SIsco4LYxuq2yNA4aNwR69RRIyXLFXCrMOR6MMUJ3ZLVithc+XNnBONx6VGwe2lDIy7CcAnoKsyjP+uiG0fxLyPxqOVD5I2ANFnn2pu4loOuADIHyokC5LL0pjuySqZwAjcse9JCUALcsvTpz+VOkjDYC/Ov90nkVLbFy6jpc58yyVXX+KMf0qvAI5I3CkqwOSp7/AEpYjJDMGjby2HTsKbdq053PuEgHBX/Gi9htdEOg3RcoSWHVcdabOYpZQ+zZIRwPeq0crRlUuNyhh8rjrUrToJkhnUmNujD/ADxQ9hrTUepktXLvFtz1B6H3zUnlrPJm2dhN2OaUSSbAjqHhBIAJ5qV4ArQvbEwzKM7c5zSL5iNI1zsnBSUdGBqeEPFGdwLQE43YwfyoiPmoY7lfLl6/WrMCzQIUxmEDG7rtoE0UjZqsXmwMGDdARyCKiXzkJaB3L9175rQlZFPAIXIyR3pt1GAGkiGWYZBHehjTsZ9x9lvPkuoRHJ6he/1qzpMVzYKywt9ot88Ix+79DVaUSHaOPM6FSKkjfDv9nLxMo5VgcGo3KjdG9ZalZxvtkWeOTsrKefxFPHikxAw2HmRyMSAJF7/jWO9wrhY7gbCOrL0/PtSS226Vo42SZQcb+68U1Ula1xNJu7Ld9d3l2Fe4csFPOBjHrUST3lvEI3y9qOSvUjPtVKNpLe4CSM65GMMeB71rG9CJi4iLBgNrrjmjfdlNvRElhb+e7SW7JLGwwVdgPwxViQC3gSGKPyYQwIiAH+eKpeXbH5xIylj0PFW4TJ5X74MVJ4KHOPqKq+liJb3J1O1VEmd7kkYHBFOKFE+/8vUE9vaqsCb28yCUAJyEkU4NPa5kgYB1OG64+Zal6l3uXI2aQKsaYI53A9anCsThD86jn6e9RpH5S7lVWRwCChqEFnbMGRI38LdKZO5FMDuXd8wJxhTjBP8ASmGAwRHah2YIyFzjHUE1M6lYgs6seScr2pLeVzwjh1b5SD1pXHdooXwIib5wGdTkHhT9KztMmdLhkjjVm2ZDMcgH2rbvJYtyLM2Sw4U8YrK/s9vNC2sm3LfdJ4Hvmn1OilJONmLFatkl/wCI8f8A1qtW9tgkZ2nPU1WM0m7yJQA6HGO2PY1et0GCzA4UcUrXZq77jih3Hcuc8dOQK04oGt4VJByRkE9PxqOONp8NyyoMAjvV43CBPK8z5uPlYdPxqoR7nPNt2RS8oGYFDsJ7Mex96zLq48+Ug8CM7RtPFXb9lC7kAXB3DA6VTRcI0xQOOSTnBxV2ZdOKTuJbhy+UUEcHGcFq3V2yIPkK98d81kxKBKJEyVIB9CPeukiEbomWG8rnI5ob6EYiWxWS2Doc7i575xUIi8ssWyIsdxzmr+FWM7eAeOehqMhiQHVhgfxDIqGjCMilEBJIQrHg8MOorRiTqSxz/Oq7W+H3BeWPBHSrlqMODyCeoakkVLuh3kbWJXI3fw1OpyqjaNoGOOtIG3E84XrnvTY9gJz0+vSgy1erLq7ZITC3MbIVYN6HrWGl+sMP2SLxFaC3QbFYw7pFX0DdD9a1Z087Tp41DHfGwynJPHasvTtQe3tLeGXRrtTGgQ7YlwSO9WjnktTe0yK3GnWyWThrYINj55Yev50UtnMLiKOTymhyMmNhtK+xFFTcZ4LKSgZfTir1p8hQKO2ff8aoI29TkjHbFXIHwwDDBHGe5rVlR2LssrOgAXlvvGqxjDM390VLHJmVlUE8c+1K5G0jv+tJsBsanyox1V+etPkcblwcgdM00M0aMrgZA4HpUYkztGBk9SelZtmkC7C5CklOc4OecU+RfLljkD8Hg8YxVSF12N5SgtjPJxTrq6eSFjt6AfQUX0Nmi08jOgGOmTuzVSWTJUN91uM9xSW7eXD8zkBgcZFOgZQytgyL3BHapsxK3Ue65jUxqVHQNgZpY0ZJcOC5PQrSSbX+aNyp6n0HtUkDPE480bouPnHUUykIY2djIjBiDgr34qwkkRk2XEe057j2pswTznKSkDdkMe9SIWZ1WWNXRuN/8vxppDT0Bl8lBjcyHjgcioZ4luFyhAkXkY7VJcM1u2zcSi55P9KqzlvLWYPsc9COjD3pp9yJK+o1Lhk/1gJyfmOP6VI8SZBjcqh9Dwap3N2iy7LgeWTznNLE7DiI4/iCnoaFLoQ49SzC7RylCofdwBin+XHkFNySqehNVRN5oPmja46YpJpcgBsE9iOtNuwrX0RYvH3ttuEwhHLLxVNk258qQtHngMcGpJJXmCl2wBxg014wAMc561m5am0aemoyA78LPGSp457CnNZvk/ZnDY42tUvlhUwuSTQoaMgjjPqaXN3FKl2KtuXtZjlC2D88R6/VT3q8pjuSz2j4dOdr9QKhRo1lPnx7kbOG6496ZJbSQzKcGSA5AkVvmH407qxm0+pqJ5VwFOCu0YI7g1LtZYxIGLAccelZMUsiuqFw0YP+sI5+jVrJKY7jI4UjoD8p/DtVC6DVlWKQRzLlXGdyjvUMsfzgxsVB/IfWrbFpF/eIoUHOUOf1oniRYPMXLKPvAdcUmO5RYP5hjuEUKGGZFPXHf2qWaxEih0mKP1XvxUgRGUBAhfdjn+L60RtKGdZERgD9zuPoaTRSb6Fe4iZFVZowp/56A8MaRIPKVZIHALde4Pt/9erkLZt9jL5icthjjB+lQvaNl/s3OOTEen4elTZAroVHivtsVxFtYLgFj973zTfLl09duRJCOFDc4/GlFoJoQY8hgNwUnoe4FSR3XlgRyDcwPKEdqtLuO/RD4445YvNQbTnlR0P4VftnKttl+QHgFarwwwzSI1uzLnkgDofenziWD5dmS3Rx1B7nHejYG76Me8Lq5kj3HsSvQ01zNEWlADLweBUsNxH5RWOTYwIA44P4UsbtIS+GIVudnA/GnIL2HLJGVyhKAjIX0/CmTEAozjc/9+M/0qxMqXEOwqPNQZ54J/HuKZAjrGGxkDgEDgj1NS/IPMSZmBBV1dAMEdPzqS5t4haiSIeW45G05p6wW00XClWJ5IPX8O9QeWxARXRSCcbh/ShX3C99iCNzMFF2gYE/K+P51K1vCIlkt2XHORn9KVGkgUh13IO4HBqSC2hmjJzhByMjGDSTKbMG7tpP3jGVlO/gHpTob2S1VkuI3K5wSvetydVlJhn27Aowx/xqvfWqwxxiU71xtV0HbtmqTZrGvdcrJLS5RYd0TkgnBOOQatJCZYCu0vk/fPrXOvbbZgd81uMcuh6++KtySXo2lJjKmQAwHI96pSvuU2r6Mv3R2OinPPQ9DnFVdkhl5IMjdMcCmKxlI8yZpCD0ar0AWJ2+RmjYc4GcfjT5uwnJJaFq2hWOBPMbcoGenOTU6fPzu2sD1Xv+FQJFLtIWRWUn+KpliaPCs/7zHH0qW9TFu+rJ1ZpU2fMWXp0w1PHmtBkE8dc9Qaht3USEv16Z6VfYJJx0xz6ZoIlZMqQbjgkk8HIPFXkX5N7n5ugBqFFO4EnC9+KtFW2YZsDsKBN9hhiYy4JG09cdqUR7ZW2Y6UMhiQ4zubAI9KmhVSTyd3fNJaMm7IJrE3ipIl7c2xUEbYTgH3NVF0iUs3mavqG7sQwrRjjOSSSTnhfao2kzOQmSAO/Umi7M+W7JLKB7eJI/OeQgY3yclvc0VBY3E00TfaLc27HkAyBiPbiikwseLxHy5flHJHSiORi+9uWbkc9ahLEHKkdMD3qa0Kgq/PpyK1bHE0oy4JCKDuHNJcMwQZ6kcgU2JgrhgWzjqO1JITJIGJO0HHvUbFJBv355LIRmmOS6qmTt6AilnOMlc7eVA9ajBJUKAA685pMtFm2PlwSgrvPrjpSyvutxnKHn8aiVhlt5bkfw1FJIUY71BBHY9KXQHqW1YvCisQ6joR1oLASbQTsAwp6VRtpiJAsY3MQc+wqfe7hPu/KOT60NlWLWzCght3fPWrCFfKQxcNj5t3rVKzdI3+bcCf7varUkscjKpBWQfeI7ntSWpSJElMbESw7kbvQmFz++ZSTke1J5w2eTIVJ6jGelLKiOgSV87hlXHGD6GqTsOwlzK4h/fptb1PRqyXuw1wbdGAZxko/3a2Zo2msDFu355Kk5xj0rlbyzntr2K7jwR92RgOSKolvQZq6y3CoChSSLON3QgVpWc5mtELnZKMCproJLGcoGRwM89D65qlOv2YRljwej+opctnclzurFtJW8xtij/aDH9anAULl+9Z9rL5wLHO7JGfXFWVZnIzwKylKxpGGmhYVlBAPI96nTkZIGO1VVUhunBqdH2qASTUc5rYnPUYOPenNGCFJ54piKJDgdKuRxE7Vxyegq46iehSQNFyFwMYzTLZZI5GA3NCxyQOxrSaOPO3DZ7g+tV2zA27AZc4ODTatqRJcw+2ignicuuSCQ3v71WFqUY7MvHnBA65qxcQbyLi3cpJt3YxwfqKbFdvhX2mKYjmN/ut9DVJmWq2JtNuAUZTKoKHcoxjPtU6MXnkXmOXqU/hI9qrxW4uWMkLokgGWA5GarTXDo4DKTtGDk8EeoNHQOW70Lzq0UqbUwx5x6ikkJkCrC2Cp+YN1FSW0jC2+0RDzoEJzu4Ip1x9kuduz5XbknHP0FDQbuwyVklMJf5ZV7n+IVIXWRGjkYifkjjBwKJgUTypstjkNjnFQog2AMGbBJBPTHsaB2FEH2qDdGy+bEQdwOM1FbwJNJm7By3R8YK1ea32lHt5Nq4BOB/T0pxlinD5j2ODjHbFDFe+g3yfLGC3nR4JwnBBqWz2TfIxEiZ43HDDNRNCqQRyJITITgqT0HsackoaHZMu2XkKW6getHUdnuLBFG8jRMrnZ0x1H+NTbTE0nllXQg7lbg1Fbu8ZVpVDhMrv71IzI7jEmWIyCOv40CerBwkqbg23HQEUtvI1tCRt3Rv2zyKgaOVVdQVZT98g4yKQRyCaKSNg8JbkHsKV7Fct0aKx7gWiXnb8p6EU6SLcqPKuHAxuB5/KopnZEV4wM5yy5qSSdvkZEwjDnPahOxNnew6MeaM/LkcFh0P4VXXy0nkETGNl5O48VNbLG7jysIo429cn1om8p9u5FdwfnB6/UUDW9hJGYyFSsMqA8r9f51SniaJUkQMADnYOmParxt1Lb45QjIP9XIOD+NN2hbXduy3P7s8EH607CtbUppNbTK/wBqD73434+7SQRxwrJGp3YGSD3pUi8/gELITypHH51Fe24VWZW2OCM5H9afoVdbDraNGmReNgH/AHya1oWMIwwyDx8vJrGtZmDNFKqsG48wDNaUEeExuVg3BkOeKSfUpx7supCWVWQgqeCAO9XY4PlIc7h0yKq2ymKMxSMC3ZlNWYMNnBGRwfemmYvXYRVVdyDlc8gDJFRKWDx7trZ6EnGBUrhvNVVIGDjnuKfbnmWNxj3Pp6UnuUh4kwoaM7xjkN1FPR/OI2ttVuOe1Rxw4faMY7MPT0qxsWOUEqBGe46fjQgukOg+cEMQGHFSoNjMzc9M5702aNdq4VQw7g9aWRCgVs5H8SntQzJ6iXrGCznlhH7xELKvqQOK45biTUDbpJqUnkRwG4uZkYJ8x6KT2x6V1t0UjgkmLny40MmD1wO1Y1mbv95CLXT0Fzb/AGhIRHkZzxuPeqQtizpU0s+lWc8xPnFOcjGfQ/lRV3Tpl1CxiuUGwunK/wB09MCip5UaLY8JQZkLEDB6VagBWNlUEt61W5LDnAHWriAqMN8uRn61qzOJbB2pgsSeuBTF+WNQwO8ntSIw3AsQOOmetKoJCEEgc1DNOo7Y3zkkkjkZpiMOVHD+lOXkbg3zAHO6oVZYyJCe2TUsodnYpI+/0IPaoJP9X82Q+7PPenkFhuJGDyfem4aXLYLY4OKTKSEhAYj5irdOKsqxVSrKDjt3ApFt12hldc9TjtRK8iJuJUkfxe1KxXoS2rF3kQENgfKTwauPkFGniOSNobtVSEBoSyxkyDGD2IqU3ZeIQyHhPX0oSHvsSzRgOMAq3ADdc0QEyt5Ur7SD2pgkJj2SN8o+ZWFMmZBMsbD7wGHFGppFaF3b5PzksjA/ePrUYAkJ8sBH7ofun6VXWWVSyTFimccjNPKBWAUlkPKt6VSepnOBnvN9jndJFIU9PaoZ2W5sAoIZQSMehq3qsKyRPvDbh8ySDsfSsWKZpiJF44+ZR2NW27NmKV3YvxDy12DjHSrMR+boeh61WjOcEcnFTKRkZJx3x2rjbOpF1SCODnHUmnqcHOQT6UyLBHA+lTgAgMRtPYU7BcvWaAIXOAFHSnwMCwO77vTHWm2z7oSoycdaEULLhztINax0sRrdmg6Ssq4iLbu+KpyKC23IjY+inFXC9wiZjdwD0GelVgN2fNTLZ5YE1cmhRTZH5ImjMaMAxPy98etQXYDr5E20SD7jnvVmFkZ8KnGeu6l1W0jYqxYAHoQc4PpUrYzaszHtY5ba6DjnAwwH86vCS3kiZnG1+cMKihuZIrwiUDaOAduPzp+obIyJAyhSPu460+her0FlSVbYtAdsRX+A8E+4pY5RcgCbaJl5BXj8aq2148DFogCG6o3Q/SrEIgeRpEUspPzpnkDuRTvfRCaaNWOcNGIZ0zKnAZujA9806LELSFfmiJwYm659qh8sRxB5182ANhHHVfY1IY5MozY2E5Q54JosTo0RyAeZuiJVgMlc9faktm32oaRSyl8MR1FXLho7lI3lAjKNtZsf54qG9T7Mwa3BLMAWj6Bh60NCT6EEtnN5byoyuin5Mf1qcTwuQtwP3gAwrDgjuM0+2dVDhEYqfndT2qG9DT5Rcsi424PIxRtqVzN6MEVolUwktHk4V+oqNoYgcyNsBOUI7H3q3CBLbo+wEkMrLnBJ7VXidUEkUqs525YDp9R9KJAmTedmLy9vzA4z2YVatwCA8AOF4ZAeTVSNZBcABhIu0bccfiKuWczbjI5IbOCvfHr+FIb20E2xhg5O3aduwHqKdK5CvGuQuM5PQ+31qzdiJ23bM5GQxHNNVQVQjChSCykcEUXsJd7Fe3wJlG4DI6pyB9anng2SKZX2MBlWUfeHvUsaxCKY24GN2Rg5x/8AWqQE3CkONynlWHr3FNWJctdBqSK+RIN5IBBI4NJtIVwiqQTjaR2708R+VMrRNjLZ6ZAout6sA7HPLAjjNNabkvfQz4NsDsy5CAZ2nn8qS8IkjHmlst0zjBHoKuxIlxJhlCnbnjjH4VUuIVMy+eu3y+hHQ5qehXUrx27wuoILIDnIHK1ZjhVo+WOzOTg8E+9TRxhSAzM3mDgg8U+KN8mOQrwPvFeooKbH3CGNRjaysOueQfapbaYrGQ4IOPvYxg1QkgaR1CgcHKkelX7SU7WSWPfsz2zn05p7E20uaEPzRKwC9ep61PJGrY2gjjtzVeFlZcQKd2Mkdqtr8m1sAbvU8inuZ3HbQiB1Ubh196iMu/aGXj09DUmdp2g9eAalRRHJ82CxOR9adguluOjhEyZQDd1P19qcLclGyQcjkHqTUgjwEZCQT1HrU7Mdm5dpboQaDJy10Mm4QeRL5sQKBSHB7rjmuWjexU5i1yRIRH5OPKJZY8/d3Yrt79C9nKiNtdoyqt/dJHWsCC4mh05bFtFuDOkXl7VUGNzjBO70PWmhOTe5c0V7GSBYNNlV0gAAHIYD1OaKh02zuVurFGiYfY7QxyT9pCxBCj1xRQUpM8KiYnGRzjJ/GtFCSihgOFA6dKzIXXduycngrVyFgSQ/ccE+tWxosW6741LYPJBFTs2ItxAB/hH9arQuWJBOMde1TyYEYfOTjAHoKi3UvfcbcTIZSIFwNv1+tVip3KW+7jIFLyhzxlh19KTJPJbkjipsaLsTB1KBQvPrSptjyFywHUA8/hUCT4AbPygde9EbpI5Cupb0zg0uUvlLkEpWMhQwDLyD1FPglQ+YjqrBhgDoc+tQPt27x1/ixUzKWt5CQMgAK47VXqTJWsPt2K4Qg45ABprKgBVzhj8ucdKbDdPP5aoo3LxknGaW3cyTbpB8gJB+tRy9ioy7i28qpmBwHyMqemafPb7GR4W+ZR93rk0t1bq1zIIvvA/L9aafMBTzFwx6N0596Hc180TTSqZSCpIZRx0waRHWErIqsU75p24XcaRxqBMmSQxxmktWBVivRhhlPrVWFstQk2vExhxuHBDDqK5S3Xy724K8KSPl7g11DW8iSbolLDGWWuduWQXrsjYyM+9Du4kWXNoXI5Mqu3jnmrcPQHHNUrZuBzg9auW7BSTnIrkkjSJfgzsBxU0YOfSmRbGU4HAqzaAOcBcehq0rg2SWzFWVc/MetTOu35twyTk1Xix5pGPm9a0UgMvYMBWkV0JbVyzKqmxDZYFepNV4lVlJGRTryXbEsCMxRfvcVNaBvL9QR1PaqlZysOCtG5j3CiOZ14Kt0z61b4nt1AJEqjJB6HFLdxnKkKODSRBnj2kbTzg1mtGEknqNiVOXJyjfKwPb61mX6+WFE5D25Pyt1xW2LfyblmiZHfb8yn+IYrOuI9oLrGHtzwYz2PbFXzaEdTnNKs9Q8gMx3W6OSJPQntj6V19jaiYeY/yTtxvHf1zVO1X7IomVDLB3UdhWsxXyI5oF+SQbdjcAe2aptdhPsFuJDM0aqGQ/eQ8DjuKnJ8qAiBi0TfKehK/WmK5/dxyRNuUct0YCocGK4KOCgzuDf3vrQRy6hN+4DOh3xEZz1I/xqeRj9kjYMNp6VWN1yxyAoOCB2q3NGoSFtweFRnB7ZpBa1hLNN++O4ZeBkZ6/nTBB9nkKMC0QbcD3H0NTkooSNgqyYyhNRM7RfvJVHknAKseh7nNMS1YYZi0yIrxN+H+TUaKLqVjjbIORk4Leo+lSW6MkwdeYG++mcY96s38MQjHlYIBwGHb8abKZTgPlGRbg4MbZUd6v2i/aog20eafmBbrUN3HiSLzkCk/KG6g/jRHvt5Szj5c8c5xUp23FuaKSLJH5bIRMACVI4IzT7u2CoHibgg5T2HpToFQyRlxtDcAsaUF/LMbkFGOOeQPpRfuLW+hWig2OWhxE+AdpHDik3bpQEQkn+6cbaswqHkKgE7Oik5/L2qoYgJtyDy5QfmUcUmVbXUllh3x72x/tZPNLGuSI5H3iPknvioTn7QPO+RgMZJ4bnipoJFZwkiAA+g7VSYnFpAQgHmqCjAcelVppZCQAFJz8zDpV1zFFnG4kfKyn3qJo1lBAQFR94+lAQ3uxGKOkJj27ieVqWFS80mesa4HuKhgWJwNqjgkDA6VPbIyMScHPT+HFCXUGRKhUN8oK9TzU1m7sxYPkdMAY4olALASAeYR1HSnQscEs2AOgxz+HrQ0O2haUK6YUcn+7UsYmeLcylSnHvikspcnhPlHrVpJx5pBfgjPNVcyTaeiHQxlUJzgE5GBT9+2M71BZenNPVCmAGzn1pogRwTIpVwePWpbCXmLFKW4XOCM49KkQsckN8x46VHgoTgrtYdutEU7ZKbfmU569abdjJjL5misbhoyfOWNipI746VzUGnrJJZA6ldbLuzaUSmbgSjGfw56e1dPezpFBLMQW8tDJgew6VirDe6hp0YbT9JNs375YmLfLu5zx35qkS0a+gOr6LZyRbhmMHBOfXPPfmiptPaVLOOKdI0cKFIi+6v09qKWo0j5uRCJMYzyT9DVuAttCEcDPJ9aqjLAnvnBqzECx5Ocd61dikyzCA4DNnrzn0qMuSp5xjv61I7BFCDGwL83HNU5CzBAuSGyxwMkAdqlpGsdx+/JAJyAefyqOMtLP5a5IU4yKozsNxwXH8RAOAKdDfzxXSiOMQxKRuJG4tSir7m8abfwmilvHHI4luI19ie1MuHtkQOuHGdu5Oimuam/eX0yAM7BiTuOMCrkERuVaERlUCgI4PU9MYob6WOqNGyTcjdtroBShJ8th1HNW4ZNyLg/d5xXL2Tvb6ksZm38FHUdjW/A+cIR09qVjKrS5GWWdftauybYzwQDwD2NOJ2bopPulshs0qrlHQlWUNxnsKbLCVkKM4IUZAos7WMeXUnG/IfJO3gHOKnWdZIxDN8ncNmqNs4TByXRux6rVvbuUZ+bHBFTZo033GMgcfeCyqOD6ioE3qWZABIpyyeopZVZF8yPJZDnBpVuUmlBBwzjp0OfX6UIVy+t6ssW5iMScL2IxXI60jWupw3AJMcvyt7elaWoO1sRLnC7grKBxz3pbqGK+tWimwRs+8OdtaJ3ViWuTUji2kA9DirkKgDJ4OOlY9g7qpt3bc8QAznkjsfyrahxsBI3Ejj2rklG7sVHQvWql1Kg8nmrSEoQF+8elUYyVIGRkdMVah3MnOCB1BppFddS5bL0ZiQOuRWnaSiNyZMkAdR2rPtUPlkNycjjsRUzA52k4HT61pH3VchrmGu5uLgt1XOPrWhaqAwQ53DqPaqsSgN2wPTvWnYjF0WRcnHTNKO5pJ2jYbq8DRQ7omSReMr0NZXmthcxkYPTuRXQX2nGSN5SxUHnA61jTx+WyjeCvfPU0VItamcGmrFuWPzAsm4h1GPU7TVRIFiuW6sWGAD0PsDWpCrRoh4mQoSQOu30qp5OJCgIAHzKHOcD0+lLzFHUpRI8NwxhDc/ei9QO3uaTcsU/kA4jkOWVhkLV/7OgYeWHEoO6M+3ce9QXaLcNuI2bhgnujf4VQidY5riQR+aI5FBU7v4l+tTHbcQskwUTIcAN1xVTDtJHGx2zoMg92FWL23SSJZkkJlHDqOGA7Gm7kb7lKIKs00MuOfu7ugNSpu8nyGxvGCGXoaddiJkgmC5dDhsc7h7+9RyCOD5hlomHGeqn0NK7sPcmu8TxLuGZYxu57+lSW7iRGt7nI3gckfr9KjiQGeMyEyFuFbsvH60+e5COCS6zx8gleq+mKfmNrSwlqDAXjlI+Ukq/qvSpGhMEkQdw0cn8Z6n8KsbVnXzVjzxuBHYdxTJh5hiiLKI3OQVGce1JiWot8HRxbhlK4DxkdCKSCRTGzSIHQZBHdfantDMhKyp86NmNyPvD0prxJ5vmAkp/Go9DTdwSRoWyrMoRm3OBjr27U6OREjIkXKMSNtUtwjkSdZG2D5Tu9KHd0A3gIjnqeQR7UmyUi/cbRGDAhLKAfr61VuJDNE0yZ3NjhsD8KgmuZLeSJN/DD5cnH1qrJGsjM/mlZOQVY8Ee/pRuVFLqSXT+fAZArLsHHfGfWnQThjF5yqCwx8vOTVeGcKQoGIQdrZOdn1pJSiXIaIfu14Zen4ii3Yp9jVMoK4YZcZBPqKI2S1jaNNx9cjPFVZHVHjQgZc5R/8aUvuUb2VmQY4+8ee9DViVsWo2UYkQHd0ORSK5Cs2SYx97A6GmyjpsJTpye4puVUtg4U5Dc9aEOI6E+Y6uDkk9ParS83DiQbSOg9q5t9Rtl1ExNIqM2doJ7Cug01zMUeQbRjAz/EKpsqScUX4cZ2Fegyrj+tSwfNMe+Rt6cUixrHvaPlAMg/zqwvlxwsVADjk0NXMUhzzqgOGywOMeoqxA/moEJww6GqYiVU3EZ756k1YtZ0Z0QptwMbu+O1Jb6hOKS0Emw2SSNy9T6iq8Llj8vrwW71ZuYQZWcMuCMY/vVXERCkbsHquewoepCSsLerIltO8AUPsO0seN2K5rThZiyiYa1OjhcsizqoDdwBjjBrdvLq7tnEcFg16jrhiXCge3PWsuSOUEk+GYsnj7yf4VaZnbU2rOX/AEWMRs0y7f8AXFtxf3zRSafE32KNvKFqdv8AqQRhPaihs2SifPasPMYHIZvyqzEBswG5xj3NVSoUksTzzn0qaIhUzjkLxWzMIlwJ+7TkklgCO9ZV3qcFpdFZWIH3GC8ZHfNacZzsxgLyx4744rhtcgkDlpiWVmweeSaIrU2WpcuLlbuZPJiZVJOcckj1x6Vd0+KRr6ZRuaO35+ZuTjtWNE32e4idSzyp1XOAD2ArXnmdbcPIQzvySODx60SVnY7KafLoQyhFuGdgJOrRqOhb371p6HHMLa5leOMHG1C/DA+1YYm+zqrLgEDgkZzmumuzNBottsG2cxBpHbrk9x74qLdTZzctGZGnRRW+rxi6G6McEnuetdxFpX2hIpbeRVkHzGJ+Mj2rza2xJep5py27lSDnrXqvh++REzlGdBvAY/cHbNXFK1mc2MnPn93oUGtmj/dzJ5cg6rJxUQVCgLMBjjKnNaOpa3bXhnA2SSISzykZA74qg98bqRZbBIEtduAJFwcAdcfWpbi2VCE5JXjYc1mu5Myja3OR1H1psYa3OyVwwP3HPT6ZqhY38rmOacRhGk2oMcMe5PtVq8uoLiGZ0kTKOP3e3hhz0pXi1oN05xeuxflVUZJQAEP3jnIzVXULAbVlt0XceQemDUem3SyQjad1u5289varYkeBgjLgZ+Qscg/SjRohpp3Io3W7hMU0aiRRtII/nVW3iFneCIJ5cbDK8cZqzcwszNMgYSA5wBjctSBY72BSkgAA455BqXoxtaHPa7bPp94L+3w0Zx5qjr+FaFtMjxq8b5SQZUirNyiXEbQy53gbTXP2cn9k6h9jumCWrtmKRhwhPY+1ZzjfVBDVW6nRxYIVcHctaUSnyeFwT61UiCF8Hg+q1pR/IqqGBA5HtWcQlImjwcKT26rS5BqGFCBlST6CraoRHkKMnqO9UG2pPCNijbg9s4rZ0qBTt5AesuNRsG1Tk88Vo2rMBnHTj6VcUkyZu6Zq3EkIQoZVLj071iahH5hYmFTjuvp61qLbLh5PLV26jPBNVAYDKFkzH22t0rR+9ozKFlsZUczW8scqEOn3Tnjr61eu4EYxsGCOOEYnp/8AWqpqNtKm8wMhVucdiKnglF3AomUGSMAI/TGO1c+zsa+ZZVVnj2yBQ6HjPGPcVXgj82R1d1W4K/K38Lj0qWVxKpk2sk/IH+FSy7ZLeMKI42ZQ6Me7elMiS6leRDdwNhsXUIyvHWiF0N5E6pgyrh1PA3etRbZZFS4jwGjf5gfTuKtX8RdFniIEnDbOoOD1/Knd7jelrjW2Wswili/1g2Efwk9jVA2zEvHuxMBnae/tV65mN3EMj5j80eejDuKqnek8e4HgZRx+ozQ9wigs8MxglIKsuAw5Kn0q2sSebGJ0G4HaGxwKrzARyrPGDhlzj+8fWtBDGQCBvS4G4HPCkfyo30BjbfFuXtpM+W7YTHTGadJZ7hhNqITuCHsaVk85SWYiZGB54xU6eY5y3EoBKsv8WKadxJdSG4uWntiJGIeEjhqpXu52LRk5IGGx09vpWhfRs6LcqqsCoVhjp6g0nynapHyr8oP94U3dvUd0tUUWBmtkkXDFM5KHp7EVDcSRSW+NzIqn5kPI+oqSJWtGVlA2sTuBz+VZWr5jBydhkwFweM+lSNRu7FaW9a52wkFnjOMjk/Wp4JZnvFeaJuBhsdGHY0tlaKMKOHPBYDvW1ZWbMvAO5eo9aUbyOiVOMVqZs1ynzhSqtnjj7/sfes8ajPNIsCpuCtkHGCPbNbWp2AmUSRIQ6HJ2joPWqosNkDOEwF7+x75qmmEIQtdlKNbhsKG3Y5GT932qSF7tAMqGcZ5z94eladjDGhDEhu2asGJAzAruI6Y4OO+Krlurl3itLFK1vjI/lyB1fG4IR1PcVr3MaXEcckJAyBuA7EVRmskY5YdB1ThhxS2E7wSCKUbwfuFR+hpWs9TGUVvEwr7wv9o1aK4juPLKSb2Ljt3HvXdrNHNMsgXGF27T1NOtYlkjyqgg8qT+tTRwDPzLg5z0pmbmm7sBllDKDnpg1IiljuwWVeuOlWiGUttAGeuBmmQB0dk2kDGfY0jNS7EOzy22ZwD+gqRYnjl3qFbOOp6Cp3iJZSxG1h2609MBRznPBJ70bhzEHzSAYACk49wKJY3ZhyTs6L6ircqbQQoBK9Md6aSzqrHAPQGk/IlmZe6jbWMyJey+QGG5VZSSR+FVv+Ek0xgVNynPQlW/wrXuphb2sk8qB9iM208k4Fcz5ustPEoeyWWe3+0Ioi4I/u59eRVIzbszo7KVJ7dJoyJIZRuVsYBHrRUelymXTrWdpPMDoCTtxz347UUh3ufOTou/G7K1ajBKsrdjjFVCMnb1HQkVPu3SFEOQcsTXUzniyxkKCFb5VB/DArL1W2W9tpVALbdrBh245rUi+7ICONh4NCMpYKU5YbBnuKi51wRy1oF+2RtdbFCqA2B2A4NTXytc3KxbmKjDKQvOMetU7ZETUpFvGKbNwfvnGcCte0RtiPErpHkuUByMY9ff0oa6m/NaTXkRututuJTKZZNwAyM7vrWvrt7GunQQyyok06BuBnYKydK0651G8yiYhzuZieAvtipbyz/tfXWgt54lIxEobptXvST6s15YNpRexnW1lLJeSQQy7ZFG9ZlOR9eK7E2y2qJBLMm+SIebKPl3nsD7etZtgy2E00NuEU7Qkjkbun8s0WQgEj+Y0jsx3bXbIHPGKOboXKLk+Ykt7H+zryYSJmORCVXORg9CafCsEJkhluAzMuwBRygx1NQ6kDMysZU8wysrFSSTjGBmnzi2muLfzhKt3Eg80gfKW7H6YrJ6bHXTcp25gjt5bqOJIZVCZIDBcMQOxHb61orZQS288XkyKoG4kfeOKSW3lg0yWdZIp5YW+UKMYXuSKZpFxJPOYZG3kqHWUnaBj/CiLs7FNOadnoigdPe0JaCdXteJBhuQCfSrupXbw2zyKGcIfkl9FPUfWpVtPs0+2OZXzk7cdPbPvUM1tLeLIpO4CJikY4xjvTWmhjNKavLoUbPWRHE6eaxmfBG4cHPIGa07S5RpSw+VuJGTHTPrXN2djHeX3lQTIHOCoGeT9K29cuHtNQtn8qNUWEh9v8T5xg01qrszr0VFrk6mzfWpdUuITlwMHb0YVga1YpewmXccFf1rW8P6pBJIIZxhVJYx568dM/Wn6lD5N83kKDb3HzAdg3cUSta6OL3ozs1qVvD0zTWESzDE8Q8t/fHQ/iK3IkGcj8BXPREWmoABf3MrbT/smuks9qsN+dvtXKnaVjSUrq5ahbywFYZ78VaiYiQHBGecetVxlYySQQasJJtXqM4wOK0ckjPfUtZJBaNc+oHarsO1Plwd/XbmqKTNFGUQYBHzVNaufNRsFl6laalqFm1c3tPchwv8PvzUl9p8czl4T789KrWzKz8ZBHXmtW2kOEwASeB6GuhaqzOZ3i7o5a8tXViDt6Y4qjEv2adZQCSG5HYiuyvrTcMqBnnqOAKxXgVWPynIGeeo9xWE6dtjqp1E1ZkkcBlZJkkDkKCq44P+zn1qoI/MEsbxEANnaByD7e/eiIPHIREeW5wOm71/+tVjLC4HmgLLkDIPDCoTBp3YyybbKS3RvlbjAPof/rU1vNhkaJ8JEpJVvf2pYzE1wWDAxk7Zk7j/AGqfqEZDMWYEoNuf7ynoaabsLdlaWBM7EABU5Zc9fce9FyInREfKJnkY9f4hReR7IljhP7wMNj49u9TvDmx86Efv1++h5B9cU07iZVjV7YrDN8oX7rex6GnRRMk7RyjYp+ZNnIYVYkhGoWySwsDInIz/ACqTH2iEBlYXEWGx2HrSC9yeIeVdxyELtYBcdR+PvT7pPKuFEA+R+QG6Z7j2qvbsXjeJwRIW3gHp+FXYkEkOJTtIP3j1B96aYlo7siRfPikXcQjNyPQ1StoNxlglk2uOhbqMelaaLiSSSLHmZwyngPjvVSYKLj7QfuOMMPQ5pp31LvujMeRoZmDsDhtoJ5zWDqjKZApzgYZM10tzaETh0fKSLkE9jWXqVszyACMIqr6fxe3tUyuVStzIS1HyBgxCg5yP61t6fJti3jnB4NYVplfmYnn72fWtK3k2DbHu56470RfKzpqR5jo5Yree2DAKJHGDznIrFXdBFLAQrODjGeq+3rWjEokhyPvg5wOKhaJWOGXDr3rffU40+XcxUgMU6LjaGGQD3xVhEPmJtw4PH0pbq4s4hIm/FxwNp5y3p7VG8vkzqQpOVJA7MuOv1zUtKO5canMaDHfGpUEMpw49RVJI45plVCVbqp+lIkkk1us0K/MBk89ce1PVHjYKdgJG76VWrNFZKxtaTOJImWUYKkZx61ptH+/QswA7EfSucgJjvFCZAfoOoHtmt+1Vk5b5VIzgnNTYwqU7O6NFQhhDEZbPJHFIsAJG7OTTEcSIFZeR37GroIKkoxcAbSKWhyy90qXULRrycIPSkUKCIyxbjIFWZC0kWNu4dT71FbqoYcYcdFpdS4v3RhxvVipzyv0pF8oI3cMODnpT9299uP8AdIqBoXV8YG00pOz0GmmRyeWIXV2XZsO/JyNuOa51baGTQ4bm1bUkW2LCJ05k8snnAPVcdK37mO3Kywb9qyxspGRkDHJrHhudTt7UWsb6W5UCNbgz44AwCV+lOL0B2NTSZbaPTbeOyDNb+WDG3dh7+9FP0ezS20yCC3kEixrw3949z+dFMS5VufNUJYOEyAoPBHOauWkQMpYrz1Y1lQnG1uhwPzrbsQXTKnOa6mjlWhOo2Kyr6H8qST5JI1JBYsCD+FTsoba4z93BoEWAhbllIOPSsmdEJXOd1a1kstSF9DC8in5ZFUZKkjrU+yf7N5WMWzR5dU+9jufwroWhF0Czjauexxkf1qGTTVZmTDZBKsQcZFDbex0xcWveMnSLk2ukXLtsJt0wpIO1s8AfWsrRtz6hEwiBw/mZAw2O9dZNpcK2P2cKCxkyy9Bgev6VZtrAW6xLCi5c4A7k9KfK3uaxnCCfKtzltQurpbjyfLC25l3BI/48+p9aZMskjIyyeX5j4EKjritbxO0+m3ciRqiEsUfI3DcMDiobeJJRFcKyuS5RoVX9c9jWUtHY68NV5oqVivKiRXymMpJFEAjKvGGPJJ960ZlDIkxSXBOCqHhwPc1Tjiskknklll3liwCfdb6VpzxRzaPLNCjWyoAGBbcBn09jUJ3OlK1vuuUE1cyXAcWfkpKTG5AyGXpg/lTbtbldTSzCsVk/eRseAy47ewq3oMsVvb7mt/MIkBdd2QvrUmueadUmkvGlcxqGgkRQqovZRSumrjUeSdrdPvLlo0crRoxywbcDjAUYxj3rIsLljdTWs8mw4byyvGR6EVqRXaELcRLkdDuPX2Nc7LzqTSrG0chz0GQPWqcrWYowUrp/0yhZvJbaoY84ZJCSe/T9K6G63SW7GV90W7CEAFiT9ayLxRDrkNxa7drIrMTwM9GrSlYG7uIWfybaIHCKOueevqTTSM21K1uxmXOnz210XjAMEYVmOc9e/wBK7m6TGjwfunQsBLFuPzNjrgelYN4EutC+1NLI625EbgLtZs9B9PapdN1S5a2xcRSAOAqlzlti9MeneqVrnJXjKpafYnvog8SXEeNrjnHb0q3od60qtFMMSx4VyRww7Gp7S1jMckA+YOnmRVSk/wBElWZRhVG2XHQqf8Kwqxtqjng+aNjdaXavy/dHWno5fB4yelVUYuqkMGjPIYelWkxux0HUGsb8zKjZaFlC24rkHHFXrT7wbOB3qnCEDBiCPb1rQtQvnIeCGOAMcD604sctjXtYtzhk+/8AeC/zAqzuIAkiPf5lP9KqQxNHKN4PXKnP3astxKXYEFjhh2z611Rbscr3LhnRowNx2sMg+lVJ4wzEhfmHzAjv71PGqEgjhs8jHDUE7cGRfkJ6gdKq9wi7PQzoQrNtkQEnJH1ppj3FXQkSRjof4h9K0bmzw6sPkJXdg9H9waz5C0VyrnJjcbRxyPrWMlZmsZKRWvIY4H+2qgycCUDuD3H0qxbMv2pbdmBikGImYdeOmadLuJf5SEPzcjj3FQ21ukcL27geWT8h6+4I+lPqDWmpHZ7ftcltMWCEEJkfd9qiINpcCLfu3ghWz99R0/EVoGNJLdHJIYrl2HXcOh+tVxbPd7t4/wBIiYH2x6ijyBO46CZLO5WYq6huGAHAb1/Gp5o9lwkkZAXPzrngqfekjUTNL5g3bgCVPXIqzaw+fAu1gZFBC+6+lJa6EXC4tFKRiPIGcq2eQfSiZ2eMFlG9weD6jsauRKn2MqvKYyhPb2qGdA8SllyvXPoRQtQT7jCplgWRRjPysM9KrTqig/LvTOHX2PT8quzIVx5eCz/OQeMjvTLiFIZIpFUPDL8rDPI9KdrDiyhMhyIyMsv3Gx1FQXG3ACPvC8up6471aP8Ao/m20rHcmTG+OlVLra1qtwwAkYhTjPNNoqO5k+XGJjChAY5ZcnqM9Ku2g/eJ6dK5IXE41Rg+TGrfNjtz2rr9GupHmkgugEuhgbgOG9DRFJq7OmV46HQafCpX943APboKlmhWF95OYZOD7GnQRkoZJGCkcOh6fUVfSENYOsTKShy27qPpXQkcUmrnL6lHYLMjyQo0z87guMfX3qM2n2qINEQxPGPpVfU0aSRmjGIw/OTjJHWrGlK63JWLcChyV7gH2rN3kzadLkipR3Kv9mPCitnBB5wccdxT7aVrjzQHQqsZCoR83Xk1rM8EqYY4OcAHo3vWcLNre+ilRAhzls9GBqkrGcZORasYiIAIiN8eCwxgt710K5eFlOCUAPHcVl2iiS6i2hhjLZ77fStuS3CcqSpZcKR6+hqJaF1ZbBboHUKwK7uhq7GghRQCeu0nFZ9hNKVwcEZx7irQmc7kOMg/LU30Oape4ithjGvChux61DcSKsigkK444PWnKVDFiSctjpUksMKyxzDBcjkHtU20BaDFkVBtB5FHmLJII/4DySfWnsuYyV6Eck/0poVCF2Z355BFNoatYp6rZpFHLdCOKRljZdzH+HuM9hXLxwiXTxdweGLcxbd+PMGSPULiuxuY0uIpYJVYxOCDj0PWuRa8aDFlDrlmsA/dGZomLhem0sPlyPWhIl+Zq6JqSSCC2azW0SSHzYAj7kdB2B7fSirNlo8VvdW7CcSWttB5VuoHPPLMT3z2opvyGkfNdxEVcbCNjMCMe4rYtIykJMYAqgwIk2OBhcFTjqK1bXHklSSGJ6e1d0onCpMtRx+ZDuPAzjFAUqRuPORk+1KCdhOTgc/hU0kY3r/tYIrnnojqplqKE7G2KDHg9e1PjXKysWxtw3PQ06JMIFY7kK7j2OakghVZlUqxVlKexxyKm9tjrhG6K8rB/wB2BhTG53nuTS2AZ7qzJG7yt0mPXAyKmOXW237QvzrjHWs7zfs7vlwAD5SnnvxWkXqVOPuDbiOPWIL2MhWuZHWVCOCshHr9KydPspYYWQxK2Hw4Vxkn1ArYe1F7cxzQRy29pbfvJXXAUEc8n146VhXJ3ai93C7fPJuZivJz0+grOrvcrBapxT0JbTS5L/UktFKwzlSUQkdPfsK2NJREhlsJWR5ZFBZOykcA5rFunaO+kYSB3IDkn7q+2altHAd5rMLGxGH4yTWKaiz2eSpUjq9CjcWZh1GdGUrsbLbWwCfUGtySXfaRtLEbi235A3coD7VHPbm6R1VBOSpbDH7xx3rI1S7msLRYACplb5Wz90AdvSlH3WVUvNKz1Rb8RuEdbaFVSBG3JsPzknqRWCbsO0XmYO1tvGQ6jPc/WtbUvMt7CB7t5kmb5C2PmycHNc9clDaqsMWAsjEueSwPeqerMITTijalX+1rXyYImL2zb1izt3r/ABc/rUcU8N0gjJK3kedmRkMc/wAVSSWN4LqO7ggaOzlILuflHOAQBWbes8F/dwiEfNIVGR1HTFW1ZanNTac7RZr7mks7m0nYl7nEeGTaFbsfwqgLG7tLordtKvl4UFskY/wqTSn3XDy3j+WRtCrnkKO/1ravgb2zHk5ZyuDtGSSOhNJLS51e15Xy9yzZXAS7t1h8xliG47z2Pv6elb0sEclzJGQPKfDLgZBB/wADXM6C0bpLEoEuI/nPQgiupdm+w2kyLjqv0qt4tnk1I8tRpFDTh5MptnIA5Kg9xnkVsRr1GAQvHvVTxFbGOCK+tAGlQh2A9O9W7SRZIw8TgxyAEH61ySXI7A9rl6KDKlgvydGb0q5aJsDZCnPBHt61VgcIMlsqTyM1fCbWUx/dPKk9/ajRmbky9EcKFUglfuk9/wDZNTKd/LA7cY57VXsDG7Ip++eMe9aCw7FLg7uzA9DW0TJuwlup3LFkAYyPWp9rFCwwVHUVWmcZjeJuP4G9/Q1fDK0S3GNqk7ZQP4T61pHULNajWYxRIrKZLc8gA8r7r6H2qlNCJHVwy4zgk9Mf41rzI0cCzwlSM/vF/hJ9fx9az54o0y8Z+Rzgo3b6j605K6CL7FExYMls+44IIPeqy7kjeK4XZJG2YyPXtirUqymaGfldpKkf3vaq10k0wJiGTEMqB/Ev/wBasTZC2gMnnSAHCNlkx931/Oo7phE0dypJh6BumQexrUhiEsRuIOHKfOvrVNovMX7KxAJXzEyP1qtkJO7IoXEziZWKDGd/Q5q5CAiZiGGB+YdifWoEh3wMrFcqc7cY/Gr9iF+0KjoSGXDe3vUoH3JVxCfJbo3IJ7ULb7XZWJMb8j2NPkiKzBHXJQ5Rs8EVKygLIckArjHvTVzO9ijPuYBD8ssZ3c96g4NshO4LuyoJ/Sp9XYmNGbOAQGx1BqrJF5UQOS6ZDBFPY96TfQ0ixmpL5ksMwQ5HySEfzxRJB+7lQgMjDrjgj1HuK0XiMblgMxOuSc55phhf91IhDRv93ngH3+tW2TzWsjmZ9KgTZKkZyr5ckZBzjBptxZzRXSSEqWf+IHFdFNCId0fzbJeTn9aqRxEWYEjBo1baCR+VJ6myqvdkVtqM8a4uI2fyz8xQ/e49K0EnuGSX7P8AKGUZLDBKn/Ci3eNpoSVXeMxnHcCpZBuOFVigOA3dR3Bpc0kiHJdihMjG5ZGBKsOh5wfrWcxntblpYSpDrsdm/wA9RXTvb74uPlcEMCOlV2t4pWaNUJy4yrDGOOo9qqLcdzSNTuY9mlxMrAxfvEPyFTwfbB9a1LO2aSMby4Zm+Uscqo9D71YgtDbvuj4jY/Ix9R71oyIII1IBXcdzKvORV8wTqLoJp8KDcS0bNyQwGQf/AK9XyirAyvkgjcOen/16qqiJHtjGUB3YHUg9xUojYZRz82NwB7ipuc07tkCx/vGZTncMknsaarkFi5XcxyM1NONxPlkgY5BqCPL543bl5HofUUrCJbQqjuOW54B9aWRSJ3ziQZDYP61HgK0TEcZ2naeSKdK6CVZN2FHAPp7Gk9R9RsRkTIGXGfu+1TA4dXOBjjHQ5oLLI5OwDsTnGT2pJSqkdDnjb6e+aaVkDIruGWSC6SFyjSRMi565IrEt9Tt7fTIrG60y6+0RxCI2ywZVjjB56EH1ro5pYYfleeOIkZBkkC59QM1Ve9tTblUuYfulR++X0+tF7EtEemRPp+k20UrfvI4hvGc49vw6UVH4VKyeH7J5WaSXyQS+c4OT1ooe4XsfOSnfMSeARgVoWbdEyOhBzWXG65Ib5Of/ANVXLRizZ6gnbmu+RwxWptkEiTkArzjHbFSRElBuYEqAwqRCEjhckNkbCPbFMij8uYKwyoBX8DXPM6qexYtc+cVdsA5FXYtxVcMRIhDfnx/SqSIZArD70TbXFalqWMjN6dsdjWex2KWlyK7hzZRbhhkPTvg9/pXJ6/P5F2ynkON4Xp7Gu4YSySRxMABNCQpznp/kV514ul83UvN3vFJEixHC8Fu+KHpENZPlkdhZzXMvhG/SBC0EzKrCMEhcexrmooozaGJ4WMrZ3Pn7pzxmo7O5vbBLWW1nZDIQJI95UE/7XbpWjfTB5UjjCyIXZRLGN3X+npWjjzxuY4aoqM3Ho2Zc1ul/D5u4eSvyuq5GfUe5FWtHggszEz7miVgCJOMk9sfSo7tJYpN8b7EQljxkKcdfxrMtrq4uWjaRlWOUkg++f0rkejPoKTlUi1zaHUvcRW97JHCrIpY7cDOR6Z7Vpvp9vFqukreKpgO7epXJJxkVzmoSPb+Rc4D7xtdgfu46DitXx9cziTSr5Qyx26h8g5OT2NOLtrIwqwlNxinuZuozi7vfEVs6q65WSNccx/SuMtI2dNx/coD98nADdq6a5ke4uDr9kQ0MyhbhCPu44xis2LSJ7hZZLeFjaOm6NnOOSfugd61epzwaheCdjsdllDZWbyalJJtaMNM3O5zycAdhXG62gh1e7iSVpUMxeBmHBBPB5qrzAhnSKQJH+6XzAdoY/wAzWnpCLqVrFHIc3FspZVIzuX0/CnJ8+hNOiqHvt3KRjaac28qgHGC4IwvPXNby25itnbTpljX++G5Zh1AzWFLDGswhk3I2cyADB/AVq263Go3lvapHhNv7tI05GazT1sdco6J3sjc0VoJ9OvZREsd7LgNIq4DoOvHY59K2dPTzdBlQ4YxDemR055FZfh+2uWe7KxmNrdCigqSXI+tbvhli/mxFRkk5HY8VqrJJHDUs5yaNDTo1vtGmiY5cpla5vSW8kzWLOA0UhC7uMj0rqvDQNvM8DD5Q5Tn0NZviDSRBqqSf89uOOmR/9aspx5kZbSaYibw+McDjFbNofNhMTEsOvHY1jQPt+UhgynHNado7Kwx35BB6VzWadmRJ3RpxoYyvmAg9HA6+xrZhn8yJJCArg/vCBww9cVnQbpihLAvjlcfeH1q3auLVgTkopwwPbPY10QVjnk7kdzGLdiQFe3OC6r12no6+1W4UFtLG0soNtKPklxlSD2aopg6vvs9k0CncBjJjPp9DSrPCIljCgW8udyN/yzb29q1irMtN2L8cj6U+ZF86xmBHJzg9x71nzspdgnz4OUb+8PSpollQSWhPmRlc+WTncPVT61SXBmRGfgfdJHOPQ1T2HFLcfsPzjdt3AYDHOKhtyEkYEqXXDAdmHep7xRcgOFCPG21wDUUUStGs6gExj05Yen1rG1tit1ckgVTI6qCqPkxn0PeiVDvC7QZISGXjqO9JCN8u3ATccrg52uP/AK1aXLsjAjeMpnHc9KfLcm9jMuo1MzPAdrEbl479x+NSLDvKlOJgCCpPX2qVMAMrjMbNyP7p9aYVcEblAIPLA8nHQ0Wsi4sN0kiRFSQF556n61fYeb+8TggYfNQx4ebY6gDv9fSplVVx50mFc4HFJaEzKd1AJYG5yAcn6etQoiMY1P3l4G7jitFrbajgMA8fQj+JfSo1ClwWOw7go3HNJpkqRCkLRt9kkP3sbD7elThZI4Xt3VSoORxyO1SAAsFZGyD1HP0wanu0d1SRCFYfeB70XdyJS1sZskfyKZFyfu5PFMeIRSKHUbJFHy9hV6CXfbzQsV2lsjvk1XtlkVZHf5lB645UZ4pproUn3M/yYxMYnGF+9Gc9Kthy8b5A3hcuPUDvU11CGw5+5xzj7p9apSQMxLRsd/OM9B/s/wD16NjSLT3LFtNhMtnaRtwOv/6qkZPJc4coTg7m5I/+tUdvtYEbUU7flBHX2qeMKyHkkEYIPX3FDuxPckAeNljZlZHJK45Gfce9XAoa2VQCWXhcentUQtxGI1YblK/I/cH3qe1lMQBMfykct15p27k3vqMVC67WbAA29MYp6ypHhWO8oMdOcU+OKUShlI2HBqMwP5gcgKuTn3+lCXUXMhkhCsCQGUjgnpVfmNFKgjDYOB2q3If3QUgkZ4YdjVWJyJmWRmGRkjGaLXFe+wwugyQSWByARUsqpKyDAHmLyezGmReXGHUcFuQT39adHM32lE25IOcjsO1A0+xFFDLGCFHQ8g88fWpRgF2wyqxBxjIq9INm2VgrljlhUAeMtKu5d20gDP8AnpT5bD5rmfLY2l8IxdW0NzImVG8ZwKpro2kxQiJtPtjlt27ZyBmm6pdXGkoLmCCK4hLgSPJIU8ts9eO3vUvm6yzDfp1lknIIuTwD+FLW1xOyZpWUcVpHHbwxRxpgAIOntxRVeHzWhC3kCC4A5RHJH4E+lFK7HufMsyFZCQc5GK2NEQOu0AAZDfUVnzL5bHPOD19au6SzLOMHC4z+FegcK2Om8gJCyEbgCGBFPt4DIctnco/T1/WltcyISx+52PcelWbRlRyMDcvGcYyD0FZyRtBtIZuEcqu4+/hW2+vrVu2RVkKsTxkAg9VP/wBemGM7Ch2n+ND396jLKjLIsm1Hxkj365/GsWdkHcsTfLbWZc5EchVmH8Iz+vSvOPGVhNFq906MTE0x+Qk/mK9JjMjyhGAIPAJ6Cuf8WWrSeaxKqVYeaTkAqR1zU2ujS/K7rzMmOB7ySO3mEUaWlmbjdt4k7/Mf0qLwxqFsL029yEZMM6GM4GMZBHtmquoXsK6RG0LsEVWifyz98dh+FcHZ3MlprMcJuGFukmUlY/dQ57fpiuyjacdDyK14y12PStZjmtbMSS3S/ZrgYDe/YfUiuXvovsZWNHXY4BKgn/P41dstXS8tzpOoFljnKmMkcLJ6n8MVoapZxWNsk16js6DykjUfe7An0Fc9ai03Y97LcfGKSlv/AFYyrTUxZ2ZVhKzsVZSDlQAeQfeu21mOXUvC1s4LRruyXI5wD0yK4WxsvtSiCAETbv8AVkdT7H2r0HwzdSLYTW0oZpBh2Q8Adjx3Fc6R6OIrKU1KK1TOQtILnQryJrjBsZuWyvBU9Tj1qhaecJLmG3mkjtomba244Hp9PwrtPEc9rJObK6hY24B24P3GPpXElWs7qWIFhA58ooTgketOL6HPOGvO1uX9dke6aAJKq29xEsig4yZAOQfRqZ4fhSPU5PNuntniQuoYHLf7ORRqJjbUraxlRmtNoaN4DjG7nPPXFKJdl+Xe5FxG3yLJGOT7H0PrTe9xJNxsaV4LW5iNzLLKGt2Ee9R8zE9Ovaq1heSWF0RHLJIW/eBkyME8fUU6VxYyOXbe3DOowcqeM4P5VTuLe6+2BrZuZuu3qg98UpPW6Lirpwvod1oVzeR2tpbXc8koIfnoMbuAffBrR0VGtr1eRjcU/L/9dVNPjVdDtjuLTlvMc57dMD+tbBiMdwshA2ttcY7A8GtpbXOJxSTSLhZrfWhkAAgEt61f8QWjXOnpIFHmK4I9qh1VNsNlOAjESYJHPFaVoVlgeInaVYcGs5KzMW1pIxxpq3Ons44kyHU9cGq0SmNzuO0dG9Ca39OVre6mtXz5T52+wPaokhjld7SQgeYmQT2Pv71LjczbbuM09kVsbst6Hoa3x5cyeW/VR0P3gP6j2rlLVbmyuvLLLNDJ90NwRjgitP7XC6pHuIQnOMZZD7GqhFJMxlT97QuQzzWdxGke0bWO04yGB9a0Lqxjvlaa0CLMBllHAb6elYU1ygAjucb2P7uQciUfXsabJqMltGs8W7aDtEink/71WmlozTklo0XVuHiXyLhWDKwIJHK+6mnQQPcyO6n99j5WIxuPpVMyz6nbytGA0qLuG0849PerGkXLfZVkRgGH3x1OPWpk76F7IlZfOCMilmZTuQnnNSRxqq5C7V6Ng9DT2Gyffz5TjehPcdx+dNijAnkiLN5LDejeoP8A9ei1ib30IURYgFiJY7ju/wAaddXG1kEZILjoO+OlS+SYZCXwzoBnb/FjvSBVbdC4A/5aRtj86Q9OpXEj+c6yADdyVDdjVyC3/wBFGBvMZ5JPJBqCS1ZkZ0GGA/i5K4rRsQGQlMqpH3e5pWCUktiGNy3Dth846dCOhpNqtOUdiAe2Ohq5LCI41IAIJ4YdaSSCOVS3LZGCO4PY0NEqSZDEfM3JlSw+XbUy26uGkz93GVPHFOhKNtY7RtwrNjnpxUyqJHU7cxY2nscfSlYVxHQKArEDaeCB29KZcziSUDyxx1J43VbSEzvGGJJxhh05pJIhs3BcnGD6ilZmW5QithbxvgAnHy4p8EYjkQsuzchDc5DVI3Gz5iUcd/UUs2JbdQP9apzn1FNbBrcoToWiCqQ0fIK9wfSq0yspQrkrjay9x6VduCqtvVckjtwMiiRT5O1gc4DbemR7Umr6my0RStImKvHvzIG3BQO9aakTIQ/yOBwQP1qCP/XRoMb2HXpn/wCvUu4LckKxDAYINCatYmT1LcB3RhAd38X/ANc0qNt3o6knBz2BNNLLGwwOOCxHQ+1R7h5m9shAecn8vwqyUTlg8YAcjoR7Yps6FFBByWPr0qrJISpVSQozuOMflSCZtuGYbDjH0pXDlFkf94zMCsYIJA6H6UjuozwWT7occUNLEyANghHIK56j1FQyAbCT8yMSMelIaXcnmVZo1ToQc7sEEcdqrxqS0chOHA+Y9KnIwqFCScjB649jVe4LLKQBld2SD6e1UmhLyLKv5rlcFVP93nFRSoAQ4UHI2nj9fapiMRxvGAq45yc1G0qk4C4PQ570NjRQ1W+s7MKt3cRxtKD8koyGHfjFMHiTRhEqrfwrgYAbOF/Sm6tHby6c7XMqwbMFZWIBjYHgjPeo7fV9JuHVPttqZWXA4A3H8sUkGpfW8+0NFLasHgfkHqCPWinIrxL+8G5SOcDgelFTylWPnNgGjjOByCuO1P0/9zcJnAGcGrEMQdXj77d49/WktoPmJONoHNdyOK6OmsQpALHIYYJWrTJ+9SX7xI2OPb1rL0yU+WV4DA7So9a3raPcuH6qMZ9qTRtFoYkJSVdmNw7eo71G8caFoZcbJAdhHT6ir6o6SNHgl1GUYdT/AI1UuojLE5hViU/ep/7MKzkjeL1Ej8yO2zhvNjI3Y7r60ahbmaNHUiTzE2Mp6Zx3qdSqpHMuTHJ0Hseoz61KIsQG2LEL1Rh29KS00Nea55RqxGkSOj25aAuHVj3B/rnimS6Lp06i7kjxFMRhGJG1j0x6CvQNWsVNrcJMiuu4LMhAIwT94Vy19YyxhYIMPCowAeoHb8qFL2abRnUpe00OS8Qn7MY0uLYQxxNiIqcgg9s+v1rrfC+sPf2hsL12lWVBDbSSEYVuwY965/WZm0+/2ebJLp0mGyyD73cEegobRYbqyafS7oAxneUjOAD1G3NdMaia1OGdB02mmdPbyQWF0sN9btZ6hGH2x5wrL61o6bfx3EJn09zHeRYLKxJVgTzXNS391qENu2pO11LCNsUhA3xn0PqK1bWeOAqWnRI3wrG3T77dx7VyypvdbHq0MRGSs/iJtditrzEscjG6DDzBjgj2qlrNhaS7ZLScebAAGBThuBg5qe+gMs1vfwOrLMD5QPfHGMD+dNvIpo5YlVlWYjr1A9jWMbrWx6clGtFcstUctfy/av3ygFwcNtONpHp7Vbs7h7fTFW3JSSWf5pCu7Zx/D/Wm3cssd2y3TLasgIliUcZ7Zx61YvZLeS1s4rNmXO4tH2Yn1PrVOLV2ZQqppRZKsUEjzTzMGuWIjmZORtz94fyqz5EK6hCsxkiY4XKdJB2zXPWUckUhYLLEmCMqeVznIPtWz4dNy1xC8rM0UEgVi3Ix1HNQlfYcnyJtM9C0uH/iQxO67PKfyyPY9K1GV7vSYdoyY1ZPQnHP41DbKz6JqKspyVUgdScHcP0NbOjWy3dpcRIwYPFvQr2OP/r10PVWOGU7LmfcegN3o0aoFBBySR7VNp5+aMyHCt+7J+nSodJgefTmt8r5gPY4IIp8IDz3Klskos0Z6cgc8elR5syXVXLF8xiaZsZeMAqR3I5/lSXilp7O92YUjPA/nU0SiVVVxzKm0HvyOP8ACotPkEummKXquVYE4wO/61LQJ9STULcSQo6BRsbeMdTnpms+U5ENxChVkPlyoB3q5o7+ZDLaTEtIpIVsYyMdahtyEupIJTtjmHRvyyPxoYlF7PoNuLP7TahIDl4vnhb1Oc4/pS26wT2T70xBcAg5/wCWbnp+tXNI3IZ7WXaJYjlCvqP6VUWANdy2cpHlXA3rjqp7j86VkU9dBmjGa3uWjbK3UXykDox/+vUuUtNSG9QEuH6qfWoNTje1WC+SQ+ajiKVs8k9s0zXAZ7B7i3ZTLCRMoA5AI5H0zQ3oKOr9TWmBhke33MFQ7kB54PcCrCu7R7yFDIQcDt6/ga56O6kuNPt70q29PvD+Lb0NakF8FIDsC2PlJ43L1H49qaempLjY1HLMqSx/wc57Ef8A1qdKmPKYqo2OGUqc4B4NY9vqSQ35jUgwtgrk5HPJX61ct7uITNbBhsfIQkc49D6YpKSYOLRoeYp3IQAJlKFfcdKS2Z1VVKgOh5OPWkyXiQHAmhYEZ4yD3pyFRICpdz0K+o/+tV7kPYs7tqOD0PQZ+6arLMqLA+M/Nhsd6squw9mibAJ64qjct9lDB1Hy/OMemal7ijZ6E13K6+YLaPI756FcfzqUSSKIJd3ySDacdR7VBCvkznLq6v8Ad/HoKvwBFi8p8bUbJJ4NLqU2krD4HZIsSc7Dwwpz5ClWPJ5561GAgKhiNudpBPQ1JO58ohRzg5J7UyHHXQjK+VCQNhJ4NVZZGjERBUDGMgcCrrBkKSOSeByejVBNbqcPHkI68g9AaQ1vZldR5glLqgXrkdM00I7tDuDEKME9PwqeGON7cYJCkFcjsamkyXTeeUxn5eGFIbdhphRonKqNyDPv+FMkMcj78KjIMMcdff60twRHIjRtjtjsahnbagPI55DD8xT0I1JpMNvOQU25wOOKiZg6ZBOQeRjPFMQkRZDcbuR7U2E7WKIQ6ucjsRntTuUhdyBAgjyR0yetNmZPsYkRMurfMp6Y71XnkLrLEQyJ1UggjPqDVWOa4YkFtuBjYR3HrSuk9S7XL0KCOYqCxR8BePu00jbJgswXkHHOT9Kr3bg+UyZ4+Y4OCD6/SpftLbirMNx5Jzgn8aSCzNDYpjBGeBzg9ajnAcoc4b1HQ1EJfNA243Y+8D1p7tHtDEbnAwQGpsjREpbYqllG0Nj8aS4cbQ5XJBPUdfaomdjEynDMcYHSoTlYyvmF/XNGw7dTG1dgb+0uZLZrqziV1ZEXcUY4w23v6VDNqmmXEYijsJbgnK+UbXB9ue31qjql1qI1ODTdPfyi+6WRwATgemfrT21K7t2SDUXAd1P2e6UY83A+6w7NRdWLcbM39GWW00u3gupSJ0QBxncF9s9/SisrRrl7vQ7OR5D9qkjGSwHJz1zRRr0BLQ8djl2SKMjcvcdKuogEYYEiOQ9cdG7is9TulI7A5H0rQsZN8LQj7r4dST/FXajgLtlGFkUtnDcBgevvW7ZyskjxkZ5wayLBA67FzuHrWnGpQsykrkfMM9feguO5qpumWKRSBJFzj0+tPMJWbcpwjfMQexP9KbDL5yrg/Njp61ox2yGMKWwxAALc4NQ0aXsZSx+VNNbPjym+ZD/dY+lQySOitA64bOVPXB7VqXSiNVyuFJ+ZQOjelUr2Mk+XHjzQuVP94elZtM1gyMgzQmZY9x2+XMh9PWstbEI4ZBieH5hn+Jf/AK1acExRZHYH7u2ROmR0z+FORPlUqdzw8n6ev0qW7HVB3Of1DSra8jdbiMNFINpYDGCfpXCXXhy80q6Btg0iuSjITjK/XpXrCxxiOSWND5P931U/1BqFbSOa3MF2F2Elo39fSmpFuCafmeYprNzZp9muoJY1TD+SygZ9Dk+tdCHtdQtoZrUpHNNhncEBUYdmHrVrW9EeSCNlz5gbY5flcentiuWuR/Zl1PbtHNEZRlHHA3eope0ktGYPCRm7x0Z01pNbjTv9KM9vcQyFYpoowyYPX6Vm6wizTqYbmeVHzlgMZwP0p9lPDJp6Ced/OkyrqgyjH1PoaynkvY5JzaOSNu4uy/KB02j0NDqX0aNaGFqKblCRH4jsrqaWG5iiUyMoRQASXAHf3rFsTPG4uDGjiGTbLAfvcev+Nd34TkZXiN4QnygM2c7j61ymtr9h8S3xkgYRSyFSRxhSaE1JXRU6VShPlbuWJogsf2x8iKZtyICduPetzQpo7zSw+2OJ4xtyBwzA+n09a47Smvi96LOPzljHmh8ghVB5XB9a9C01Le8066kZ4rGHbnzGy37z3A7elVy8pyyqbX3TO4trhbcWU0i74nAhkXGOnQ1R0rVLj7elhZIwEcroZBwcE8VasJ1uvD8BwpKyL83Y+9SssVtr0MsLLukGWOecikpLdm0o8ysTaRLPbtMxYnZJ84ZsYBPH61pNtgvbS44ZQuwqevUj+tRCCI3rKW2JcRsCp67l54p8avd6Sl0cFrc+U4zg7T0pGbSvoTsPKCTc7o5SjY6YzxUdrKVvLq24ZXkLJxjPGakvyYrWFYAzfaoij5H8S9/yqOecx39q4AP7oHJ7jHH0NS9xpXH3MsEWo27RqQs0YWRT0z0FQ6jCYZklchmQcD2PBp2txtnfGQZVRXAHpnmrU4N1ZQ3CqGJUxsM9Ce9Te90XFWs0RXrRxfZbyHK70CsBzzS3ifarQXUYIlik2gjrn3qGx3fZPLO4hDuC7eQM4PP1qaxjaG8ltrkcTjcGznJI60r9ybWQwx/bLVpHC4ceVOjHkdg31zWNpMkz3d1p52nyS0YbucjGD7VsTSCxuWTBeKRP3mD+BH9azZYUt9djlUFRKoO/OAx7EfpQJPRr7izot6IbM28oUOP3JBGAD0rM1m6kgjSFHzG5yox0PfmrOoRNCL6YRh3yGIHcdyKgBTU/LhlcIrDenGSrVSs42KhZS5x9kYyo3A7CCPoe1aqq0sXmKcEruUjr9KyLFvKm2z5QA/MuehFdfp7Q4RVKmNume4q6aTVjStOyvYrR3Rmto5QP3qDDD2q3GwE7eWMCRFZTno3pWTKRa6i6bsYLExtwGU9RViylaSMoVBcKTG3rg9Pwqb2ZzOPVGyWLxyRMD5hHb+GopE8xAHUcLtxnOD2qkLhnIkiYqwHQ/qKfFLIrjygCVUMp9V9PrSbuRyNajjjyFk3AvHjcM9V9avCTzZyIWDAqOv05BqmjIZFYjG/IOR09cipgjKqqCA6tkf7Q9aQ9yyxAADMQuMEgfrVuSSOWCN4nyQMH6e9ZkkwUneCySd/Q+tQ28hgMioygOPujv7Um7aDcbmojySM0UvT+AUSzgArGrAjAOeQT61SimIkTZuyem88A06KZd58wgMR1B5GDQhcutywZcqWVSpxkgY61HE6LbsTufLZB9KqrdgSAbcRyDhl5wasQ3A2eWT3wSBkE/SgbWg9UO5gACjLuHqKrT5aU5clDxn1NSZaI+YBiPIB571HvUsXIIUdcUbhZDIA7ytvKrgZx6+1ExRpAwUOM5AzjaaViMsezddopDEwC7sFH7Dpn/Gi9hWRXdiZy6JhFHzbeh96iiT7O0jfeU8knnk9/pVlD5Eowp8ojk9qd5JaPAA2YOOeaB3KksqLIgjcKGG3AHDCgCONQsi71zw2Pu1E0WQpGOPXsfWkcKjMyuUJ4BJzyKWu47ovWyrBtII5PU9Kt+ZGq/NuLYyTjqKzbcARKjIzBTkgdj7VK8hYNtONvCkntTTMWrsS6QZBVuG+6c8g0ySQxKN2cDhSepqFp1ZuFD+uG/WmtP+9Hz5UDKn+lJ6miTsN1C1ivWXz4FDKwaNwSjA/Udj6UX9qlwpgu4keF8AjsD/snsay9d1CZEKwsYwE8yVlXLKucYX/aJ4FV75ZLeK2W3luxNMwC+bIZIw2MhXB6E+o9KpK4G7a2kNnbrDETsiXYpPOB70Vn216s0EEgBAkXJ9vUfnmilqKz6HjjoAqsOinBHtWnY4Z0bJGPbp71nJ0b2JA+lXkGHiI4PHSu44kbNuMSrKuT83zex9a1nT5x0ViNyM3APtWZYgfaFHY8EVqp+90ol/mMchCe1C1ZptqPsyYnBwcMeVH9K14XDbN5wrcI/wDQ1nTgfJ/ug/jU0B3WsmecNke1I2tdF17hVuiJl+V8RyjqPZhVOWFYpvIkOHLZicDp/wDWNaCAPFDIwBcADd3p2pRI1gGK/NGxCH0rNrQE7OxltCbiMsqkSov7xD/Fiqi2+1w1mf3mMgHpIO4+o9K0XdgtrKGPmEEE+oqncKBe8cdG4459aiSWhvBtBGrnEtoSQAdyY6juK0lSHyU3xf6LLwQvOw1DbfLexovCyHLAdDxViElpY4z9xo+R64qUauTaM6aze2aWNwJ4XG7K+nr+ArMv9NWWHyWVbiM4YHHzIPat+wYtdSRscqsZcA9jnrRc28Qa9wgGxA6kdQfWhvQu9ziYtAsUuC8Us8R5+QYZRVqPQ91uVdreSYA8yHyxIO3B4rqNas7eOLTJY4lR51zIV43fUVk2iK2oTQsMxAnCnnFacqJ5Wlo7GHJpN3ZwCHyLZlC7g/nBs+3FZHi/SI7iKLypommMSsdpPUfwkV09yoClgMEPisqZQ2/IH3zS5UloXLmk02zzbR7mfS9V+a2EglzE8TNtyD3Fem6Jax/2bcMyB5pOrDtgdKxpIo5UMskaNIGwGIGQPb0rotJ5sXz/AHDSepzuKu2augzD+ypYW58vGVA71a1WU+ZaSpgHng9yP6Vi+H3Zbi4AY4wf6Vu6miiG3cAbix5/CpWxqnZmg86/a7GUDZGwIOT0bjNTWzbFvIicBmIYY49RVWQA6RadfvetTDjVbsdjGpI/CqtqRuaHnKLOTcCfLPykj7pHQ/QinXYDSeUvyrgtG/cAj+Qqnp3zz3qP8y/Z84PqKuwcrpOecsR+HPFQ11IW5Yu8Yg3MqCWLYWBztI71nafKyNPZsM7cMAO+P8auAAxQZAPzEciqlu7Lr1qQeSwU+4x0qXoaQfujYnkt710jOWLnr0ZWq5qSFbASsT5iqVTjGCD0qxcwRLMCqAFTge3NF9924TqpZcg8ipS0Bu72KlxE1zChlI80AEHueODVDUVF1pIQA+daPnPoM1et2PkWRJJwSBn8abaxq8t+rAFdvShENWK0qm7sI5k6FPLdT0x2NUFUBnjVWAicPG564PBH1rQ09mbRLhSThSoA9BVKNQVjY9WlIJz1FPqibtXRX1qSKyEVxLLsVzhi443eorR0y/juIYnilUrjII9a474gMxhs4izGNpcFc8Ec1u6NaW9vbkQxKgMK9PpVRdnZHRa8Fc6S/hi1F4vMdFdhjJ4GR6ntWTN5un3kaSyFSpKrnjJ+tPhYmIgnI8s8HmqmsqJtKYSZPCNnJBzn161UlfUUdNOh0FvNukCMSBIvO4YG4VYF0ibQp2FGywznjuB7VlWjHyY8knGMZ57VR8VO0NrPJEdjiHIYdc1AuVSZ1SOlzvxt+Vtw9ae0iOo2P+8jPHuKx/DUjvpVpK5zI6ZZj1PFXmRVScqADtzxTWwnTSuW0YSL5f3hgEk9cVUddkm6MbSh5J7rUWhO0ttmQljk8mp7rowyfzpNJkXs7ElxM6gKVDAcgt2NV1dri5O/YGT7vYHPWqetO0WnXUkZIdIMqfQ1z3hO9uLp1a4laRmTJJ70WT0CKudpEDvEboPkYHGe1WofLw0inGD19KyowBMpHXb1q1ET9nk/3hSQpFyd0diwOFI5OM8ihWj8lXJGG+UGmj7g6dKrXRwcDpkcUWM3sTPKGjKIvzDt60yEtNFskV1fqPeo7EfPOR1zRcEhVAJ5PPNPckkaQ4dX+4vcdqrLKy5cnC9sHrTZWITgnrVK2ZpF2ucqHIANK2pe5cmkUxsFJHOV29jWeHJbyQTsbksRyTTbt2LbSTjB6cVXuP8AVo+TuBHOaTdmVE0IJiAQCS/Tp0qXcucO4dm4B9azLVm25yc5BqfpGpHB3Z4qnorklt/L8vaWKYHy1AZk3/vQpAGMj+dRXLH7IvPUjNU1JLAnrtoBBqsKy/vo0eSPYY5VVvmK5yGX3BGcVT+1yTSITLNeSIwZE8jylDDo0jHsPQVqL/F9BTZiTLGD0x0piaJtOhSK0jg3JJtX5mU8k9T+tFInyrheOaKLIlux/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tense bullae, erosions, and crusts on skin of patient with epidermolysis bullosa acquisita.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_36_22085=[""].join("\n");
var outline_f21_36_22085=null;
var title_f21_36_22086="Cholesteatoma extension";
var content_f21_36_22086=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F64096&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F64096&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Paths of extension by acquired cholesteatoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 417px; height: 419px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PS: posterior superior quadrant toward mastoid; PF: pars flaccida toward attic (pneumatized space just superior to the middle ear); TS: retraction at old tube site toward middle ear.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Isaacson G. Diagnosis of pediatric cholesteatoma. Pediatrics 2007; 120:603. Copyright &copy; 2007 by the AAP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_36_22086=[""].join("\n");
var outline_f21_36_22086=null;
var title_f21_36_22087="Overview of hiccups";
var content_f21_36_22087=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of hiccups",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/36/22087/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/36/22087/contributors\">",
"     Anthony J Lembo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/36/22087/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/36/22087/contributors\">",
"     Mark D Aronson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/36/22087/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/36/22087/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/36/22087/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hiccups are a common and usually transient condition affecting almost all people in their lifetime. Rarely, hiccups become intractable and can lead to adverse outcomes.",
"   </p>",
"   <p>",
"    This topic will discuss the pathophysiology, etiology, evaluation, and treatment of hiccups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A hiccup is an involuntary, intermittent, spasmodic contraction of the diaphragm and intercostal muscles. Muscle contraction results in a sudden inspiration and ends with abrupt closure of the glottis, thereby generating the characteristic &lsquo;hic&rsquo; sound. Hiccups often occur with a frequency of 4 to 60 per minute, remaining relatively constant in a given individual.",
"   </p>",
"   <p>",
"    The medical term for hiccups (also referred to as &lsquo;hiccoughs&rsquo;) is singultus, derived from the Latin singult, which means &lsquo;a gasp&rsquo; or &lsquo;a sob.&rsquo; Hiccups can be divided into three categories based upon their duration [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22087/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A &lsquo;hiccup bout&rsquo; is an episode of hiccups lasting up to 48 hours",
"     </li>",
"     <li>",
"      &lsquo;Persistent hiccups&rsquo; are hiccups that continue longer than 48 hours and up to one month",
"     </li>",
"     <li>",
"      &lsquo;Intractable hiccups&rsquo; are hiccups that continue longer than one month",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1999149430\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Little is known about the incidence and prevalence of persistent or intractable hiccups, as most studies of hiccups are small case reports. No racial, geographic, or socioeconomic variation in hiccups has been documented. One case series of 220 patients with intractable hiccups found the majority of patients to be older men (approximately 80 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22087/abstract/2\">",
"     2",
"    </a>",
"    ]. Many patients in this study had comorbid conditions: vascular disease (20 percent), postoperative state (18 percent), central nervous system disease (17 percent), duodenal ulcer (5 percent). In another case series, reflux esophagitis was the most frequent comorbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22087/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with advanced cancer, 1 to 9 percent have hiccups that are persistent or intractable [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22087/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hiccups can lead to significant adverse outcomes including malnutrition, weight loss, fatigue, dehydration, insomnia, mental stress, and decreased quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22087/abstract/1,5\">",
"     1,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact mechanism provoking hiccups remains unknown. Hiccups involve unilateral contraction of the left hemidiaphragm in approximately 80 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22087/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several neural pathways make up the hiccup reflex arc [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22087/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An afferent limb including the phrenic and vagus nerves, as well as the sympathetic chain",
"     </li>",
"     <li>",
"      A central mediator",
"     </li>",
"     <li>",
"      An efferent limb including the phrenic nerve with accessory efferent neural connections to the glottis and inspiratory intercostal muscles",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The central connections are not well defined. They were previously attributed to an anatomic location in the spinal cord between C3 and C5. It is now thought that the central connection for hiccups involves an interaction among the medulla oblongata and reticular formation of the brainstem, phrenic nerve nuclei, and the hypothalamus [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22087/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is unclear if hiccups have a physiologic role. In utero, hiccups may be a programmed exercise of the inspiratory muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22087/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hiccup bouts are usually caused by gastric distention from overeating, carbonated beverages, aerophagia (eg, swallowing with chewing gum or smoking), and gastric insufflation during endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22087/abstract/9\">",
"     9",
"    </a>",
"    ]. Other causes include sudden changes in ambient or gastrointestinal temperature or excessive alcohol ingestion. Sudden excitement or other emotional stress can also precipitate hiccups. Hiccup bouts can be induced in up to 40 percent of healthy individuals with inflation of proximal esophageal balloons [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22087/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intractable hiccups may reflect serious underlying disease, such as an infection (eg, meningitis, encephalitis) or a structural lesion (eg, intracranial neoplasm, hydrocephalus).",
"   </p>",
"   <p>",
"    Potential causes of persistent and intractable hiccups are shown by category in a table (",
"    <a class=\"graphic graphic_table graphicRef82395 \" href=\"UTD.htm?12/47/13053\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H163445842\">",
"    <span class=\"h2\">",
"     Central nervous system disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central nervous system causes of persistent or intractable hiccups include vascular, infectious and structural processes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22087/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. These conditions are thought to release the normal inhibition of the hiccup reflex. Vascular lesions (usually arteriovenous malformations) and infectious causes (encephalitis and meningitis) are the most common, followed by structural lesions, which include intracranial and brainstem mass lesions, multiple sclerosis, hydrocephalus, and syringomyelia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Vagus and phrenic nerve irritation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Irritation of the vagus and phrenic nerve are common causes of persistent or intractable hiccups [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22087/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Causes of nerve irritation include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pharyngitis, laryngitis, or tumors of the neck that stimulate the recurrent laryngeal nerve (a branch of the vagus nerve).",
"     </li>",
"     <li>",
"      Goiters, tumors, or cysts in the neck, mediastinal masses, and abnormalities of the diaphragm that irritate the phrenic nerve.",
"     </li>",
"     <li>",
"      Foreign bodies in contact with the tympanic membrane that irritate the auricular branch of the vagus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several of the disorders below likely irritate vagus and phrenic nerves, which can lead to hiccups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H163445849\">",
"    <span class=\"h2\">",
"     Gastrointestinal disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal disorders include gastric distention, gastritis, gastroesophageal reflux, diaphragmatic eventration (protrusion), peptic ulcer disease, pancreatitis, pancreatic cancer, gastric carcinoma, abdominal abscesses, gallbladder disease, inflammatory bowel disease, hepatitis, aerophagia, esophageal distention, and esophagitis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22087/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intractable hiccups are also an uncommon complication of AIDS, particularly when associated with esophageal diseases such as esophageal candidiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22087/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H163445856\">",
"    <span class=\"h2\">",
"     Thoracic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thoracic disorders associated with hiccups include enlarged lymph nodes secondary to infection or neoplasm, pneumonia, empyema, bronchitis, asthma, pleuritis, aortic aneurysm, mediastinitis, mediastinal tumors, and chest trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22087/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H163445863\">",
"    <span class=\"h2\">",
"     Cardiac disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main cardiac disorders associated with hiccups are myocardial infarction and pericarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22087/abstract/19-21\">",
"     19-21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Toxic-metabolic or drug-related disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxic-metabolic and drug-related states may cause hiccups by affecting the central nervous system or the",
"    <span class=\"nowrap\">",
"     vagus/phrenic",
"    </span>",
"    nerves. Intractable hiccups can occur with uremia and hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22087/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1999149489\">",
"    <span class=\"h2\">",
"     Postoperative",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common reasons for hiccups postoperatively include general anesthesia, intubation (with glottic stimulation), and visceral irritation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22087/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1999149496\">",
"    <span class=\"h2\">",
"     Drug-related",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications that lead to hiccups include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    , barbiturates,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , certain chemotherapeutic agents, and alpha",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/15/28918?source=see_link\">",
"     methyldopa",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22087/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18038200\">",
"    <span class=\"h2\">",
"     Psychogenic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychogenic factors that have been associated with hiccups include anxiety, stress, excitement, and malingering [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22087/abstract/26\">",
"     26",
"    </a>",
"    ]. A psychogenic cause should be considered only after a thorough medical evaluation has been performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hiccup bouts are common and do not require a detailed medical evaluation. However, persistent and intractable hiccups necessitate a thorough evaluation to determine the underlying etiology and guide successful treatment (",
"    <a class=\"graphic graphic_algorithm graphicRef79155 \" href=\"UTD.htm?0/60/975\">",
"     algorithm 1",
"    </a>",
"    ). Several of the conditions associated with persistent and intractable hiccups can be diagnosed by a thorough history and physical examination. In many patients, however, a specific cause is not found [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22087/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The history should include the severity and duration of hiccups, associated medical conditions and previous surgery, alcohol and illicit drug use, and a complete review of medications. The persistence of hiccups during sleep suggests an organic rather than psychogenic etiology.",
"   </p>",
"   <p>",
"    In the physical examination, the external auditory canals should be examined to rule out potential irritants of tympanic membranes such as an infection or a foreign body. A detailed head and neck examination is important to exclude an enlarged thyroid and lymphadenopathy. Additional components of the physical examination that are important include a thorough neurologic examination (including cranial nerve assessment), auscultation of the chest, and an abdominal examination to palpate for any mass lesions.",
"   </p>",
"   <p>",
"    Laboratory tests to obtain in patients with persistent or intractable hiccups include: a complete blood count, electrolytes, blood urea nitrogen (BUN), creatinine, calcium, liver function tests, and",
"    <span class=\"nowrap\">",
"     amylase/lipase.",
"    </span>",
"   </p>",
"   <p>",
"    Additional testing may be considered in patients with specific symptoms or risk factors. An electrocardiogram should be considered to evaluate myocardial ischemia in patients at risk for cardiovascular disease. A chest radiograph or chest computed tomography (CT) scan is helpful to detect pulmonary and mediastinal abnormalities irritating the vagal or phrenic nerves or the diaphragm in patients presenting with dyspnea. An upper endoscopy, especially in patients with dysphagia or other esophageal symptoms, should be considered to detect esophagitis, esophageal stricture, and malignancy.",
"   </p>",
"   <p>",
"    Other studies to consider in the appropriate clinical settings include [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22087/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Magnetic resonance imaging of the head in patients with neurologic symptoms or worsening headaches",
"     </li>",
"     <li>",
"      Lumbar puncture in patients with possible infection of the central nervous system (eg, meningitis) or possible malignancy",
"     </li>",
"     <li>",
"      Bronchoscopy in patients with pulmonary symptoms or lesions seen on imaging",
"     </li>",
"     <li>",
"      Esophageal manometry in patients with dysphagia not explained by endoscopy",
"     </li>",
"     <li>",
"      Pulmonary function tests with shortness of breath or wheezing otherwise not explained",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with advanced cancer, the cause of intractable hiccups is often multifactorial, and a lengthy workup to find a cause is unlikely to alter management [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22087/abstract/4\">",
"     4",
"    </a>",
"    ]. Therefore, the focus in these patients should be treating symptoms rather than an extensive evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Much of the approach to hiccup therapy is based upon observational studies, case reports and small series that do not directly compare treatment options [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22087/abstract/1,30-32\">",
"     1,30-32",
"    </a>",
"    ]. The specific illness causing the hiccups, if known, guides the choice of treatment. As an example, treatment with a proton pump inhibitor or an H2 blocker should be given if gastroesophageal reflux disease is a likely cause (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link\">",
"     \"Medical management of gastroesophageal reflux disease in adults\"",
"    </a>",
"    ). If no cause can be identified, empiric therapy with physical maneuvers is first-line treatment. These maneuvers are easy to perform and have a low risk of complications. Pharmacologic therapy should be reserved for treatment of hiccups when physical maneuvers have failed. In the absence of data comparing pharmacologic treatments, we suggest initiating pharmacologic treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    , which has good efficacy and is generally well-tolerated at low doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Physical maneuvers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical maneuvers include (",
"    <a class=\"graphic graphic_table graphicRef50687 \" href=\"UTD.htm?18/41/19100\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Interrupt normal respiratory function (eg, breath holding, Valsalva maneuver)",
"     </li>",
"     <li>",
"      Stimulate nasopharynx or uvula (eg, sipping cold water, gargling with water, swallowing a teaspoon of dry sugar)",
"     </li>",
"     <li>",
"      Increase vagal stimulation (eg, pressing on the eyeballs)",
"     </li>",
"     <li>",
"      Counteract irritation of the diaphragm (eg, pulling knees to chest, leaning forward to compress the chest)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The efficacy of these maneuvers has only been suggested by case reports and is not confirmed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug therapy should be reserved for treatment of hiccups when physical maneuvers have failed. A variety of drug classes have been used for treatment (",
"    <a class=\"graphic graphic_table graphicRef50687 \" href=\"UTD.htm?18/41/19100\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In the absence of data comparing drug treatments, we suggest using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    as first-line drug therapy. Chlorpromazine has been one of the most commonly used drugs for hiccups, has good efficacy, and is generally well-tolerated at low doses.",
"   </p>",
"   <p>",
"    If hiccups subside following treatment, drug treatment can usually be stopped the day after cessation of hiccups. Most drug treatments can be used for seven to ten days. If hiccups persist, it is reasonable to consider another pharmacologic or nonpharmacologic treatment option.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1999149528\">",
"    <span class=\"h3\">",
"     Chlorpromazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     Chlorpromazine",
"    </a>",
"    , a phenothiazine antipsychotic, is one of the most widely-used drugs to treat hiccups [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22087/abstract/30,33,34\">",
"     30,33,34",
"    </a>",
"    ]. Although chlorpromazine is the only medication approved by the US Food and Drug Administration (FDA) for hiccups, evidence of its efficacy is available only through small case series [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22087/abstract/30\">",
"     30",
"    </a>",
"    ]. Initial oral dose is 25 mg three times daily for up to seven to ten days. The dose can be titrated up to 50 mg four times daily for improved control. Intravenous administration may be more effective, although the drug must be infused in 500 to 1000 mL saline with the patient in the supine position to prevent hypotension. Although there are several adverse effects associated with higher dosing used for psychotic disorders, the lower dosing for hiccups is generally well-tolerated. Potential side effects with short-term usage include dystonic reactions and drowsiness. Long-term therapy increases the risk of tardive dyskinesia. Chlorpromazine is contraindicated in elderly patients with dementia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=see_link&amp;anchor=H272233906#H272233906\">",
"     \"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\", section on 'Chlorpromazine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36264?source=see_link\">",
"     \"Tardive dyskinesia: Etiology and epidemiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1999149535\">",
"    <span class=\"h3\">",
"     Metoclopramide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     Metoclopramide",
"    </a>",
"    , a dopamine antagonist and gastric motility agent, is another treatment option, for which efficacy is demonstrated largely through case series [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22087/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. The usual oral dose is 10 mg three or four times daily for up to 7 to 10 days. Metoclopramide is also associated with tardive dyskinesia, especially at high doses and with chronic use [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22087/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1999149542\">",
"    <span class=\"h3\">",
"     Baclofen",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"     Baclofen",
"    </a>",
"    , a skeletal muscle relaxant, is another agent used for intractable hiccups [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22087/abstract/36,38,39\">",
"     36,38,39",
"    </a>",
"    ]. One prospective cohort study evaluated 37 patients who had a bout or recurring bouts of hiccups for at least seven days; baclofen was given as initial treatment in those without evidence of gastroesophageal disease (n = 17) and in those who had hiccups despite treatment for a gastroesophageal disorder (n = 20) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22087/abstract/39\">",
"     39",
"    </a>",
"    ]. Baclofen produced long-term complete resolution (18 cases) or a considerable reduction (10 cases) of hiccups. The most common adverse effects are drowsiness and dizziness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1999149549\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of other drug treatments are also available, for which efficacy is demonstrated by small case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22087/abstract/30-32,40-45\">",
"     30-32,40-45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anticonvulsants (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      , valproic acid,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Antidepressants (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Central nervous system stimulants (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"       methylphenidate",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Antiarrhythmic drugs (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"       quinidine",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Nefopam (a centrally acting nonopioid analgesic)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       Olanzapine",
"      </a>",
"     </li>",
"     <li>",
"      Marijuana",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"       Amantadine",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Complementary and alternative medicine",
"    </span>",
"    &nbsp;&mdash;&nbsp;When hiccups fail to respond to physical maneuvers and drug therapy, complementary and alternative medicine (CAM) treatments such as acupuncture and hypnosis may be tried.",
"   </p>",
"   <p>",
"    Acupuncture has been reported in several observational studies to improve intractable hiccups [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22087/abstract/46-49\">",
"     46-49",
"    </a>",
"    ]. One case series reported 13 out of 16 cancer patients experienced complete remission while the remaining three patients reported a decrease in hiccup severity with acupuncture [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22087/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the benefit of acupuncture for hiccups remains uncertain, it is generally considered a safe procedure and has been used in a variety of other treatment settings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28457?source=see_link\">",
"     \"Acupuncture\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypnosis has also been used in some cases with success in treating intractable hiccups [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22087/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1213673576\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical approaches, including phrenic nerve crushing or blocking with a local anesthetic, may be successful in refractory cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22087/abstract/9\">",
"     9",
"    </a>",
"    ]. One case report described five patients with intractable hiccups for up to 13 years who were successfully treated with an implantable breathing pacemaker, a device that controls excursions of the diaphragm by electrical stimulation of the phrenic nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22087/abstract/52\">",
"     52",
"    </a>",
"    ]. Another case report described complete resolution of intractable hiccups due to a posterior fossa stroke with implantation of a vagus nerve stimulator [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22087/abstract/14\">",
"     14",
"    </a>",
"    ]. A case report from Korea described resolution of intractable hiccups with short-term positive pressure ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22087/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/6/22625?source=see_link\">",
"       \"Patient information: Hiccups (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1213673819\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A hiccup, also known as singultus, is an involuntary, spasmodic contraction of the diaphragm and intercostal muscles that results in sudden inspiration and ends with abrupt closure of the glottis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are numerous causes of hiccups (",
"      <a class=\"graphic graphic_table graphicRef82395 \" href=\"UTD.htm?12/47/13053\">",
"       table 1",
"      </a>",
"      ). Hiccups are usually caused by gastric distention (eg, overeating, carbonated beverages). In rare cases, hiccups can be a manifestation of severe underlying disease (eg, malignancy, multiple sclerosis). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bouts of hiccups (&le;48 hours) are common and usually do not require medical evaluation. Persistent (&gt;48 hours and &le;one month) and intractable (&gt;one month) hiccups may necessitate a thorough medical evaluation. Many associated conditions can be diagnosed by history and physical examination. Other diagnostic testing is indicated in select patients. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment should be directed toward the specific illness causing the hiccups, if known. If no cause can be identified, we suggest empiric therapy with physical maneuvers, such as interrupting normal respiratory function (eg, breath holding, Valsalva maneuver) or",
"      <span class=\"nowrap\">",
"       nasopharyngeal/uvula",
"      </span>",
"      stimulation (eg, sipping cold water, gargling with water) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Physical maneuvers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If physical maneuvers fail, we suggest initiating pharmacologic treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"       chlorpromazine",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Other pharmacologic agents include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"       baclofen",
"      </a>",
"      , anticonvulsants, and antidepressants, among others. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Pharmacologic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acupuncture and surgery are additional treatment options if hiccups fail to respond to physical maneuvers and drug therapy. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Complementary and alternative medicine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1213673576\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1818651079\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Mary Fishman, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/1\">",
"      Kolodzik PW, Eilers MA. Hiccups (singultus): review and approach to management. Ann Emerg Med 1991; 20:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/2\">",
"      Souadjian JV, Cain JC. Intractable hiccup. Etiologic factors in 220 cases. Postgrad Med 1968; 43:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/3\">",
"      Cabane J, Desmet V, Derenne JP, et al. [Chronic hiccups]. Rev Med Interne 1992; 13:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/4\">",
"      Calsina-Berna A, Garc&iacute;a-G&oacute;mez G, Gonz&aacute;lez-Barboteo J, Porta-Sales J. Treatment of chronic hiccups in cancer patients: a systematic review. J Palliat Med 2012; 15:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/5\">",
"      Smith HS, Busracamwongs A. Management of hiccups in the palliative care population. Am J Hosp Palliat Care 2003; 20:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/6\">",
"      SAMUELS L. Hiccup; a ten year review of anatomy, etiology, and treatment. Can Med Assoc J 1952; 67:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/7\">",
"      Kobayashi Z, Tsuchiya K, Uchihara T, et al. Intractable hiccup caused by medulla oblongata lesions: a study of an autopsy patient with possible neuromyelitis optica. J Neurol Sci 2009; 285:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/8\">",
"      Kahrilas PJ, Shi G. Why do we hiccup? Gut 1997; 41:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/9\">",
"      Lewis JH. Hiccups: causes and cures. J Clin Gastroenterol 1985; 7:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/10\">",
"      Fass R, Higa L, Kodner A, Mayer EA. Stimulus and site specific induction of hiccups in the oesophagus of normal subjects. Gut 1997; 41:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/11\">",
"      Witter F, Dipietro J, Costigan K, Nelson P. The relationship between hiccups and heart rate in the fetus. J Matern Fetal Neonatal Med 2007; 20:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/12\">",
"      Park MH, Kim BJ, Koh SB, et al. Lesional location of lateral medullary infarction presenting hiccups (singultus). J Neurol Neurosurg Psychiatry 2005; 76:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/13\">",
"      Nagayama T, Kaji M, Hirano H, et al. Intractable hiccups as a presenting symptom of cerebellar hemangioblastoma. Case report. J Neurosurg 2004; 100:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/14\">",
"      Payne BR, Tiel RL, Payne MS, Fisch B. Vagus nerve stimulation for chronic intractable hiccups. Case report. J Neurosurg 2005; 102:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/15\">",
"      Renes SH, van Geffen GJ, Rettig HC, et al. Ultrasound-guided continuous phrenic nerve block for persistent hiccups. Reg Anesth Pain Med 2010; 35:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/16\">",
"      Pooran N, Lee D, Sideridis K. Protracted hiccups due to severe erosive esophagitis: a case series. J Clin Gastroenterol 2006; 40:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/17\">",
"      Albrecht H, Stellbrink HJ. Hiccups in people with AIDS. J Acquir Immune Defic Syndr 1994; 7:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/18\">",
"      Yamazaki Y, Sugiura T, Kurokawa K. Sinister hiccups. Lancet 2008; 371:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/19\">",
"      Doshi H, Vaidyalingam R, Buchan K. Atrial pacing wires: an uncommon cause of postoperative hiccups. Br J Hosp Med (Lond) 2008; 69:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/20\">",
"      Krysiak W, Szabowski S, Stepie M, et al. Hiccups as a myocardial ischemia symptom. Pol Arch Med Wewn 2008; 118:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/21\">",
"      Ng JL, Aziz EF, Herzog E. Electrocardiogram for hiccups? Am J Med 2011; 124:e5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/22\">",
"      Krahn A, Penner SB. Use of baclofen for intractable hiccups in uremia. Am J Med 1994; 96:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/23\">",
"      George J, Thomas K, Jeyaseelan L, et al. Hyponatraemia and hiccups. Natl Med J India 1996; 9:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/24\">",
"      Hansen BJ, Rosenberg J. Persistent postoperative hiccups: a review. Acta Anaesthesiol Scand 1993; 37:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/25\">",
"      Van Damme PA. Post operative hiccups. Int J Oral Maxillofac Surg 2008; 37:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/26\">",
"      Theohar C, McKegney FP. Hiccups of psychogenic origin: a case report and review of the literature. Compr Psychiatry 1970; 11:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/27\">",
"      Rousseau P. Hiccups. South Med J 1995; 88:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/28\">",
"      Shay SS, Myers RL, Johnson LF. Hiccups associated with reflux esophagitis. Gastroenterology 1984; 87:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/29\">",
"      Marsot-Dupuch K, Bousson V, Cabane J, Tubiana JM. Intractable hiccups: the role of cerebral MR in cases without systemic cause. AJNR Am J Neuroradiol 1995; 16:2093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/30\">",
"      Marinella MA. Diagnosis and management of hiccups in the patient with advanced cancer. J Support Oncol 2009; 7:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/31\">",
"      Friedman NL. Hiccups: a treatment review. Pharmacotherapy 1996; 16:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/32\">",
"      Viera AJ, Sullivan SA. Remedies for prolonged hiccups. Am Fam Physician 2001; 63:1684, 1686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/33\">",
"      Howard RS. Persistent hiccups. BMJ 1992; 305:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/34\">",
"      FRIEDGOOD CE, RIPSTEIN CB. Chlorpromazine (thorazine) in the treatment of intractable hiccups. J Am Med Assoc 1955; 157:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/35\">",
"      Madanagopolan N. Metoclopramide in hiccup. Curr Med Res Opin 1975; 3:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/36\">",
"      Pinczower GR. Stop those hiccups! Anesth Analg 2007; 104:224.",
"     </a>",
"    </li>",
"    <li>",
"     www.fda.gov/medwAtch/safety/2009/safety09.htm#Metoclopramide (Accessed on October 17, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/38\">",
"      Ram&iacute;rez FC, Graham DY. Treatment of intractable hiccup with baclofen: results of a double-blind randomized, controlled, cross-over study. Am J Gastroenterol 1992; 87:1789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/39\">",
"      Guelaud C, Similowski T, Bizec JL, et al. Baclofen therapy for chronic hiccup. Eur Respir J 1995; 8:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/40\">",
"      Hern&aacute;ndez JL, Pajar&oacute;n M, Garc&iacute;a-Regata O, et al. Gabapentin for intractable hiccup. Am J Med 2004; 117:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/41\">",
"      Gilson I, Busalacchi M. Marijuana for intractable hiccups. Lancet 1998; 351:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/42\">",
"      Bilotta F, Rosa G. Nefopam for severe hiccups. N Engl J Med 2000; 343:1973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/43\">",
"      Askenasy JJ, Boiangiu M, Davidovitch S. Persistent hiccup cured by amantadine. N Engl J Med 1988; 318:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/44\">",
"      Wilcox SK, Garry A, Johnson MJ. Novel use of amantadine: to treat hiccups. J Pain Symptom Manage 2009; 38:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/45\">",
"      Alderfer BS, Arciniegas DB. Treatment of intractable hiccups with olanzapine following recent severe traumatic brain injury. J Neuropsychiatry Clin Neurosci 2006; 18:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/46\">",
"      Lin YC. Acupuncture for persistent hiccups in a heart and lung transplant recipient. J Heart Lung Transplant 2006; 25:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/47\">",
"      Ge AX, Ryan ME, Giaccone G, et al. Acupuncture treatment for persistent hiccups in patients with cancer. J Altern Complement Med 2010; 16:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/48\">",
"      Chang CC, Chang YC, Chang ST, et al. Efficacy of near-infrared irradiation on intractable hiccup in custom-set acupoints: evidence-based analysis of treatment outcome and associated factors. Scand J Gastroenterol 2008; 43:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/49\">",
"      Schiff E, River Y, Oliven A, Odeh M. Acupuncture therapy for persistent hiccups. Am J Med Sci 2002; 323:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/50\">",
"      Smedley WP, Barnes WT. Postoperative use of hypnosis on a cardiovascular service. Termination of persistent hiccups in a patient with an aortorenal graft. JAMA 1966; 197:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/51\">",
"      BENDERSKY G, BAREN M. Hypnosis in the termination of hiccups unresponsive to conventional treatment. Arch Intern Med 1959; 104:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/52\">",
"      Dobelle WH. Use of breathing pacemakers to suppress intractable hiccups of up to thirteen years duration. ASAIO J 1999; 45:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22087/abstract/53\">",
"      Byun SH, Jeon YH. Treatment of idiopathic persistent hiccups with positive pressure ventilation -a case report-. Korean J Pain 2012; 25:105.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6892 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-221.179.173.170-189A616C48-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_36_22087=[""].join("\n");
var outline_f21_36_22087=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1213673819\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1999149430\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H163445842\">",
"      Central nervous system disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Vagus and phrenic nerve irritation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H163445849\">",
"      Gastrointestinal disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H163445856\">",
"      Thoracic disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H163445863\">",
"      Cardiac disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Toxic-metabolic or drug-related disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1999149489\">",
"      Postoperative",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1999149496\">",
"      Drug-related",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18038200\">",
"      Psychogenic factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Physical maneuvers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1999149528\">",
"      - Chlorpromazine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1999149535\">",
"      - Metoclopramide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1999149542\">",
"      - Baclofen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1999149549\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Complementary and alternative medicine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1213673576\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1213673819\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1818651079\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6892\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6892|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?0/60/975\" title=\"algorithm 1\">",
"      Evaluation intractable hiccups",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6892|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/47/13053\" title=\"table 1\">",
"      Causes intractable hiccups",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/41/19100\" title=\"table 2\">",
"      Treatments for hiccups",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28457?source=related_link\">",
"      Acupuncture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=related_link\">",
"      First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=related_link\">",
"      Medical management of gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/6/22625?source=related_link\">",
"      Patient information: Hiccups (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36264?source=related_link\">",
"      Tardive dyskinesia: Etiology and epidemiology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_36_22088="Evaluation of the adult with hip pain";
var content_f21_36_22088=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of the adult with hip pain",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/36/22088/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/36/22088/contributors\">",
"     Bruce C Anderson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/36/22088/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/36/22088/contributors\">",
"     Karl B Fields, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/36/22088/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/36/22088/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/36/22088/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hip pain is a common symptom with a number of possible causes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22088/abstract/1\">",
"     1",
"    </a>",
"    ]. In a survey of 6596 adults ages 60 years and older, 14.3 percent reported significant hip pain on most days over the past six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22088/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Trochanteric and gluteus medius bursitis, osteoarthritis, and fractures of the femur are the most common conditions affecting the hip. The character and location of the pain, the movement and positions that reproduce the pain, and the affect on ambulation can be used to distinguish the conditions affecting soft tissues from disorders affecting the hip joint and adjacent bones.",
"   </p>",
"   <p>",
"    This review will provide a general approach to the evaluation of patients with hip pain. More in-depth discussions of the diagnosis and treatment of specific disorders of the hip are found separately. The diagnostic approach to hip pain in children is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16729?source=see_link\">",
"     \"Overview of hip pain in childhood\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hip joint is formed by the rounded head of the femur and its articulation with the acetabulum. The latter is formed by the union of the ilium, ischium, and pubis. The hip joint is a ball-and-socket joint that is relatively fixed to the body by the pelvic girdle. Because of this relative immobility, a primary abnormality of the hip or pelvis can cause symptoms in the lumbar spine or knee, and a primary abnormality in the lumbar spine or knee may cause a secondary abnormality in the hip [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22088/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The femoral neck is approximately 8 to 10 cm in length. Two bony prominences project from the femoral neck: the greater trochanter laterally and the lesser trochanter medially. The greater trochanter is the site of attachment for the abductor muscles (gluteus medius and gluteus minimus) and the external rotators of the hip. The main hip extensors are gluteus maximus and the hamstrings; the former attaches to the proximal femur, just distal to the greater trochanter. The lesser trochanter is the attachment site for the major hip flexor, the iliopsoas muscle.",
"   </p>",
"   <p>",
"    The major blood supply to the head and neck of the femur is usually the medial femoral circumflex artery, a branch of the common femoral artery. Fracture of the femoral neck can disrupt the blood supply and result in osteonecrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28346?source=see_link\">",
"     \"Osteonecrosis (avascular necrosis of bone)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are approximately 18 bursae in the hip region. The deep trochanteric bursa (also referred to as the gluteus medius bursa) lies between the tendon of the gluteus maximus and the posterolateral prominence of the greater trochanter and is a common source of inflammation and hip pain [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22088/abstract/4\">",
"     4",
"    </a>",
"    ]. A more superficial bursa directly over the greater trochanter may also become inflamed and tender (",
"    <a class=\"graphic graphic_figure graphicRef60606 \" href=\"UTD.htm?8/53/9042\">",
"     figure 1",
"    </a>",
"    ). Other bursa that can become a source of hip pathology include the iliopsoas bursa, located between the psoas tendon and the hip capsule, and the ischiogluteal bursa, located between the gluteus maximus muscle and the ischial tuberosity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain is the most common complaint in patients with hip problems. In most cases, a careful history and physical examination can determine the etiology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pain patterns",
"    </span>",
"    &nbsp;&mdash;&nbsp;The character and location of pain is the key element in the differential diagnosis of hip pain. Increased pain with or after use (particularly with weight-bearing) and improvement with rest is the hallmark of a structural joint problem, particularly osteoarthritis. By comparison, constant pain, especially pain at night, suggests an infectious, inflammatory, or neoplastic process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Lateral hip pain aggravated by direct pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lateral hip pain is unlikely to be due to hip joint disease. Lateral hip pain that is aggravated by direct pressure is the classic pattern of trochanteric bursitis. Depending upon the degree of inflammation and swelling, pressure sensitivity ranges from mild morning pain and stiffness to intolerance to sleeping on the affected side.",
"   </p>",
"   <p>",
"    Progressive lateral hip pain that is aggravated by direct pressure and weight bearing can also be seen with direct involvement of the femur (eg, with metastatic cancer). Thus, patients who otherwise may be at risk for malignancy (eg, older individuals with weight loss, history of cancer) may need radiographic testing to rule out bone involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Lateral hip pain associated with paresthesias and hypesthesias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lateral hip pain accompanied by paresthesias or hypesthesias is the classic presentation of meralgia paresthetica (lateral femoral cutaneous nerve entrapment). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39061?source=see_link\">",
"     \"Meralgia paresthetica (lateral femoral cutaneous nerve entrapment)\"",
"    </a>",
"    .) Meralgia paresthetica is characterized by a localized area of pain (often described as a burning or an uncomfortable, heightened sensation) that is not influenced by direct pressure, hip movement, or lower back movement. In contrast, lumbar radiculopathy, particularly involving L4-5, causes lateral hip pain that extends over a much wider area, radiating down the leg and into the foot, with or without associated foot numbness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/10/18601?source=see_link&amp;anchor=H9#H9\">",
"     \"Approach to the diagnosis and evaluation of low back pain in adults\", section on 'Sciatica'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Anterior hip or groin pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anterior hip or groin pain suggests primary involvement of the hip joint itself. A gradual onset of pain in association with variable degrees of impaired movement is consistent with osteoarthritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12056?source=see_link\">",
"     \"Clinical manifestations of osteoarthritis\"",
"    </a>",
"    .) The differential diagnosis of acute onset of groin pain and impairment of weight bearing includes osteonecrosis (particularly in the setting of risk factors such as glucocorticoid use), occult fracture (eg, following trauma), acute synovitis, or, uncommonly, septic arthritis.",
"   </p>",
"   <p>",
"    Anterior hip pain that is neither aggravated by direct pressure nor repetitive flexion of the hip suggests the presence of an inguinal hernia, lower abdominal pathology, or, less commonly, referred pain from higher lumbar spinal nerve roots (eg, L2-3).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Posterior hip pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posterior (gluteal) hip pain is the least common pain pattern affecting the hip. It is most often a sign of sacroiliac joint disease, lumbar radiculopathy, herpes zoster, or an unusual presentation of the hip joint. Patients with posterior hip pain often undergo extensive examination and radiographic testing of the back and hip in order to define a precise cause.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Lower anterior thigh pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients presenting with lower anterior thigh pain pose the greatest clinical challenge. Primary disease of the hip joint, primary and secondary lesions of the upper femur, stress fracture of the femoral neck, and upper lumbar radiculopathy can refer pain to the lower thigh (or even the anterior knee). Unless the pain can be reproduced by passive rotation (hip joint), by applying torque to the thigh (femur), or by maneuvers designed to elicit radicular symptoms (eg, straight leg raising), most patients with lower anterior thigh pain require specific radiographic procedures to define a precise cause.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Trochanteric bursitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned, inflammation of the trochanteric bursa is one of the most common causes of hip pain. It is caused by an exaggerated movement of the gluteus medius tendon and the tensor fascia lata over the outer femur. Even subtle gait impairment can increase friction and pressure over the trochanteric process. Common gait abnormalities that may result in trochanteric bursitis include lumbosacral spine stiffness, leg length discrepancy, knee arthritis, and ankle sprain. Untreated, the normally paper thin bursal wall thickens, fibroses, and gradually loses its ability to lubricate the outer hip.",
"   </p>",
"   <p>",
"    Patients typically complain of lateral hip pain, with point tenderness over the trochanteric bursa. The point of tenderness usually lies approximately one inch posterior and superior to the greater trochanter, and is located about 7.5 cm deep to the skin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18966?source=see_link\">",
"     \"Trochanteric bursitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Hip osteoarthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoarthritis most commonly presents in patients over 40 years of age. The principal symptom associated with osteoarthritis of the hip is pain, which is typically exacerbated by activity and relieved by rest. With more advanced disease, pain may be noted with progressively less activity, eventually occurring at rest and at night. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12056?source=see_link\">",
"     \"Clinical manifestations of osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to the lateral hip pain associated with bursitis, osteoarthritis usually presents with groin pain that is aggravated by movement rather than by direct pressure. Other key clinical features suggestive of osteoarthritis include internal rotation of less than 15 degrees, pain on internal rotation, morning stiffness (less than 30 to 60 minutes), and flexion less than 115 degrees [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22088/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33287?source=see_link&amp;anchor=H18#H18\">",
"     \"Diagnosis and classification of osteoarthritis\", section on 'Osteoarthritis of the hip'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Meralgia paresthetica",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lateral femoral cutaneous nerve, a pure sensory nerve, is susceptible to compression as it courses from the lumbosacral nerve plexus, through the abdominal cavity, under the inguinal ligament, and into the subcutaneous tissue of the thigh. Symptoms range from numbness and tingling (hypesthesia) to burning pain (paresthesia) over the upper outer thigh. Pain referred beyond the upper outer thigh or pain accompanied by impaired reflexes or muscular weakness suggests either trochanteric bursitis or lumbar radiculopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39061?source=see_link\">",
"     \"Meralgia paresthetica (lateral femoral cutaneous nerve entrapment)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Osteonecrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteonecrosis, also known as aseptic necrosis, avascular necrosis, ischemic necrosis, and osteochondritis dissecans, is a pathological process that has been associated with numerous conditions and therapeutic interventions. The mechanisms by which this disorder develops are not fully understood. However, compromise of the bone vasculature leading to the death of bone and marrow cells, and ultimate mechanical failure, appear to be common to most proposed etiologies. The process is most often progressive, resulting in joint destruction within three to five years if left untreated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28346?source=see_link\">",
"     \"Osteonecrosis (avascular necrosis of bone)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A variety of traumatic and nontraumatic factors contribute to the etiology of osteonecrosis (",
"    <a class=\"graphic graphic_table graphicRef69502 \" href=\"UTD.htm?38/56/39819\">",
"     table 1",
"    </a>",
"    ). A definitive etiologic role has been established for some of these factors, but the majority is probable relationships. Corticosteroid use and excessive alcohol intake are reported to account for more than 90 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22088/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common presenting symptom of osteonecrosis is pain [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22088/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Groin pain is most usual in patients with femoral head disease, followed by thigh and buttock pain. Weight-bearing and motion-induced pain are seen in most cases. Rest pain occurs in two-thirds of patients, and night pain in approximately one-third.",
"   </p>",
"   <p>",
"    Early diagnosis of osteonecrosis may provide the opportunity to prevent collapse and ultimately the need for joint replacement. However, most patients present late in the course of the disease. Thus, a high index of suspicion is necessary for those with known or probable risk factors, particularly high dose steroid use. The diagnosis is made radiographically. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28346?source=see_link\">",
"     \"Osteonecrosis (avascular necrosis of bone)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Occult hip fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;An occult hip fracture (nondisplaced fracture of the femoral neck) can be difficult to diagnose. It should be suspected in patients with severe anterolateral hip tenderness, severe pain with even partial weight bearing, and intolerance to passive rotation of the hip. Routine hip x-rays can be normal in this setting; the patient must remain non-weight bearing if the diagnosis is suspected until MR imaging or serial examination of the hip rules out the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Aortoiliac vascular occlusive disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with aortoiliac occlusive disease (Leriche's syndrome) may complain of buttock, hip, and, in some cases, thigh claudication. The pain is often described as aching in nature and may be associated with weakness of the hip or thigh with walking. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30201?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease\", section on 'Buttock and hip claudication'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Physical examination may reveal diminished pulses beginning in the groin area bilaterally, with occasional bruits over the iliac and femoral arteries. Other findings include muscle atrophy and slow wound healing in the legs. The examination of the hip joint and soft tissues are essentially normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Referred pain from the lumbosacral spine or sacroiliac joint",
"    </span>",
"    &nbsp;&mdash;&nbsp;The back and sacroiliac joints commonly refer pain to or through the hip. The lower lumbar roots refer pain through the gluteus and posterolateral thigh areas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/10/18601?source=see_link\">",
"     \"Approach to the diagnosis and evaluation of low back pain in adults\"",
"    </a>",
"    .) The sacroiliac joints refer pain to the gluteal area. Referred pain from these locations should be suspected whenever back symptoms accompany the pain, the pain extends past the knee, paresthesias or hypesthesias accompany the pain, and the examination of the hip joint and soft tissues are unremarkable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;All significant diagnoses at the hip can affect ambulation. Thus, the first priority in examining the hip is to evaluate the patient's gait, tolerance of squatting, and general ability to move in the examination room.",
"   </p>",
"   <p>",
"    Next, the integrity of the hip joint is assessed by performing passive internal and external rotation, noting the patient's tolerance of the maneuver and any endpoint stiffness. Impairment of range of motion and severe pain at the endpoints of motion suggest the need for immediate evaluation for osteonecrosis, occult fracture, acute synovitis, or metastatic involvement of the femur. If range of motion is normal, palpation of the trochanteric bursa is performed.",
"   </p>",
"   <p>",
"    The examination is completed by looking for sources of referred pain to the hip from the lumbar spinal nerves (straight leg raise), sacroiliac joint (palpation of the joint), lateral femoral cutaneous nerve (sensation in the upper outer thigh), and the lower abdominal vascular structures (lower extremity pulses) (",
"    <a class=\"graphic graphic_table graphicRef69960 \" href=\"UTD.htm?5/21/5469\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Overall hip function",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general function of the hip is assessed by observing the patient's gait and the ability to change positions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Gait",
"    </span>",
"    &nbsp;&mdash;&nbsp;The objective of observing the patient's gait is to assess the impact of the patient's hip condition on their overall mobility by observing the ability to perform simple movements.",
"   </p>",
"   <p>",
"    The patient is asked to walk in the examination room; the maneuver is enhanced by asking the patient to toe and heel walk. Impairment of ambulation and inability to change position smoothly can be affected by severe hip arthritis, involvement of the bony femur (eg, osteonecrosis or metastatic disease), dramatic loss of muscular support, or dramatic loss of lumbosacral nerve function. In general, meralgia paresthetica, mild hip arthritis, and most cases of bursitis have only a minimal impact upon ambulation.",
"   </p>",
"   <p>",
"    Specific gait patterns may also be recognized with hip abnormalities.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With a Trendelenburg gait, the patient shifts the torso over the affected hip, thereby reducing the load on the hip and decreasing pain. This suggests the presence of hip joint disease",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      weakness of the gluteus medius muscle.",
"     </li>",
"     <li>",
"      The patient with an antalgic gait spends a shorter time weight bearing on the affected side because of pain.",
"     </li>",
"     <li>",
"      The short leg limp is secondary to leg length discrepancy, and is characterized by an increase in the up and down movement of the head and shoulders as the body falls onto the short leg and then rises up on the long leg.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Position change",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient can be observed climbing onto the examination table. This maneuver requires a flexible hip joint, strong iliopsoas and quadriceps muscle, and normal lumbosacral nerve roots. Inability to change position smoothly can be affected by severe hip arthritis, involvement of the bony femur (eg, osteonecrosis or metastatic disease), dramatic loss of muscular support, or dramatic loss of lumbosacral nerve function. In general, meralgia paresthetica, mild hip arthritis, and most cases of bursitis have only a minimal impact upon ambulation.",
"   </p>",
"   <p>",
"    The patient also can be asked to squat as far as their pain level allows, either free standing or holding onto the examination table. The ability to squat is influenced by the supporting musculature, the hip joint, and the lubricating ability of the trochanteric bursa. Thus, squatting may be impaired by moderate to advanced hip arthritis, moderate to severe bursitis, and any condition reducing the effective strength of the supporting muscles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Inspection for pelvic obliquity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inspection for pelvic obliquity is used primarily as a screening maneuver for leg length discrepancy (",
"    <a class=\"graphic graphic_picture graphicRef80105 \" href=\"UTD.htm?41/59/42928\">",
"     picture 1",
"    </a>",
"    ). Asymmetry of the iliac crests is seen with leg length discrepancy, pelvic fracture, scoliosis, and unilateral paraspinal muscle spasm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Maneuvers assessing specific conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with mild to moderate hip pain and stiffness, normal gait, and normal range of motion of the hip joint, it may be reasonable to treat empirically and avoid further investigation. Empiric treatment includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Minimizing weight bearing activities (walking and standing)",
"     </li>",
"     <li>",
"      Avoid physically demanding work, especially work that involves repetitious bending or twisting at the waist",
"     </li>",
"     <li>",
"      Avoid direct pressure over the outer hip",
"     </li>",
"     <li>",
"      Sleep with a pillow between the legs",
"     </li>",
"     <li>",
"      Perform daily cross-leg, passive stretching exercises",
"     </li>",
"     <li>",
"      Use nonsteroidal antiinflammatory drugs (NSAIDs) for 7 to 10 days",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with persistent or chronic symptoms despite these measures, or those with moderate to severe hip pain and stiffness, an antalgic gait, moderate to severe trochanteric bursal tenderness, or acute loss of range of motion of the hip joint need a more comprehensive hip examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Internal and external rotation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Internal and external rotation are measured to assess the integrity of the hip joint and to evaluate for pain and stiffness (",
"    <a class=\"graphic graphic_picture graphicRef74743 \" href=\"UTD.htm?40/0/40960\">",
"     picture 2",
"    </a>",
"    ). Internal and external rotation can be reduced by the loss of articular cartilage and outgrowth of acetabular osteophytes with osteoarthritis, and the pain and muscle spasm of acute synovitis. A 50-year-old patient averages 45 to 50 degrees of internal and external rotation. Severe osteoarthritis, acute synovitis, and septic arthritis may have as little as 5 to 10 degrees of rotation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Patrick (Fabere) test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Patrick test (also referred to as the FABERE test) allows an assessment of the hip and the sacroiliac joint. The examiner Flexes, ABducts, Externally Rotates, and Extends the affected leg so that the ankle of that leg is on top of the opposite knee (a figure of 4 configuration). The affected leg is then slowly lowered toward the examining table. A negative result occurs when the test leg falls at least parallel to the opposite leg. A positive test result occurs when the affected leg remains above the opposite leg, and may be indicative of hip disease, iliopsoas spasm, or sacroiliac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22088/abstract/9\">",
"     9",
"    </a>",
"    ]. Pain with this maneuver in the absence of pain with passive hip joint motion suggests discomfort arising from the sacroiliac joint.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Palpation of the trochanteric bursa",
"    </span>",
"    &nbsp;&mdash;&nbsp;The trochanter is palpated in either the sitting or lateral decubitus position (",
"    <a class=\"graphic graphic_picture graphicRef58500 \" href=\"UTD.htm?14/48/15104\">",
"     picture 3",
"    </a>",
"    ). Bursitis is the most common cause of trochanteric tenderness. However, tenderness is also seen with occult fracture, stress fracture, and metastatic disease of the femur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Sensation of the anterolateral thigh",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sensation of the anterolateral thigh is examined in patients with suspected meralgia paresthetica (",
"    <a class=\"graphic graphic_picture graphicRef62268 \" href=\"UTD.htm?31/44/32463\">",
"     picture 4",
"    </a>",
"    ). Loss of sensation (hypesthesia) or a feeling of heightened sensation (dysesthesia or hyperesthesia) is characteristic of the condition. Changes in motor function do not occur since the nerve provides only sensation to the skin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Straight leg raise",
"    </span>",
"    &nbsp;&mdash;&nbsp;The straight leg raise maneuver is used to determine the degree of irritation of the nerve roots (",
"    <a class=\"graphic graphic_picture graphicRef64671 \" href=\"UTD.htm?36/47/37616\">",
"     picture 5",
"    </a>",
"    ). A positive test elicits pain in the leg, buttock, or back at 60 degrees or less of leg elevation. The pain is usually worsened by dorsiflexion at the ankle and relieved by flexion of the knee and hip. A positive test typically indicates S1 or L5 root irritation. The straight leg raise test has a sensitivity of about 0.80 (indicating relatively few false negative tests) and a lower specificity of about 0.40 (indicating many false positive tests) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22088/abstract/10\">",
"     10",
"    </a>",
"    ]. Thus, a negative test makes a herniated disc unlikely, although its presence is nonspecific. The test is inconclusive if tightness or pain is felt only in the hamstring area. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/10/18601?source=see_link\">",
"     \"Approach to the diagnosis and evaluation of low back pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Lower extremity neurologic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sensory testing of the feet for light touch, pinprick, and deep pain sensation are combined with motor testing of dorsiflexion and plantarflexion to determine the integrity of lower extremity neurologic function. The 5th lumbar root (L4-5 disk) is responsible for sensation over the top of the foot and for dorsiflexion. The S1 root (L5-S1 disk) is responsible for sensation on the bottom of the foot and plantarflexion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Palpation of the sacroiliac joint",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sacroiliac joint is palpated for local tenderness if an intrinsic condition of the hip is unlikely and the patient describes posterior hip pain (",
"    <a class=\"graphic graphic_picture graphicRef80967 \" href=\"UTD.htm?21/40/22159\">",
"     picture 6",
"    </a>",
"    ). Sacroiliac strain and sacroiliitis cause focal tenderness over an area of approximately three centimeters in diameter. Diffuse tenderness extending over a wide area is seen with severe paraspinal muscle spasm. Local tenderness that does not conform to the typical area of the joint suggests involvement of the adjacent bone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Palpation of lower extremity pulses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dorsalis pedis and posterior tibialis arteries are palpated in patients with suspected aortoiliac vascular occlusive disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     CONFIRMATORY MANEUVERS AND PROCEDURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;A plain radiograph should be performed in patients with acute hip pain to exclude fracture. Further imaging studies, especially magnetic resonance imaging (MRI), may be necessary when the history, physical examination, and plain radiographs are inconclusive. Radionuclide scans to localize osteoblastic activity or to localize sites of soft tissue inflammation have largely been supplanted by MRI, especially when MRI is performed with gadolinium enhancement, but scintigraphy can be used if gadolinium contrast-enhanced MRI is unavailable or relatively contraindicated (eg, in patients with severe renal functional impairment). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25210?source=see_link\">",
"     \"Radiologic evaluation of the painful hip in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If gadolinium-based imaging must be performed in a patient with moderate to severely impaired renal function (eg, estimated glomerular filtration rate &lt;15 to 30",
"    <span class=\"nowrap\">",
"     mL/min),",
"    </span>",
"    there may be a role for dialysis to reduce the risk of development of nephrogenic systemic fibrosis. Causes and approaches to prevention of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=see_link&amp;anchor=H24#H24\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\", section on 'If gadolinium must be given'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Plain radiographs are also recommended (and are the imaging modality of choice) for patients with moderate to severe chronic hip pain. Further imaging may be required based upon these results in combination with previous clinical findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Weight bearing AP pelvis x-ray",
"    </span>",
"    &nbsp;&mdash;&nbsp;A weight bearing AP pelvis x-ray assesses the articular width of the hip joints, pelvic obliquity, general bone density, and the integrity of the sacroiliac joints. The normal articular width is 4 to 5 mm. Marked joint space narrowing, sclerosis of the joint space margins, and periarticular osteophyte formation are consistent with osteoarthritis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56376 \" href=\"UTD.htm?12/5/12383\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI is the radiographic study of choice for suspected fracture not demonstrated by plain x-ray, early diagnosis and accurate staging of osteonecrosis, as well as evaluation for infection and tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Radionuclide bone scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radionuclide bone scan is reserved for suspected fracture or osteonecrosis not demonstrated by plain film radiography when MRI is not available or contraindicated. Increased activity is nonspecific and can be seen with fracture, osteonecrosis, acute and chronic arthritis, and metastatic bone lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic ultrasonography is primarily used to evaluate children for hip effusions. In adults, ultrasound primarily is used to guide aspiration attempts [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22088/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Local anesthetic block",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local anesthetic block can be helpful in difficult cases in differentiating the pain of trochanteric bursitis from the dysesthetic pain of meralgia paresthetica or referred pain from the lumbosacral spine.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Local anesthetic block placed below the gluteus medius tendon at the periosteum of the trochanteric process can be used to confirm the presence of trochanteric bursitis (",
"      <a class=\"graphic graphic_picture graphicRef54728 \" href=\"UTD.htm?36/22/37217\">",
"       picture 7",
"      </a>",
"      ). Local anesthetic block of the deeper gluteus medius bursa can also be performed (",
"      <a class=\"graphic graphic_picture graphicRef57328 \" href=\"UTD.htm?23/55/24436\">",
"       picture 8",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Local anesthetic block of the lateral femoral cutaneous nerve can be used to distinguish meralgia paresthetica from referred pain from the lumbosacral roots (",
"      <a class=\"graphic graphic_picture graphicRef55118 \" href=\"UTD.htm?23/24/23939\">",
"       picture 9",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Local anesthetic block at the sacroiliac joint can confirm this as the source of posterior hip pain (",
"      <a class=\"graphic graphic_picture graphicRef65226 \" href=\"UTD.htm?8/56/9089\">",
"       picture 10",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Hip aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediate arthrocentesis is recommended when hip pain is acute and severe or if there is other suggestive evidence of infection (",
"    <a class=\"graphic graphic_picture graphicRef56933 \" href=\"UTD.htm?16/31/16895\">",
"     picture 11",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20360?source=see_link\">",
"     \"Synovial fluid analysis and the diagnosis of septic arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the deep seated location of the hip joint, diagnostic aspiration requires fluoroscopic, CT, or ultrasound guidance. The choice of imaging modality depends mainly upon the preference of the clinician who performs the study and availability. If no fluid is withdrawn, a small amount of contrast should be instilled to confirm the intraarticular location of the needle tip.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/25/43409?source=see_link\">",
"       \"Patient information: Hip pain in older people (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/46/23266?source=see_link\">",
"       \"Patient information: Aseptic necrosis of the hip (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/46/24289?source=see_link\">",
"       \"Patient information: Hip pain (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H312216260\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In most cases, a careful history and physical examination can determine the etiology of hip pain. The character and location of the pain is the key element in establishing the diagnosis. Increased pain with or after use (particularly with weight-bearing) and improvement with rest is the hallmark of a structural joint problem, particularly osteoarthritis. By comparison, constant pain, especially pain at night, suggests an infectious, inflammatory, or neoplastic process. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology and presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hip pain can be categorized broadly based upon its location (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Pain patterns'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Lateral hip pain is unlikely to be due to hip joint disease. Lateral hip pain that is aggravated by direct pressure is the classic pattern of trochanteric bursitis. Progressive lateral hip pain that is aggravated by direct pressure and weight bearing can also be seen with direct involvement of the femur (eg, with metastatic cancer). Lateral hip pain accompanied by paresthesias or hypesthesias is the classic presentation of meralgia paresthetica (lateral femoral cutaneous nerve entrapment).",
"     </li>",
"     <li>",
"      Anterior hip or groin pain suggests primary involvement of the hip joint itself. A gradual onset of pain in association with variable degrees of impaired movement is consistent with osteoarthritis. Acute groin pain associated with impairment of weight bearing may be caused by osteonecrosis (particularly in the setting of risk factors such as glucocorticoid use), occult fracture (eg, following trauma), acute synovitis, or, uncommonly, septic arthritis. Anterior hip pain may also be caused by an inguinal hernial or lower abdominal pathology.",
"     </li>",
"     <li>",
"      Posterior (gluteal) hip pain is the least common pain pattern affecting the hip. It is most often a sign of sacroiliac joint disease, lumbar radiculopathy, herpes zoster, or an unusual presentation of hip joint pathology. Diagnostic imaging may be needed to determine the cause.",
"     </li>",
"     <li>",
"      Anterior thigh pain poses a significant clinical challenge. Primary disease of the hip joint, primary and secondary lesions of the upper femur, stress fracture of the femoral neck, and upper lumbar radiculopathy can refer pain to the anterior thigh. Unless the pain can be reproduced by passive rotation (hip joint), by applying torque to the thigh (femur), or by maneuvers designed to elicit radicular symptoms (eg, straight leg raising), diagnostic imaging is often needed to determine a precise cause.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Examination of the hip follows a standard approach, including inspection, palpation, strength and motor testing, and special tests. It is important to evaluate the patient's gait, tolerance of squatting, and general mobility. A screening neurovascular examination should be performed. Details of the hip examination are provided in the text. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cause of subacute or chronic hip pain can be difficult to determine and diagnostic imaging may be needed. This is reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25210?source=see_link\">",
"       \"Radiologic evaluation of the painful hip in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Anderson BC. Office Orthopedics for Primary Care: Diagnosis and Treatment, 2nd, WB Saunders, Philadelphia 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22088/abstract/2\">",
"      Christmas C, Crespo CJ, Franckowiak SC, et al. How common is hip pain among older adults? Results from the Third National Health and Nutrition Examination Survey. J Fam Pract 2002; 51:345.",
"     </a>",
"    </li>",
"    <li>",
"     Steinberg GG, Seybold EA. Hip and pelvis. In: Orthopaedics in Primary Care, 3rd, Steinberg GG, Akins CM, Baran DT.  (Eds), Lippincott Williams and Wilkins, Baltimore 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22088/abstract/4\">",
"      Swezey RL, Spiegel TM. Evaluation and treatment of local musculoskeletal disorders in elderly patients. Geriatrics 1979; 34:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22088/abstract/5\">",
"      Altman R, Alarc&oacute;n G, Appelrouth D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 1991; 34:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22088/abstract/6\">",
"      Mont MA, Hungerford DS. Non-traumatic avascular necrosis of the femoral head. J Bone Joint Surg Am 1995; 77:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22088/abstract/7\">",
"      Zizic TM, Marcoux C, Hungerford DS, Stevens MB. The early diagnosis of ischemic necrosis of bone. Arthritis Rheum 1986; 29:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22088/abstract/8\">",
"      LaPorte DM, Mont MA, Mohan V, et al. Multifocal osteonecrosis. J Rheumatol 1998; 25:1968.",
"     </a>",
"    </li>",
"    <li>",
"     Moder KG, Hunder GG. Examination. In: Textbook of Rheumatology, 5th, Kelly WN, Harris ED, Ruddy S, et al.  (Eds), WB Saunders, Philadelphia 1997. p.364.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22088/abstract/10\">",
"      Deyo RA, Rainville J, Kent DL. What can the history and physical examination tell us about low back pain? JAMA 1992; 268:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22088/abstract/11\">",
"      Cardinal E, Chhem RK, Beauregard CG. Ultrasound-guided interventional procedures in the musculoskeletal system. Radiol Clin North Am 1998; 36:597.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 252 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-00FF42CD0A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_36_22088=[""].join("\n");
var outline_f21_36_22088=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H312216260\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY AND PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pain patterns",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Lateral hip pain aggravated by direct pressure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Lateral hip pain associated with paresthesias and hypesthesias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Anterior hip or groin pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Posterior hip pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Lower anterior thigh pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Trochanteric bursitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Hip osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Meralgia paresthetica",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Osteonecrosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Occult hip fracture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Aortoiliac vascular occlusive disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Referred pain from the lumbosacral spine or sacroiliac joint",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Overall hip function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Gait",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Position change",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Inspection for pelvic obliquity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Maneuvers assessing specific conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Internal and external rotation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Patrick (Fabere) test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Palpation of the trochanteric bursa",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Sensation of the anterolateral thigh",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Straight leg raise",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Lower extremity neurologic examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Palpation of the sacroiliac joint",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Palpation of lower extremity pulses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      CONFIRMATORY MANEUVERS AND PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Radiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Weight bearing AP pelvis x-ray",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Radionuclide bone scan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Local anesthetic block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Hip aspiration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H312216260\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/252\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/252|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?12/5/12383\" title=\"diagnostic image 1\">",
"      Hip osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/252|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/53/9042\" title=\"figure 1\">",
"      Trochanteric bursa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/252|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/59/42928\" title=\"picture 1\">",
"      Inspection for pelvic obliquity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/0/40960\" title=\"picture 2\">",
"      Internal external hip rotation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/48/15104\" title=\"picture 3\">",
"      Palpation trochanteric bursa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/44/32463\" title=\"picture 4\">",
"      Sensation anterolateral thigh",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/47/37616\" title=\"picture 5\">",
"      Straight leg raise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/40/22159\" title=\"picture 6\">",
"      Palpation sacroiliac joint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/22/37217\" title=\"picture 7\">",
"      Injection at mid trochanter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/55/24436\" title=\"picture 8\">",
"      Injection superior trochanter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/24/23939\" title=\"picture 9\">",
"      Local anesthetic block of the lateral femoral cutaneous nerve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/56/9089\" title=\"picture 10\">",
"      Local anesthetic block of the sacroiliac joint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/31/16895\" title=\"picture 11\">",
"      Hip aspiration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/252|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/56/39819\" title=\"table 1\">",
"      Etiology of osteonecrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/21/5469\" title=\"table 2\">",
"      Hip examination",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/10/18601?source=related_link\">",
"      Approach to the diagnosis and evaluation of low back pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30201?source=related_link\">",
"      Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12056?source=related_link\">",
"      Clinical manifestations of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33287?source=related_link\">",
"      Diagnosis and classification of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39061?source=related_link\">",
"      Meralgia paresthetica (lateral femoral cutaneous nerve entrapment)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28346?source=related_link\">",
"      Osteonecrosis (avascular necrosis of bone)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16729?source=related_link\">",
"      Overview of hip pain in childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/46/23266?source=related_link\">",
"      Patient information: Aseptic necrosis of the hip (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/46/24289?source=related_link\">",
"      Patient information: Hip pain (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/25/43409?source=related_link\">",
"      Patient information: Hip pain in older people (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25210?source=related_link\">",
"      Radiologic evaluation of the painful hip in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20360?source=related_link\">",
"      Synovial fluid analysis and the diagnosis of septic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18966?source=related_link\">",
"      Trochanteric bursitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_36_22089="Moraxella catarrhalis infections";
var content_f21_36_22089=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Moraxella catarrhalis infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/36/22089/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/36/22089/contributors\">",
"     Timothy F Murphy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/36/22089/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/36/22089/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/36/22089/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/36/22089/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/36/22089/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1052223437\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Moraxella catarrhalis is a gram-negative diplococcus that commonly colonizes the upper respiratory tract, particularly in children. For much of the last century, the bacterium was regarded as a commensal. However, research has established that M. catarrhalis is an important and common human respiratory tract pathogen, in particular as a cause of acute otitis media in children and of exacerbations in adults with chronic obstructive pulmonary disease (COPD).",
"   </p>",
"   <p>",
"    The epidemiology, pathogenesis, clinical manifestations, diagnosis, treatment, and prevention of infections caused by M. catarrhalis will be reviewed here. Acute otitis media, COPD, and rhinosinusitis are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=see_link\">",
"     \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8760?source=see_link\">",
"     \"Acute otitis media in children: Diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21514?source=see_link\">",
"     \"Acute otitis media in children: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/62/39913?source=see_link\">",
"     \"Acute otitis media in adults (suppurative and serous)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7866?source=see_link\">",
"     \"Management of infection in acute exacerbations of chronic obstructive pulmonary disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11273?source=see_link\">",
"     \"Acute bacterial rhinosinusitis in children: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42921?source=see_link\">",
"     \"Acute bacterial rhinosinusitis in children: Microbiology and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39688?source=see_link\">",
"     \"Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2297?source=see_link\">",
"     \"Acute sinusitis and rhinosinusitis in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1052223445\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. catarrhalis is an exclusively human pathogen with an ecologic niche in the human upper respiratory tract.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1052223553\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20297225\">",
"    <span class=\"h3\">",
"     Prevalence of colonization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of M. catarrhalis colonization is highly dependent on age. Whereas healthy adults are rarely colonized with this organism, most infants have upper respiratory tract colonization at some time in the first several years of life [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Substantial geographic variation in the rate of colonization has been observed. As an example, a study in Buffalo, New York showed that 66 percent of infants were colonized at least once in the first year of life, whereas a study in G&ouml;teborg, Sweden showed colonization of approximately one-half that rate [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Active turnover of colonizing strains occurs. Differences in colonization rates are affected by multiple factors, including living conditions, hygiene, household smoking, and genetics of the population, among others.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20297242\">",
"    <span class=\"h3\">",
"     Impact of pneumococcal vaccination on colonization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the pathogenesis of bacterial otitis media involves the migration of bacteria from the nasopharynx to the middle ear via the eustachian tube, patterns of nasopharyngeal colonization directly affect the distribution of pathogens that cause otitis media. The widespread administration of pneumococcal conjugate vaccines is resulting in changing patterns of nasopharyngeal colonization in populations with vaccination programs. Since the introduction of the 7-valent pneumococcal conjugate vaccine as part of routine childhood immunizations in the United States in 2000, colonization by vaccine serotypes of Streptococcus pneumoniae has decreased, and colonization by nonvaccine serotypes of S. pneumoniae, nontypeable Haemophilus influenzae, and M. catarrhalis had increased, resulting in a shift of pathogens that cause otitis media [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. One study demonstrated an increased prevalence of nasopharyngeal colonization by M. catarrhalis during episodes of otitis media in children who received the 7-valent pneumococcal conjugate vaccine, compared with the prevalence in children with otitis media before introduction of the vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/7\">",
"     7",
"    </a>",
"    ]. Similar shifts have been observed in children and adults with sinusitis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 13-valent pneumococcal conjugate vaccine was licensed in the United States in 2010 and a 10-valent vaccine was licensed in Europe in 2009. Conjugate vaccines that contain 9, 10, 11, and 15 serotypes have also been developed (",
"    <a class=\"graphic graphic_table graphicRef77274 \" href=\"UTD.htm?14/59/15293\">",
"     table 1",
"    </a>",
"    ). Thus, surveillance of nasopharyngeal colonization will be important; further changes are inevitable as programs with these vaccines are implemented. Pneumococcal conjugate vaccines are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=see_link\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/37/601?source=see_link\">",
"     \"Impact of universal infant immunization with pneumococcal (Streptococcus pneumoniae) conjugate vaccines in the United States\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1052223561\">",
"    <span class=\"h2\">",
"     Adults with chronic obstructive pulmonary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper airway colonization with M. catarrhalis is uncommon in healthy adults, occurring in approximately 1 to 5 percent of individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. By contrast, strains of M. catarrhalis are regularly acquired and cleared from the sputum of adults with chronic obstructive pulmonary disease (COPD) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/10\">",
"     10",
"    </a>",
"    ]. Acquisition of a new strain of M. catarrhalis is associated with exacerbations of COPD approximately one-half of the time [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/10,11\">",
"     10,11",
"    </a>",
"    ] Longitudinal analysis demonstrates that once a strain is cleared, protection from reacquisition of the same strain occurs. The median duration of carriage of a strain is rather short (approximately one month) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/10\">",
"     10",
"    </a>",
"    ]. This pattern of colonization in the setting of COPD is in contrast to that of H. influenzae, in which a subset of patients demonstrates persistent colonization with a single strain for months to years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7866?source=see_link&amp;anchor=H4#H4\">",
"     \"Management of infection in acute exacerbations of chronic obstructive pulmonary disease\", section on 'Bacterial infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1052223625\">",
"    <span class=\"h2\">",
"     Nosocomial transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. catarrhalis is transmitted among patients in hospitals and in healthcare facilities, particularly in multiple bed wards and during winter months [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. M. catarrhalis can cause hospital-acquired (nosocomial) pneumonia. However, one must be cautious in drawing conclusions regarding the etiology of pneumonia based on a positive sputum culture in these settings, since M. catarrhalis can simply colonize the respiratory tract in adults with pneumonia caused by other pathogens, such as S. pneumoniae. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12183?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\", section on 'Microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20297701\">",
"    <span class=\"h2\">",
"     Other Moraxella species",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other Moraxella species are normal commensals of the upper respiratory tract, and are rarely recovered from the skin and urogenital tract [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/15\">",
"     15",
"    </a>",
"    ]. They have been reported to cause eye infections, including conjunctivitis, keratitis, and occasionally, endophthalmitis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/15-18\">",
"     15-18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1052223653\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1052223660\">",
"    <span class=\"h2\">",
"     Otitis media",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial step in the pathogenesis of otitis media is colonization of the nasopharynx. Otitis media occurs when bacteria migrate from the nasopharynx to the normally sterile middle ear space via the eustachian tube. This migration is usually precipitated by an acute viral upper respiratory tract infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=see_link&amp;anchor=H15#H15\">",
"     \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1052223668\">",
"    <span class=\"h2\">",
"     Exacerbations of chronic obstructive pulmonary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Healthy human airways below the vocal cords are sterile by culture. However, adults with chronic obstructive pulmonary disease (COPD) have altered mucociliary function, which leads to airway colonization and infection. Exacerbations of COPD are driven by the acquisition of new strains of bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/11,19\">",
"     11,19",
"    </a>",
"    ]. Among adults with COPD, approximately one-half of new strain acquisitions of M. catarrhalis are associated with clinical signs of exacerbations.",
"   </p>",
"   <p>",
"    Several lines of evidence support the role of M. catarrhalis in exacerbations of COPD:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Bacteriologic studies of the lower airways",
"      </strong>",
"      &mdash; M. catarrhalis is isolated from the lower airways of adults with exacerbations of COPD when the distal airways are sampled using bronchoscopy [",
"      <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/20-23\">",
"       20-23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Acquisition of new strains and exacerbations",
"      </strong>",
"      &mdash; Acquisition of new strains of M. catarrhalis trigger COPD exacerbations [",
"      <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/10,11\">",
"       10,11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Antibody responses to M. catarrhalis in COPD",
"      </strong>",
"      &mdash; Adults with COPD make new antibody responses to M. catarrhalis following acquisition and clearance of a strain [",
"      <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/10,24-26\">",
"       10,24-26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Protective responses to M. catarrhalis in COPD",
"      </strong>",
"      &mdash; Clearance of M. catarrhalis is associated with strain-specific protection [",
"      <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Airway inflammation and M. catarrhalis",
"      </strong>",
"      &mdash; In patients with COPD exacerbations, acquisition of a new strain of M. catarrhalis is associated with increased airway inflammation compared with patients with negative cultures [",
"      <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/27-29\">",
"       27-29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Protease-antiprotease imbalance",
"      </strong>",
"      &mdash; Acquisition of M. catarrhalis perturbs the protease-antiprotease balance in the airways [",
"      <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1052223706\">",
"    <span class=\"h2\">",
"     Molecular mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recognition of M. catarrhalis as an important human respiratory tract pathogen has stimulated active investigation into molecular mechanisms of pathogenesis, as illustrated by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Adherence to respiratory epithelium",
"      </strong>",
"      &mdash; M. catarrhalis expresses a dozen or more adhesins, each with different binding specificities for host structures [",
"      <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]. Several of these adhesins are being evaluated as potential vaccine antigens. (See",
"      <a class=\"local\" href=\"#H432138274\">",
"       'Prevention'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Intracellular invasion",
"      </strong>",
"      &mdash; While long viewed as an exclusively extracellular organism, studies have established that M. catarrhalis invades multiple cell types, including bronchial epithelial cells, small airway epithelial cells, and type 2 alveolar cells [",
"      <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/32\">",
"       32",
"      </a>",
"      ]. Furthermore, M. catarrhalis resides intracellularly in human pharyngeal lymphoid tissue, acting as a reservoir for persistence in the human respiratory tract [",
"      <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Complement resistance",
"      </strong>",
"      &mdash; M. catarrhalis employs several mechanisms to inactivate complement, rendering most strains resistant to killing by human serum [",
"      <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/34,35\">",
"       34,35",
"      </a>",
"      ]. Serum resistance has been associated with increased virulence in some studies [",
"      <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/36,37\">",
"       36,37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Biofilm formation",
"      </strong>",
"      &mdash; Biofilms are important in the pathogenesis of otitis media and bacterial infections in patients with COPD. A biofilm is a community of bacteria encased in an extracellular matrix adherent to a surface. M. catarrhalis biofilms are present in the middle ear of children with recurrent and chronic otitis media [",
"      <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/38\">",
"       38",
"      </a>",
"      ]. Bacteria in biofilms are more resistant to antibiotics and host clearance mechanisms compared with bacteria that are not associated with biofilms.",
"     </li>",
"     <li>",
"      <strong>",
"       Induction of inflammation",
"      </strong>",
"      &mdash; M. catarrhalis induces activation of signaling pathways, which results in secretion of inflammatory cytokines by bronchial epithelial cells [",
"      <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/39-41\">",
"       39-41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       M. catarrhalis as a copathogen",
"      </strong>",
"      &mdash; M. catarrhalis is often isolated simultaneously with Streptococcus pneumoniae and Haemophilus influenzae in respiratory tract cultures [",
"      <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/42,43\">",
"       42,43",
"      </a>",
"      ]. M. catarrhalis may facilitate infection by other pathogens through several mechanisms, including:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Releasing vesicles that promote survival of H. influenzae during complement-mediated attacks [",
"      <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Responding to autoinducer-2 signal produced by H. influenzae, enhancing biofilm formation [",
"      <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Conferring beta-lactam resistance to bacteria in close proximity by releasing beta-lactamase into the local environment [",
"      <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/46-49\">",
"       46-49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1052224084\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. catarrhalis is a common cause of otitis media in children and exacerbations in adults with chronic obstructive pulmonary disease (COPD). Less commonly, M. catarrhalis causes pneumonia, bacteremia, periorbital cellulitis, neonatal meningitis, septic arthritis, and conjunctivitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1052224091\">",
"    <span class=\"h2\">",
"     Acute otitis media in children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on cultures of middle ear fluid obtained by tympanocentesis, the gold standard for determining etiology, M. catarrhalis is the third most common bacterial cause of otitis media after nontypeable Haemophilus influenzae and Streptococcus pneumoniae. M. catarrhalis causes 15 to 20 percent of episodes of otitis media [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/30,50-58\">",
"     30,50-58",
"    </a>",
"    ]. There appears to be substantial geographic variation in rates of colonization and infection with M. catarrhalis. As an example, in a multicenter trial in Finland, cultures of middle ear fluid grew M. catarrhalis in 23 percent of children with acute otitis media [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/59\">",
"     59",
"    </a>",
"    ]. By contrast, in a trial in Israel, M. catarrhalis was cultured from the middle ear fluid of approximately 5 percent of children with acute otitis media [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/60\">",
"     60",
"    </a>",
"    ]. The reason for this geographic variation is not known.",
"   </p>",
"   <p>",
"    Otitis media caused by H. influenzae and M. catarrhalis appear to be milder than pneumococcal otitis media [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/61\">",
"     61",
"    </a>",
"    ]. In a review of 12,799 episodes of otitis media over more than seven years, including 501 episodes that yielded positive middle ear fluid cultures for M. catarrhalis, several clinical and epidemiologic features of M. catarrhalis otitis media were identified that differed from otitis media caused by S. pneumoniae and H. influenzae [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/60\">",
"     60",
"    </a>",
"    ]. Compared with other bacterial pathogens, M. catarrhalis otitis media was characterized by:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A higher proportion of mixed bacterial infections",
"     </li>",
"     <li>",
"      Younger age at diagnosis",
"     </li>",
"     <li>",
"      A lower proportion of spontaneous perforation of the tympanic membrane",
"     </li>",
"     <li>",
"      No associated mastoiditis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is worth noting, however, that there is substantial overlap in clinical features of otitis media of different etiologies, and it is not possible to use these features to establish an etiologic diagnosis in an individual patient. The clinical manifestations of otitis media in children are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=see_link&amp;anchor=H21#H21\">",
"     \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1052224345\">",
"    <span class=\"h2\">",
"     Recurrent otitis media and otitis media with effusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Otitis media with effusion refers to the presence of middle ear fluid without clinical signs of acute otitis media. Analysis of middle ear fluid samples from children with otitis media with effusion using sensitive methods, such as the polymerase chain reaction (PCR), reveal that up to 80 percent of samples contain bacterial DNA from H. influenzae, M. catarrhalis, or S. pneumoniae, suggesting that bacteria may play a role in the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. Biofilms of bacterial pathogens of otitis media, including M. catarrhalis, are present in biopsy tissues of children with chronic and recurrent otitis media [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/38\">",
"     38",
"    </a>",
"    ]. Although the presence of bacterial DNA is consistent with the presence of unculturable bacteria (in the form of biofilms, for example), the significance of these observations is not clear.",
"   </p>",
"   <p>",
"    Otitis media with effusion is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22153?source=see_link\">",
"     \"Otitis media with effusion (serous otitis media) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1052224362\">",
"    <span class=\"h2\">",
"     Exacerbations of chronic obstructive pulmonary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The course of COPD is characterized by intermittent worsening of disease called exacerbations, which results in substantial morbidity. Approximately one-half of exacerbations are caused by bacterial infection, with viral infections and noninfectious causes accounting for one-half [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/19\">",
"     19",
"    </a>",
"    ]. M. catarrhalis is the second most common bacterial cause of COPD exacerbations, after nontypeable H. influenzae (",
"    <a class=\"graphic graphic_table graphicRef70203 \" href=\"UTD.htm?28/48/29451\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <br/>",
"    The clinical manifestations of exacerbations caused by M. catarrhalis are indistinguishable from those of other bacterial etiologies. Patients present with increased sputum volume, increased sputum purulence (manifested by a change in color of sputum usually to yellow or green), and increased dyspnea (compared with baseline symptoms). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30954?source=see_link&amp;anchor=H5#H5\">",
"     \"Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1052224590\">",
"    <span class=\"h2\">",
"     Rhinosinusitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small proportion of viral upper respiratory tract infections are complicated by bacterial rhinosinusitis. Approximately 20 percent of sinus aspirates from children with bacterial sinusitis obtained by sinus puncture are culture-positive for M. catarrhalis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. M. catarrhalis accounts for a smaller proportion of cases of bacterial sinusitis in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/8\">",
"     8",
"    </a>",
"    ]. The clinical manifestations of M. catarrhalis sinusitis are the same as those for other bacterial pathogens, including S. pneumoniae and H. influenzae. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42921?source=see_link&amp;anchor=H2#H2\">",
"     \"Acute bacterial rhinosinusitis in children: Microbiology and treatment\", section on 'Microbiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11273?source=see_link&amp;anchor=H7#H7\">",
"     \"Acute bacterial rhinosinusitis in children: Clinical features and diagnosis\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39688?source=see_link\">",
"     \"Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1052224630\">",
"    <span class=\"h2\">",
"     Pneumonia, bacteremia, and other infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. catarrhalis is an uncommon cause of pneumonia. When it occurs, elderly people and those with underlying cardiopulmonary conditions are most often affected [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/67\">",
"     67",
"    </a>",
"    ]. Bacteremia and other invasive infections are rare. A 2007 review of the literature reported only 75 cases of invasive infection; these included bacteremia, endocarditis, pneumonia, periorbital cellulitis, neonatal meningitis, and septic arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/68\">",
"     68",
"    </a>",
"    ]. Seventy-two of the 75 patients (96 percent) had bacteremia. No particular immunocompromising condition was associated with invasive M. catarrhalis infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31514?source=see_link\">",
"     \"Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/55/2938?source=see_link\">",
"     \"Epidemiology, pathogenesis, and etiology of pneumonia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    M. catarrhalis can also cause bacterial conjunctivitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20760?source=see_link&amp;anchor=H4#H4\">",
"     \"Conjunctivitis\", section on 'Bacterial conjunctivitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1052224666\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases of infection caused by M. catarrhalis, such as otitis media and exacerbations of chronic obstructive pulmonary disease (COPD), no microbiologic diagnosis is attempted and patients are treated empirically. Even when a specimen is obtained, many microbiology laboratories will not speciate organisms that have the morphology of Neisseria spp since they appear identical to Neisseria spp on Gram stain and Neisseria spp are part of the normal upper airway flora (",
"    <a class=\"graphic graphic_picture graphicRef74078 \" href=\"UTD.htm?18/17/18710\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1052224673\">",
"    <span class=\"h2\">",
"     Otitis media",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clinical diagnosis of otitis media is made by pneumatic otoscopy (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8760?source=see_link&amp;anchor=H8#H8\">",
"     \"Acute otitis media in children: Diagnosis\", section on 'Otoscopy'",
"    </a>",
"    ). In order to determine the etiology of an individual episode of otitis media, tympanocentesis is required; using this method, middle ear fluid can be obtained for Gram stain and culture. However, tympanocentesis is generally performed only as part of research studies. Thus, in clinical practice, the etiology of individual cases is not known and cases are treated empirically. (See",
"    <a class=\"local\" href=\"#H1052224713\">",
"     'Treatment'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21514?source=see_link\">",
"     \"Acute otitis media in children: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1052224693\">",
"    <span class=\"h2\">",
"     Exacerbations of COPD",
"    </span>",
"    &nbsp;&mdash;&nbsp;An exacerbation of COPD is defined by clinical criteria that rely largely on patient history. This generally includes an acute increase in one or more of the following cardinal symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cough increases in frequency and severity",
"     </li>",
"     <li>",
"      Sputum production increases in volume",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      changes character",
"     </li>",
"     <li>",
"      Dyspnea increases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A Gram stain of expectorated sputum that shows a predominance of gram-negative diplococci and a positive sputum culture for M. catarrhalis are suggestive of etiology but are not diagnostic, since M. catarrhalis can colonize the respiratory tract in the absence of signs of active infection. Many adults with exacerbations of COPD are seen as outpatients, where cultures and smears of sputum are often not performed. Thus, many exacerbations are managed empirically. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7866?source=see_link\">",
"     \"Management of infection in acute exacerbations of chronic obstructive pulmonary disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1052224705\">",
"    <span class=\"h2\">",
"     Laboratory diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. catarrhalis is an aerobic gram-negative diplococcus that appears identical to Neisseria spp on Gram stain (",
"    <a class=\"graphic graphic_picture graphicRef74078 \" href=\"UTD.htm?18/17/18710\">",
"     picture 1",
"    </a>",
"    ). It grows as round opaque colonies on blood and chocolate agar. Colonies can be slid across the surface of the agar without disruption (the so-called &ldquo;hockey puck sign&rdquo;). M. catarrhalis colonies closely resemble colonies of commensal Neisseria spp that are part of the normal human upper airway flora. It is this phenotypic similarity to Neisseria spp that has contributed to M. catarrhalis being overlooked as a pathogen for so long. In many cases, microbiology laboratories will not speciate organisms that have the morphology of Neisseria spp since they are part of the normal upper airway flora.",
"   </p>",
"   <p>",
"    The most helpful indications of M. catarrhalis in culture are the hockey puck sign and the observation that after 48 hours, M. catarrhalis colonies tend to take on a pink color. However, it is sometimes necessary to pick colonies and perform further testing to definitively identify M. catarrhalis in cultures that contain mixed upper airway flora.",
"   </p>",
"   <p>",
"    Various biochemical assays can be used to distinguish M. catarrhalis from Neisseria spp. M. catarrhalis produces oxidase, catalase, and DNAse, which are detected by using DNAse test agar with methyl green. M. catarrhalis also reduces nitrate and nitrite, and hydrolyzes tributyrin, but does not ferment carbohydrates. Commercially available kits exploit these biochemical characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/69,70\">",
"     69,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More sensitive assays, such as polymerase chain reaction (PCR), to detect respiratory pathogens including M. catarrhalis are under development but are not yet commercially available [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/62,64,71\">",
"     62,64,71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H528736984\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since several pathogens can cause otitis media and exacerbations of chronic obstructive pulmonary disease (COPD), the differential diagnosis for these conditions includes not only M. catarrhalis, but also other bacterial species (eg, Streptococcus pneumoniae, Haemophilus influenzae), and respiratory viruses (eg, respiratory syncytial virus, rhinovirus, coronaviruses, influenza viruses, adenoviruses). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=see_link&amp;anchor=H16#H16\">",
"     \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\", section on 'Microbiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7866?source=see_link&amp;anchor=H2#H2\">",
"     \"Management of infection in acute exacerbations of chronic obstructive pulmonary disease\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1052224713\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most episodes of otitis media in children and exacerbations of chronic obstructive pulmonary disease (COPD) in adults are treated empirically with oral antibiotics that have activity against M. catarrhalis and other common etiologies. Most strains of M. catarrhalis are susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    , extended-spectrum cephalosporins (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/44/16070?source=see_link\">",
"     cefixime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/44/27333?source=see_link\">",
"     cefpodoxime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/11/27829?source=see_link\">",
"     cefaclor",
"    </a>",
"    , loracarbef,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    ), newer macrolides (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ), tetracyclines, and fluoroquinolones [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/72\">",
"     72",
"    </a>",
"    ]. M. catarrhalis rapidly acquired beta-lactamases in the 1970s and 1980s and susceptibility patterns have remained relatively stable since then [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/73\">",
"     73",
"    </a>",
"    ]. Nearly all strains express beta-lactamase from a chromosomal locus and are thus resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    and penicillin.",
"   </p>",
"   <p>",
"    Any of these agents can be used for the empiric therapy of infections caused by M. catarrhalis, but the choice of agent and duration of treatment depend on the clinical manifestations of the infection and on the individual patient (eg, tetracyclines are avoided in children &lt;8 years of age; fluoroquinolones are often avoided in children). Treatment recommendations for acute otitis media, infection in acute exacerbations of COPD, and rhinosinusitis are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21514?source=see_link\">",
"     \"Acute otitis media in children: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/62/39913?source=see_link&amp;anchor=H17#H17\">",
"     \"Acute otitis media in adults (suppurative and serous)\", section on 'Treatment of AOM'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42921?source=see_link&amp;anchor=H3#H3\">",
"     \"Acute bacterial rhinosinusitis in children: Microbiology and treatment\", section on 'Empiric antibiotic therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2297?source=see_link\">",
"     \"Acute sinusitis and rhinosinusitis in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H432138274\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Research programs are working toward developing vaccines to prevent infections caused by M. catarrhalis, particularly otitis media and exacerbations of chronic obstructive pulmonary disease (COPD) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22089/abstract/31,74,75\">",
"     31,74,75",
"    </a>",
"    ]. A challenge to this work is the absence of an animal model that simulates human M. catarrhalis infections. No vaccines are commercially available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1052224888\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Moraxella catarrhalis is an aerobic gram-negative diplococcus that is an exclusively human pathogen whose ecological niche is the human upper respiratory tract (",
"      <a class=\"graphic graphic_picture graphicRef74078 \" href=\"UTD.htm?18/17/18710\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1052223445\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The widespread use of pneumococcal conjugate vaccines is changing patterns of upper respiratory tract colonization and the distribution of pathogens that cause otitis media, with M. catarrhalis taking on in increasingly important role. (See",
"      <a class=\"local\" href=\"#H20297242\">",
"       'Impact of pneumococcal vaccination on colonization'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      M. catarrhalis is a common cause of otitis media in children and exacerbations in adults with chronic obstructive pulmonary disease (COPD). Less commonly, M. catarrhalis causes pneumonia, bacteremia, periorbital cellulitis, neonatal meningitis, septic arthritis, and conjunctivitis. (See",
"      <a class=\"local\" href=\"#H1052224084\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Otitis media results from contiguous spread of M. catarrhalis from the nasopharynx to the middle ear via the eustachian tube, often precipitated by a viral upper respiratory tract infection. The majority of exacerbations of COPD are caused by airway infection, with acquisition of new strains of bacteria often precipitating symptoms. (See",
"      <a class=\"local\" href=\"#H1052223660\">",
"       'Otitis media'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1052223668\">",
"       'Exacerbations of chronic obstructive pulmonary disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      M. catarrhalis is the third most common cause of bacterial otitis media and is clinically milder than pneumococcal otitis media. Compared with other pathogens (Streptococcus pneumoniae and Haemophilus influenzae), M. catarrhalis otitis media is characterized by a higher proportion of mixed infection, younger age at diagnosis, and lower proportion of spontaneous perforation of the tympanic membrane. (See",
"      <a class=\"local\" href=\"#H1052224091\">",
"       'Acute otitis media in children'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      M. catarrhalis is the second most common bacterial cause of exacerbations of COPD and is clinically indistinguishable from exacerbations caused by other pathogens (",
"      <a class=\"graphic graphic_table graphicRef70203 \" href=\"UTD.htm?28/48/29451\">",
"       table 2",
"      </a>",
"      ). The cardinal symptoms are increased sputum volume, increased sputum purulence (change in color of sputum), and increased dyspnea compared to baseline symptoms. (See",
"      <a class=\"local\" href=\"#H1052224362\">",
"       'Exacerbations of chronic obstructive pulmonary disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In most cases of infection caused by M. catarrhalis, such as otitis media and exacerbations of COPD, no microbiologic diagnosis is attempted and patients are treated empirically. Even when a specimen is obtained, many microbiology laboratories will not speciate organisms that have the morphology of M. catarrhalis, since they appear identical to Neisseria spp on Gram stain and Neisseria spp are part of the normal upper airway flora (",
"      <a class=\"graphic graphic_picture graphicRef74078 \" href=\"UTD.htm?18/17/18710\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1052224666\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Most strains of M. catarrhalis are susceptible to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"       amoxicillin-clavulanate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      , extended-spectrum cephalosporins, newer macrolides, tetracyclines, and fluoroquinolones. Any of these agents can be used for the empiric therapy of infections caused by M. catarrhalis, but the choice of agent and duration of treatment depend on the clinical manifestations of the infection and on the individual patient (eg, tetracyclines are avoided in children &lt;8 years of age, fluoroquinolones are often avoided in children). Most strains of M. catarrhalis produce beta-lactamase and are thus resistant to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      and penicillin. (See",
"      <a class=\"local\" href=\"#H1052224713\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment recommendations for the empiric treatment of acute otitis media in children and exacerbations of COPD are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21514?source=see_link\">",
"       \"Acute otitis media in children: Treatment\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7866?source=see_link\">",
"       \"Management of infection in acute exacerbations of chronic obstructive pulmonary disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      There is no currently licensed vaccine for M. catarrhalis, but active research is underway to develop such vaccines that would have an impact on otitis media and exacerbations in adults with COPD. (See",
"      <a class=\"local\" href=\"#H432138274\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/1\">",
"      Vaneechoutte M, Verschraegen G, Claeys G, et al. Respiratory tract carrier rates of Moraxella (Branhamella) catarrhalis in adults and children and interpretation of the isolation of M. catarrhalis from sputum. J Clin Microbiol 1990; 28:2674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/2\">",
"      Ejlertsen T, Thisted E, Ebbesen F, et al. Branhamella catarrhalis in children and adults. A study of prevalence, time of colonisation, and association with upper and lower respiratory tract infections. J Infect 1994; 29:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/3\">",
"      Faden H, Harabuchi Y, Hong JJ. Epidemiology of Moraxella catarrhalis in children during the first 2 years of life: relationship to otitis media. J Infect Dis 1994; 169:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/4\">",
"      Aniansson G, Alm B, Andersson B, et al. Nasopharyngeal colonization during the first year of life. J Infect Dis 1992; 165 Suppl 1:S38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/5\">",
"      Block SL, Hedrick J, Harrison CJ, et al. Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. Pediatr Infect Dis J 2004; 23:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/6\">",
"      Casey JR, Pichichero ME. Changes in frequency and pathogens causing acute otitis media in 1995-2003. Pediatr Infect Dis J 2004; 23:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/7\">",
"      Revai K, McCormick DP, Patel J, et al. Effect of pneumococcal conjugate vaccine on nasopharyngeal bacterial colonization during acute otitis media. Pediatrics 2006; 117:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/8\">",
"      Brook I, Gober AE. Recovery of interfering and beta-lactamase-producing bacteria from group A beta-haemolytic streptococci carriers and non-carriers. J Med Microbiol 2006; 55:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/9\">",
"      Brook I, Gober AE. Frequency of recovery of pathogens from the nasopharynx of children with acute maxillary sinusitis before and after the introduction of vaccination with the 7-valent pneumococcal vaccine. Int J Pediatr Otorhinolaryngol 2007; 71:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/10\">",
"      Murphy TF, Brauer AL, Grant BJ, Sethi S. Moraxella catarrhalis in chronic obstructive pulmonary disease: burden of disease and immune response. Am J Respir Crit Care Med 2005; 172:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/11\">",
"      Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 347:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/12\">",
"      Murphy TF, Brauer AL, Schiffmacher AT, Sethi S. Persistent colonization by Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/13\">",
"      Masaki H, Asoh N, Kawazoe K, et al. Possible relationship of PFGE patterns of Moraxella catarrhalis between hospital- and community-acquired respiratory infections in a community hospital. Microbiol Immunol 2003; 47:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/14\">",
"      Hays JP, Eadie K, Verduin CM, et al. Changes in genetic types and population dynamics of Moraxella catarrhalis in hospitalized children are not associated with an exacerbation of existing disease. J Med Microbiol 2003; 52:815.",
"     </a>",
"    </li>",
"    <li>",
"     Murphy TF. Moraxella catarrhalis, Kingella, and other gram-negative cocci. In: Mandell, Douglas, and Bennett's Principles and Practices of Infectious Diseases, 7th ed, Mandell GL, Bennett JE, Dolin R.  (Eds), Churchill Livingstone Elsevier, Philadelphia 2010. Vol 2, p.2771.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/16\">",
"      Schaefer F, Bruttin O, Zografos L, Guex-Crosier Y. Bacterial keratitis: a prospective clinical and microbiological study. Br J Ophthalmol 2001; 85:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/17\">",
"      Das S, Constantinou M, Daniell M, Taylor HR. Moraxella keratitis: predisposing factors and clinical review of 95 cases. Br J Ophthalmol 2006; 90:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/18\">",
"      Laukeland H, Bergh K, Bevanger L. Posttrabeculectomy endophthalmitis caused by Moraxella nonliquefaciens. J Clin Microbiol 2002; 40:2668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/19\">",
"      Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008; 359:2355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/20\">",
"      Mons&oacute; E, Ruiz J, Rosell A, et al. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995; 152:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/21\">",
"      Fagon JY, Chastre J, Trouillet JL, et al. Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Use of the protected specimen brush technique in 54 mechanically ventilated patients. Am Rev Respir Dis 1990; 142:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/22\">",
"      Soler N, Torres A, Ewig S, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998; 157:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/23\">",
"      Nicotra B, Rivera M, Luman JI, Wallace RJ Jr. Branhamella catarrhalis as a lower respiratory tract pathogen in patients with chronic lung disease. Arch Intern Med 1986; 146:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/24\">",
"      LaFontaine ER, Snipes LE, Bullard B, et al. Identification of domains of the Hag/MID surface protein recognized by systemic and mucosal antibodies in adults with chronic obstructive pulmonary disease following clearance of Moraxella catarrhalis. Clin Vaccine Immunol 2009; 16:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/25\">",
"      Murphy TF, Brauer AL, Aebi C, Sethi S. Identification of surface antigens of Moraxella catarrhalis as targets of human serum antibody responses in chronic obstructive pulmonary disease. Infect Immun 2005; 73:3471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/26\">",
"      Murphy TF, Brauer AL, Aebi C, Sethi S. Antigenic specificity of the mucosal antibody response to Moraxella catarrhalis in chronic obstructive pulmonary disease. Infect Immun 2005; 73:8161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/27\">",
"      Parameswaran GI, Wrona CT, Murphy TF, Sethi S. Moraxella catarrhalis acquisition, airway inflammation and protease-antiprotease balance in chronic obstructive pulmonary disease. BMC Infect Dis 2009; 9:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/28\">",
"      Sethi S, Wrona C, Eschberger K, et al. Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/29\">",
"      Sethi S, Muscarella K, Evans N, et al. Airway inflammation and etiology of acute exacerbations of chronic bronchitis. Chest 2000; 118:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/30\">",
"      Murphy TF, Parameswaran GI. Moraxella catarrhalis, a human respiratory tract pathogen. Clin Infect Dis 2009; 49:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/31\">",
"      Tan TT, Riesbeck K. Current progress of adhesins as vaccine candidates for Moraxella catarrhalis. Expert Rev Vaccines 2007; 6:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/32\">",
"      Slevogt H, Seybold J, Tiwari KN, et al. Moraxella catarrhalis is internalized in respiratory epithelial cells by a trigger-like mechanism and initiates a TLR2- and partly NOD1-dependent inflammatory immune response. Cell Microbiol 2007; 9:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/33\">",
"      Heiniger N, Spaniol V, Troller R, et al. A reservoir of Moraxella catarrhalis in human pharyngeal lymphoid tissue. J Infect Dis 2007; 196:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/34\">",
"      Nordstr&ouml;m T, Blom AM, Tan TT, et al. Ionic binding of C3 to the human pathogen Moraxella catarrhalis is a unique mechanism for combating innate immunity. J Immunol 2005; 175:3628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/35\">",
"      Attia AS, Ram S, Rice PA, Hansen EJ. Binding of vitronectin by the Moraxella catarrhalis UspA2 protein interferes with late stages of the complement cascade. Infect Immun 2006; 74:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/36\">",
"      Bootsma HJ, van der Heide HG, van de Pas S, et al. Analysis of Moraxella catarrhalis by DNA typing: evidence for a distinct subpopulation associated with virulence traits. J Infect Dis 2000; 181:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/37\">",
"      Wirth T, Morelli G, Kusecek B, et al. The rise and spread of a new pathogen: seroresistant Moraxella catarrhalis. Genome Res 2007; 17:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/38\">",
"      Hall-Stoodley L, Hu FZ, Gieseke A, et al. Direct detection of bacterial biofilms on the middle-ear mucosa of children with chronic otitis media. JAMA 2006; 296:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/39\">",
"      Slevogt H, Schmeck B, Jonatat C, et al. Moraxella catarrhalis induces inflammatory response of bronchial epithelial cells via MAPK and NF-kappaB activation and histone deacetylase activity reduction. Am J Physiol Lung Cell Mol Physiol 2006; 290:L818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/40\">",
"      N'Guessan PD, Temmesfeld-Wollbr&uuml;ck B, Zahlten J, et al. Moraxella catarrhalis induces ERK- and NF-kappaB-dependent COX-2 and prostaglandin E2 in lung epithelium. Eur Respir J 2007; 30:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/41\">",
"      Slevogt H, Maqami L, Vardarowa K, et al. Differential regulation of Moraxella catarrhalis-induced interleukin-8 response by protein kinase C isoforms. Eur Respir J 2008; 31:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/42\">",
"      Verhaegh SJ, Snippe ML, Levy F, et al. Colonization of healthy children by Moraxella catarrhalis is characterized by genotype heterogeneity, virulence gene diversity and co-colonization with Haemophilus influenzae. Microbiology 2011; 157:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/43\">",
"      Pettigrew MM, Gent JF, Revai K, et al. Microbial interactions during upper respiratory tract infections. Emerg Infect Dis 2008; 14:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/44\">",
"      Tan TT, Morgelin M, Forsgren A, Riesbeck K. Haemophilus influenzae survival during complement-mediated attacks is promoted by Moraxella catarrhalis outer membrane vesicles. J Infect Dis 2007; 195:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/45\">",
"      Armbruster CE, Hong W, Pang B, et al. Indirect pathogenicity of Haemophilus influenzae and Moraxella catarrhalis in polymicrobial otitis media occurs via interspecies quorum signaling. MBio 2010; 1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/46\">",
"      Hol C, Van Dijke EE, Verduin CM, et al. Experimental evidence for Moraxella-induced penicillin neutralization in pneumococcal pneumonia. J Infect Dis 1994; 170:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/47\">",
"      Budhani RK, Struthers JK. Interaction of Streptococcus pneumoniae and Moraxella catarrhalis: investigation of the indirect pathogenic role of beta-lactamase-producing moraxellae by use of a continuous-culture biofilm system. Antimicrob Agents Chemother 1998; 42:2521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/48\">",
"      Brook I. Direct and indirect pathogenicity of Branhamella catarrhalis. Drugs 1986; 31 Suppl 3:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/49\">",
"      Wardle JK. Branhamella catarrhalis as an indirect pathogen. Drugs 1986; 31 Suppl 3:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/50\">",
"      Wald ER. Acute otitis media and acute bacterial sinusitis. Clin Infect Dis 2011; 52 Suppl 4:S277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/51\">",
"      Ruohola A, Meurman O, Nikkari S, et al. Microbiology of acute otitis media in children with tympanostomy tubes: prevalences of bacteria and viruses. Clin Infect Dis 2006; 43:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/52\">",
"      Arguedas A, Dagan R, Pichichero M, et al. An open-label, double tympanocentesis study of levofloxacin therapy in children with, or at high risk for, recurrent or persistent acute otitis media. Pediatr Infect Dis J 2006; 25:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/53\">",
"      Kilpi T, Herva E, Kaijalainen T, et al. Bacteriology of acute otitis media in a cohort of Finnish children followed for the first two years of life. Pediatr Infect Dis J 2001; 20:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/54\">",
"      McCarty J. A multicenter, open label trial of azithromycin for the treatment of children with acute otitis media. Pediatr Infect Dis J 1996; 15:S10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/55\">",
"      Aspin MM, Hoberman A, McCarty J, et al. Comparative study of the safety and efficacy of clarithromycin and amoxicillin-clavulanate in the treatment of acute otitis media in children. J Pediatr 1994; 125:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/56\">",
"      Chonmaitree T, Owen MJ, Patel JA, et al. Effect of viral respiratory tract infection on outcome of acute otitis media. J Pediatr 1992; 120:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/57\">",
"      Del Beccaro MA, Mendelman PM, Inglis AF, et al. Bacteriology of acute otitis media: a new perspective. J Pediatr 1992; 120:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/58\">",
"      Faden H, Bernstein J, Brodsky L, et al. Effect of prior antibiotic treatment on middle ear disease in children. Ann Otol Rhinol Laryngol 1992; 101:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/59\">",
"      Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001; 344:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/60\">",
"      Broides A, Dagan R, Greenberg D, et al. Acute otitis media caused by Moraxella catarrhalis: epidemiologic and clinical characteristics. Clin Infect Dis 2009; 49:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/61\">",
"      Rodriguez WJ, Schwartz RH. Streptococcus pneumoniae causes otitis media with higher fever and more redness of tympanic membranes than Haemophilus influenzae or Moraxella catarrhalis. Pediatr Infect Dis J 1999; 18:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/62\">",
"      Post JC, Preston RA, Aul JJ, et al. Molecular analysis of bacterial pathogens in otitis media with effusion. JAMA 1995; 273:1598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/63\">",
"      Hendolin PH, Markkanen A, Ylikoski J, Wahlfors JJ. Use of multiplex PCR for simultaneous detection of four bacterial species in middle ear effusions. J Clin Microbiol 1997; 35:2854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/64\">",
"      Hendolin PH, Paulin L, Ylikoski J. Clinically applicable multiplex PCR for four middle ear pathogens. J Clin Microbiol 2000; 38:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/65\">",
"      Wald ER. Microbiology of acute and chronic sinusitis in children and adults. Am J Med Sci 1998; 316:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/66\">",
"      American Academy of Pediatrics. Subcommittee on Management of Sinusitis and Committee on Quality Improvement. Clinical practice guideline: management of sinusitis. Pediatrics 2001; 108:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/67\">",
"      Wright PW, Wallace RJ Jr. Pneumonia due to Moraxella (Branhamella) catarrhalis. Semin Respir Infect 1989; 4:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/68\">",
"      Tolentino LF. Causes of Moraxella catarrhalis pathogenicity: review of literature and hospital epidemiology. Lab Med 2007; 38:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/69\">",
"      Speeleveld E, Foss&eacute;pr&eacute; JM, Gordts B, Van Landuyt HW. Comparison of three rapid methods, tributyrine, 4-methylumbelliferyl butyrate, and indoxyl acetate, for rapid identification of Moraxella catarrhalis. J Clin Microbiol 1994; 32:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/70\">",
"      Janda WM, Montero MC, Wilcoski LM. Evaluation of the BactiCard Neisseria for identification of pathogenic Neisseria species and Moraxella catarrhalis. Eur J Clin Microbiol Infect Dis 2002; 21:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/71\">",
"      Johansson N, Kalin M, Tiveljung-Lindell A, et al. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis 2010; 50:202.",
"     </a>",
"    </li>",
"    <li>",
"     Schreckenberger PC, Daneshvar MI, Hollis DG. Acinetobacter, Achromobacter, Chryseobacterium, Moraxella, and other nonfermentative gram-negative rods. In: Manual of Clinical Microbiology, 9th ed, Murray PR, Baron EJ, Landry ML, et al.  (Eds), ASM Press, Washington DC 2007. Vol 1, p.770.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/73\">",
"      Nissinen A, Gr&ouml;nroos P, Huovinen P, et al. Development of beta-lactamase-mediated resistance to penicillin in middle-ear isolates of Moraxella catarrhalis in Finnish children, 1978-1993. Clin Infect Dis 1995; 21:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/74\">",
"      Murphy TF. Vaccine development for Moraxella catarrhalis: rationale, approaches and challenges. Expert Rev Vaccines 2009; 8:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22089/abstract/75\">",
"      Ruckdeschel EA, Kirkham C, Lesse AJ, et al. Mining the Moraxella catarrhalis genome: identification of potential vaccine antigens expressed during human infection. Infect Immun 2008; 76:1599.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17122 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-2D9DC08A38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_36_22089=[""].join("\n");
var outline_f21_36_22089=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1052224888\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1052223437\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1052223445\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1052223553\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20297225\">",
"      - Prevalence of colonization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20297242\">",
"      - Impact of pneumococcal vaccination on colonization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1052223561\">",
"      Adults with chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1052223625\">",
"      Nosocomial transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20297701\">",
"      Other Moraxella species",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1052223653\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1052223660\">",
"      Otitis media",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1052223668\">",
"      Exacerbations of chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1052223706\">",
"      Molecular mechanisms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1052224084\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1052224091\">",
"      Acute otitis media in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1052224345\">",
"      Recurrent otitis media and otitis media with effusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1052224362\">",
"      Exacerbations of chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1052224590\">",
"      Rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1052224630\">",
"      Pneumonia, bacteremia, and other infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1052224666\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1052224673\">",
"      Otitis media",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1052224693\">",
"      Exacerbations of COPD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1052224705\">",
"      Laboratory diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H528736984\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1052224713\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H432138274\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1052224888\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/17122\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/17122|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/17/18710\" title=\"picture 1\">",
"      Moraxella catarrhalis Gram stain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/17122|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/59/15293\" title=\"table 1\">",
"      Pneumococcal vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/48/29451\" title=\"table 2\">",
"      Bacterial pathogens in AECOPD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11273?source=related_link\">",
"      Acute bacterial rhinosinusitis in children: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42921?source=related_link\">",
"      Acute bacterial rhinosinusitis in children: Microbiology and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/62/39913?source=related_link\">",
"      Acute otitis media in adults (suppurative and serous)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8760?source=related_link\">",
"      Acute otitis media in children: Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=related_link\">",
"      Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21514?source=related_link\">",
"      Acute otitis media in children: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39688?source=related_link\">",
"      Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2297?source=related_link\">",
"      Acute sinusitis and rhinosinusitis in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30954?source=related_link\">",
"      Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20760?source=related_link\">",
"      Conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/55/2938?source=related_link\">",
"      Epidemiology, pathogenesis, and etiology of pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31514?source=related_link\">",
"      Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12183?source=related_link\">",
"      Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/37/601?source=related_link\">",
"      Impact of universal infant immunization with pneumococcal (Streptococcus pneumoniae) conjugate vaccines in the United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7866?source=related_link\">",
"      Management of infection in acute exacerbations of chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22153?source=related_link\">",
"      Otitis media with effusion (serous otitis media) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_36_22090="Management of mild to moderate ulcerative colitis";
var content_f21_36_22090=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of mild to moderate ulcerative colitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/36/22090/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/36/22090/contributors\">",
"     Richard P MacDermott, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/36/22090/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/36/22090/contributors\">",
"     Paul Rutgeerts, MD, PhD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/36/22090/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/36/22090/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/36/22090/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ulcerative colitis is a chronic inflammatory condition characterized by relapsing and remitting episodes of inflammation limited to the mucosal layer of the colon. It almost invariably involves the rectum and may extend in a proximal and continuous fashion to involve other portions of the colon.",
"   </p>",
"   <p>",
"    This topic will review the management of mild to moderate ulcerative colitis. The management of severe ulcerative colitis, steroid-dependent, and steroid-refractory ulcerative colitis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3319?source=see_link\">",
"     \"Management of severe ulcerative colitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24250?source=see_link\">",
"     \"Approach to adults with steroid-refractory and steroid-dependent ulcerative colitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H350978455\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients may present with active symptoms of ulcerative colitis as the initial manifestation or as a clinical recurrence of their disease. The clinical manifestations and diagnosis of ulcerative colitis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11386?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When a patient presents with recurrent symptoms, some aspects of the initial evaluation should be repeated in order to exclude alternative or comorbid conditions as a cause for the symptoms, as well as to assess the current extent and severity of disease. These features are important to guide treatment. In most cases, laboratory studies and endoscopy are required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1226801230\">",
"    <span class=\"h2\">",
"     Definitions of disease extent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Different terms are used to describe the extent of involvement of ulcerative colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ulcerative proctitis refers to disease limited to the rectum",
"     </li>",
"     <li>",
"      Ulcerative proctosigmoiditis refers to disease limited to the rectum and sigmoid colon and not involving the descending colon",
"     </li>",
"     <li>",
"      Left-sided or distal ulcerative colitis refers to disease that extends beyond the rectum and as far proximally as the splenic flexure",
"     </li>",
"     <li>",
"      Extensive colitis refers to disease extending proximal to the splenic flexure but sparing the cecum",
"     </li>",
"     <li>",
"      Pancolitis refers to disease extending proximal to the splenic flexure and involving the cecum",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Extension of colonic disease may occur over time [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. While clinical symptoms can suggest probable sites of disease activity, colonoscopy is required to determine the extent of involvement. (See",
"    <a class=\"local\" href=\"#H350979203\">",
"     'Colonoscopy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1226801754\">",
"    <span class=\"h2\">",
"     Assessment of clinical severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients can present with mild, moderate, or severe disease. Stratification based on clinical severity is important in guiding management [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H432583317\">",
"     'Treatment of mildly or moderately active disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Mild",
"      </strong>",
"      &ndash; Patients with mild clinical disease have four or fewer stools per day with or without blood, no signs of systemic toxicity, and a normal erythrocyte sedimentation rate (ESR). Mild crampy pain, tenesmus, and periods of constipation are also common, but severe abdominal pain, profuse bleeding, fever, and weight loss are not part of the spectrum of mild disease.",
"     </li>",
"     <li>",
"      <strong>",
"       Moderate",
"      </strong>",
"      &ndash; Patients with moderate clinical disease have frequent loose, bloody stools (&gt;4 per day), mild anemia not requiring blood transfusions, and abdominal pain that is not severe. Patients have minimal signs of systemic toxicity, including a low grade fever. Adequate nutrition is usually maintained and weight loss is not associated with moderate clinical disease.",
"     </li>",
"     <li>",
"      <strong>",
"       Severe",
"      </strong>",
"      &ndash; Patients with a severe clinical presentation typically have frequent loose bloody stools (&ge;6 per day) with severe cramps and evidence of systemic toxicity as demonstrated by a fever (temperature &ge;37.5&ordm;C), tachycardia (HR &ge;90",
"      <span class=\"nowrap\">",
"       beats/minute),",
"      </span>",
"      anemia (hemoglobin &lt;10.5",
"      <span class=\"nowrap\">",
"       g/dL),",
"      </span>",
"      or an elevated ESR (&ge;30",
"      <span class=\"nowrap\">",
"       mm/hour).",
"      </span>",
"      Patients may have rapid weight loss. The management of severe ulcerative colitis is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3319?source=see_link\">",
"       \"Management of severe ulcerative colitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1226801399\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood counts, liver tests, and measurement of C-reactive protein (CRP) and ESR should be performed. CRP and ESR can help determine the severity of the underlying inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1226801754\">",
"     'Assessment of clinical severity'",
"    </a>",
"    above.) In addition, CRP levels may have a role in distinguishing between patients with active ulcerative colitis from those with symptoms caused by concomitant functional disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/7-11\">",
"     7-11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1226796987\">",
"     'Management of persistent symptoms'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition, specific serologic testing for sexually transmitted diseases including Neisseria gonorrhea, HSV, and Treponema pallidum should be considered, particularly in patients with severe rectal symptoms including urgency and tenesmus and with risk factors for these diseases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/35/26166?source=see_link\">",
"     \"Diagnosis of gonococcal infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/12/28872?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39624?source=see_link\">",
"     \"Diagnostic testing for syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Stool studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stool studies should include stool Clostridium difficile toxin, routine stool cultures (salmonella, shigella, campylobacter, yersinia), and specific testing for E. coli 0157:H7. Microscopy for ova and parasites (three samples) and a Giardia stool antigen test should also be performed, particularly if the patient has risk factors such as recent travel. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32025?source=see_link&amp;anchor=H2#H2\">",
"     \"Approach to the adult with acute diarrhea in developed countries\", section on 'Etiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=see_link&amp;anchor=H15443523#H15443523\">",
"     \"Clostridium difficile in adults: Clinical manifestations and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H350979203\">",
"    <span class=\"h2\">",
"     Colonoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic evaluation is required to confirm the presence, severity, and extent of inflammation and to exclude the presence of an infection such as CMV with histology and culture of the tissue obtained on biopsy. Cultures for Neisseria gonorrhea and HSV should be performed in patients with severe rectal symptoms. Ileocolonoscopy with biopsies in the ileum and the colon is also important in differentiating between ulcerative colitis and Crohn&rsquo;s disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/35/26166?source=see_link\">",
"     \"Diagnosis of gonococcal infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/12/28872?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14089?source=see_link&amp;anchor=H9#H9\">",
"     \"Endoscopic diagnosis of inflammatory bowel disease\", section on 'Role in differential diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11386?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A full colonoscopy should be avoided in hospitalized patients with severe colitis because of the potential to precipitate toxic megacolon. (See",
"    <a class=\"local\" href=\"#H1226801754\">",
"     'Assessment of clinical severity'",
"    </a>",
"    above.) In such patients, a flexible sigmoidoscopy should be performed and evaluation limited to the rectum and distal sigmoid colon. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14089?source=see_link\">",
"     \"Endoscopic diagnosis of inflammatory bowel disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/30/18920?source=see_link\">",
"     \"Toxic megacolon\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H432583317\">",
"    <span class=\"h1\">",
"     TREATMENT OF MILDLY OR MODERATELY ACTIVE DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial treatment of ulcerative colitis is based upon disease severity and extent. (See",
"    <a class=\"local\" href=\"#H1226801754\">",
"     'Assessment of clinical severity'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H1226801230\">",
"     'Definitions of disease extent'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H350979203\">",
"     'Colonoscopy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H113301576\">",
"    <span class=\"h2\">",
"     Ulcerative proctitis or proctosigmoiditis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100504367\">",
"    <span class=\"h3\">",
"     Initial approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical 5-aminosalicylic acid (5-ASA) medications are first-line treatment in those who are willing to use rectal therapy. 5-ASA suppositories",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    enemas given rectally induce remission in more than 90 percent of patients with mild to moderate proctitis or proctosigmoiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/12-18\">",
"     12-18",
"    </a>",
"    ]. Remission rates as high as 93 percent have been reported with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"     mesalamine",
"    </a>",
"    enemas [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/14,17\">",
"     14,17",
"    </a>",
"    ]. Furthermore, they can maintain remission in approximately 75 percent of patients. Topical therapies also provide a quicker response time than oral preparations and typically require less frequent dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    5-ASA agents are widely available as suppositories or enemas (",
"    <a class=\"graphic graphic_table graphicRef86774 \" href=\"UTD.htm?13/37/13918\">",
"     table 1",
"    </a>",
"    ). 5-ASA foam and gel preparations, available in many countries around the world, are not available in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Enemas reach the proximal sigmoid colon and splenic flexure in virtually all patients who are able to retain them [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/21\">",
"     21",
"    </a>",
"    ]. In contrast, foam preparations generally reach only the mid-sigmoid colon [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/22\">",
"     22",
"    </a>",
"    ], while suppositories are effective only in the distal 5 to 8 cm of the rectum. &nbsp;",
"   </p>",
"   <p>",
"    Topical 5-ASA medications are preferred over topical steroids in those who are willing to use topical therapy. A meta-analysis of seven trials concluded that 5-ASA enemas were significantly superior to corticosteroid enemas for the induction of remission and improving endoscopic and histologic severity (odds ratio [OR] 2.4, 1.9, and 2.0, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/23\">",
"     23",
"    </a>",
"    ]. A second meta-analysis concluded that the efficacy and side effect profile of topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"     mesalamine",
"    </a>",
"    were dose-dependent and superior to oral therapies and topical steroids. Topical 5-ASA therapy was also associated with lower overall patient costs [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/24\">",
"     24",
"    </a>",
"    ]. The side effects of 5-ASA medications are discussed separately.",
"    <em>",
"    </em>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=see_link&amp;anchor=H11#H11\">",
"     \"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with mild to moderate disease confined to the distal 5 to 8 cm of rectum, we recommend treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"     mesalamine",
"    </a>",
"    suppository twice daily (",
"    <a class=\"graphic graphic_table graphicRef86774 \" href=\"UTD.htm?13/37/13918\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/25\">",
"     25",
"    </a>",
"    ]. Although there are data to suggest that once daily dosing of a 5-ASA suppository may be sufficient [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/26\">",
"     26",
"    </a>",
"    ], we find that twice daily administration of topical medications is often needed initially to treat severe urgency and tenesmus.",
"   </p>",
"   <p>",
"    For patients with mildly to moderately active disease that involves greater than 8 cm of distal rectum, or the rectum plus sigmoid colon (proctosigmoiditis), we begin treatment with 5-ASA enemas given twice daily in addition to 5-ASA suppositories twice daily (",
"    <a class=\"graphic graphic_table graphicRef86774 \" href=\"UTD.htm?13/37/13918\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Patients who cannot retain enemas due to rectal irritability should be treated with 5-ASA foam preparations where available.",
"   </p>",
"   <p>",
"    Symptomatic improvement and a decrease in bleeding can be seen within a few days. However, complete healing usually requires four to six weeks or longer, and we recommend continued treatment for six to eight weeks followed by a gradual taper and discontinuation as tolerated. (See",
"    <a class=\"local\" href=\"#H1226801081\">",
"     'Maintenance therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H777082426\">",
"    <span class=\"h3\">",
"     Subsequent and alternative approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other treatment approaches may be required for patients whose symptoms do not respond to topical treatment with 5-ASA medications, who cannot tolerate topical 5-ASA medications, or who cannot tolerate topical therapy in general:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who are unwilling or unable to tolerate topical medications can be treated with oral 5-ASA medications alone (",
"      <a class=\"graphic graphic_table graphicRef86774 \" href=\"UTD.htm?13/37/13918\">",
"       table 1",
"      </a>",
"      ). Although oral therapy alone is effective in the induction of remission in patients with proctitis and proctosigmoiditis, response rates are lower than topical therapy alone [",
"      <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/27\">",
"       27",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      Patients who cannot tolerate topical 5-ASA medications should be treated with steroid suppositories for the induction of remission, if ulcerative proctitis involves 5 to 8 cm of the distal rectum. Steroid foam preparations or enemas twice daily in combination with steroid suppositories twice daily should be used if the colitis involves greater than 8 cm of the rectum or the sigmoid colon (",
"      <a class=\"graphic graphic_table graphicRef86774 \" href=\"UTD.htm?13/37/13918\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/28-31\">",
"       28-31",
"      </a>",
"      ]. A response is usually seen three to four weeks. In patients with a clear improvement in symptoms, topical steroid treatment can be tapered gradually to a nightly regimen. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=see_link&amp;anchor=H11#H11\">",
"       \"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease\", section on 'Side effects'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who do not respond to topical 5-ASA medications alone in four to six weeks, a combination of topical 5-ASA and topical steroids should be used [",
"      <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/31\">",
"       31",
"      </a>",
"      ]. However, this strategy is supported by limited evidence from one controlled trial in which patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/7/33904?source=see_link\">",
"       beclomethasone",
"      </a>",
"      dipropionate and 5-ASA enemas had higher rates of clinical, histologic, and endoscopic improvement after four weeks of treatment compared with patients who used single-agent therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients who do not have an adequate response to topical therapy should be treated with the combination of oral 5-ASA and topical 5-ASA enemas or suppositories (",
"      <a class=\"graphic graphic_table graphicRef86774 \" href=\"UTD.htm?13/37/13918\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/27,33\">",
"       27,33",
"      </a>",
"      ]. Controlled trials have demonstrated the efficacy of both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      and oral forms of 5-ASA in the induction and maintenance of remission in mildly to moderately active ulcerative colitis [",
"      <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/34-43\">",
"       34-43",
"      </a>",
"      ]. In one randomized trial, for example, 4.8",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      of oral 5-ASA was significantly more likely than placebo to induce complete (24 versus 5 percent) or partial remission (50 versus 13 percent) in patients with mild to moderate ulcerative colitis [",
"      <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/34\">",
"       34",
"      </a>",
"      ]. We suggest the use of oral 5-ASAs to sulfasalazine, except in patients with arthritis associated with IBD, because of their better side effect profile. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=see_link&amp;anchor=H11#H11\">",
"       \"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease\", section on 'Side effects'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25289?source=see_link&amp;anchor=H14#H14\">",
"       \"Arthritis associated with gastrointestinal disease\", section on 'Recommendations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with mild symptoms, oral 5-ASA medications should be started at the lower dose and increased to the maximum tolerated dose in patients who remain symptomatic (",
"    <a class=\"graphic graphic_table graphicRef86774 \" href=\"UTD.htm?13/37/13918\">",
"     table 1",
"    </a>",
"    ). Patients with moderate symptoms, those with previous steroid use, those with frequent relapses, and those previously treated with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"     mesalamine",
"    </a>",
"    , rectal therapy, or multiple medications are more likely to benefit from a higher dose [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral mesalazine generally acts in two to four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/27\">",
"     27",
"    </a>",
"    ]. Patients who fail to respond to combination therapy with oral 5-ASA and topical",
"    <span class=\"nowrap\">",
"     5-ASA/steroids",
"    </span>",
"    require treatment with oral glucocorticoids, as discussed under left-sided colitis below. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Subsequent approach'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H1226796987\">",
"     'Management of persistent symptoms'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1226801081\">",
"    <span class=\"h3\">",
"     Maintenance therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance therapy is",
"    <strong>",
"     not",
"    </strong>",
"    recommended in patients with a first episode of mild ulcerative",
"    <strong>",
"     proctitis",
"    </strong>",
"    that has responded promptly to treatment. Many such patients may continue for long periods of time without a relapse and, if it does occur, the response to therapy is often prompt and complete.",
"   </p>",
"   <p>",
"    Maintenance therapy is recommended in patients with ulcerative proctitis who have more than one relapse a year and in all patients with proctosigmoiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/46\">",
"     46",
"    </a>",
"    ]. Discontinuation of medication in these patients should only be considered if they have been in remission for two years and are averse to taking medication [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients on topical therapy for induction of remission, we recommend a maintenance regimen of one 5-ASA suppository in patients with proctitis and 5-ASA enema every night in patients with proctosigmoiditis (",
"    <a class=\"graphic graphic_table graphicRef86774 \" href=\"UTD.htm?13/37/13918\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/47-51\">",
"     47-51",
"    </a>",
"    ]. In our experience, patients treated with less frequent maintenance therapy (every other day) often have poor compliance and risk relapse; we therefore rarely recommend a maintenance regimen less frequent than one every night [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/52\">",
"     52",
"    </a>",
"    ]. Steroid enemas should be avoided for the maintenance of remission as their efficacy has not been established and they may be associated with steroid side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who require an oral 5-ASA to achieve remission or have multiple relapses on topical therapy should be continued on oral 5-ASAs to maintain remission (",
"    <a class=\"graphic graphic_table graphicRef86774 \" href=\"UTD.htm?13/37/13918\">",
"     table 1",
"    </a>",
"    ). Patients with frequent relapses may benefit from a higher dose of maintenance therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/43\">",
"     43",
"    </a>",
"    ]. A systematic review estimated that oral 5-ASA medications were associated with more than a 50 percent decrease in the risk of relapse compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Left-sided colitis, extensive colitis, and pancolitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with mildly or moderately active left-sided colitis and pancolitis benefit most from combination therapy with oral 5-ASA medications, 5-ASA or steroid suppositories, and 5-ASA or steroid enemas or foam (",
"    <a class=\"graphic graphic_table graphicRef86774 \" href=\"UTD.htm?13/37/13918\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H777082449\">",
"    <span class=\"h3\">",
"     Initial approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination of oral plus rectal 5-ASA has been associated with a higher rate and a reduced time to remission compared with either therapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/27,54\">",
"     27,54",
"    </a>",
"    ]. In a placebo-controlled trial, 127 ambulatory patients with",
"    <span class=\"nowrap\">",
"     mild/moderate",
"    </span>",
"    extensive ulcerative colitis received 4",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"     mesalamine",
"    </a>",
"    for eight weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/54\">",
"     54",
"    </a>",
"    ]. During the initial four weeks, they additionally received an enema at bedtime containing 1 g of mesalamine or placebo. Remission rates were higher in patients treated with oral and topical mesalamine compared to oral mesalamine alone both at four weeks (44 versus 34 percent) and eight weeks (64 versus 43 percent). The increased response with combination therapy may be due to the additive effects of oral plus rectal 5-ASA, since the efficacy of 5-ASA is dose-dependent.",
"   </p>",
"   <p>",
"    A number of different formulations of oral 5-ASA have been developed that permit site-specific, targeted delivery of higher concentrations of 5-ASA. All",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"     mesalamine",
"    </a>",
"    &nbsp;preparations appear to be equally effective [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/55-59\">",
"     55-59",
"    </a>",
"    ]. However, a 2009 meta-analysis suggested that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/53/8021?source=see_link\">",
"     balsalazide",
"    </a>",
"    may be marginally more effective than mesalamine in the induction of remission, but not in rates of relapse or adverse events [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=see_link\">",
"     \"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oral 5-ASA medications can be started at the lowest dose (",
"    <a class=\"graphic graphic_table graphicRef86774 \" href=\"UTD.htm?13/37/13918\">",
"     table 1",
"    </a>",
"    ). In patients who remain symptomatic despite combination therapy (oral 5-ASA and topical",
"    <span class=\"nowrap\">",
"     5-ASA/steroids),",
"    </span>",
"    the dose of oral 5-ASA medications should be increased to the maximum tolerated dose [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to oral 5-ASA, we recommend treatment with 5-ASA enemas given twice daily in addition to 5-ASA suppositories twice daily (",
"    <a class=\"graphic graphic_table graphicRef86774 \" href=\"UTD.htm?13/37/13918\">",
"     table 1",
"    </a>",
"    ). Patients who cannot retain enemas due to rectal irritability should be treated with 5-ASA foam preparations where available. These patients may have an improvement in urgency or tenesmus with topical treatment aimed at the rectum despite also having more proximal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    5-ASA medications exert their effect in two to four weeks and are effective in 40 to 80 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/24,63\">",
"     24,63",
"    </a>",
"    ]. Patients who do not respond in two weeks should be treated with topical rectal therapy with steroid-containing foam twice daily",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    suppositories twice daily combined with oral 5-ASA therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Subsequent approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who do not tolerate or who have an inadequate response to the combination of oral 5-ASA and topical",
"    <span class=\"nowrap\">",
"     5-ASA/steroids",
"    </span>",
"    within two to four weeks or patients with systemic symptoms, oral glucocorticoids (",
"    <a class=\"graphic graphic_table graphicRef86774 \" href=\"UTD.htm?13/37/13918\">",
"     table 1",
"    </a>",
"    ) are highly effective in inducing remission in patients with active ulcerative colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/12,64-66\">",
"     12,64-66",
"    </a>",
"    ]. In one study, oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    induced remission in 77 percent of 118 patients with mild to moderate disease within two weeks, compared with 48 percent treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/67\">",
"     67",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    is usually effective within 10 to 14 days, after which the dose can be tapered gradually. (See",
"    <a class=\"local\" href=\"#H1226800906\">",
"     'Maintenance therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients who have an inadequate response to glucocorticoids should be carefully evaluated to determine the cause for persistent symptoms (see",
"    <a class=\"local\" href=\"#H1226796987\">",
"     'Management of persistent symptoms'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1226800906\">",
"    <span class=\"h3\">",
"     Maintenance therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance therapy is recommended in all patients with left-sided colitis, pancolitis, or extensive colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/46\">",
"     46",
"    </a>",
"    ]. 5-ASA medications are highly effective in the maintenance of remission in patients with ulcerative colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/68-73\">",
"     68-73",
"    </a>",
"    ]. In a 2011 meta-analysis of 11 randomized controlled trials, the risk of relapse was significantly lower in patients with quiescent ulcerative colitis treated with 5-ASAs as compared with placebo (relative risk 0.65, 95% CI 0.55-0.76) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/73\">",
"     73",
"    </a>",
"    ]. Combination therapy with oral and intermittent rectal therapy may be better than oral therapy alone for maintaining remission [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After an adequate clinical response",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    remission has been achieved, usually in six to eight weeks, oral 5-ASAs should be continued to maintain remission (",
"    <a class=\"graphic graphic_table graphicRef86774 \" href=\"UTD.htm?13/37/13918\">",
"     table 1",
"    </a>",
"    ). In our experience, a dose of at least 3",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    is efficacious in maintaining remission, but in some patients, tapering the dose below 3 to 3.6",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    can lead to earlier relapse. Patients with exacerbations on lower maintenance doses will often require higher doses to prevent recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency of 5-ASA enemas",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    suppositories can be gradually reduced from twice daily to once daily for long-term maintenance therapy. In our experience, patients treated with less frequent maintenance therapy (every other day) often have poor compliance and risk relapse. Steroid enemas should be avoided for the maintenance of remission as their efficacy has not been established and they may be associated with steroid side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral glucocorticoids including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and once-daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    MMX should",
"    <strong>",
"     not",
"    </strong>",
"    be used for maintenance of remission, since they have not been proven to be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/66,74\">",
"     66,74",
"    </a>",
"    ]. Glucocorticoids should be tapered after the patient has been stable for two to four weeks. Steroids should be tapered over eight weeks by decreasing the dose by 5 to 10 mg every week until a daily dose of 20 mg is reached, and then by 2.5 mg every week [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/75\">",
"     75",
"    </a>",
"    ]. More rapid reduction has also been associated with early relapse and may be associated with adrenal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22103?source=see_link\">",
"     \"Glucocorticoid withdrawal\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If glucocorticoids cannot be tapered to less than 10 mg daily within three months of starting steroids without recurrent disease, or if relapse occurs within three months of stopping glucocorticoids, patients are considered to have steroid-dependent ulcerative colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/76\">",
"     76",
"    </a>",
"    ]. Such patients should be carefully evaluated to determine the cause of persistent symptoms (see",
"    <a class=\"local\" href=\"#H1226796987\">",
"     'Management of persistent symptoms'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24250?source=see_link&amp;anchor=H526355188#H526355188\">",
"     \"Approach to adults with steroid-refractory and steroid-dependent ulcerative colitis\", section on 'Steroid-dependent ulcerative colitis'",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1226796987\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF PERSISTENT SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the approaches described above, some patients continue to have severe gastrointestinal symptoms. Patients with continued symptoms should be carefully reassessed, paying specific attention to the type of ongoing symptoms, the degree to which symptoms have improved or worsened, and compliance with medications.",
"   </p>",
"   <p>",
"    Reassessment of the extent of disease is indicated if a patient has a recurrence of symptoms after initial improvement that does not mimic the initial presentation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14089?source=see_link&amp;anchor=H9#H9\">",
"     \"Endoscopic diagnosis of inflammatory bowel disease\", section on 'Role in differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who fail to respond fall into the following categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Those whose symptoms are not due to inflammatory bowel disease. These patients may have an alternative or concomitant diagnosis. (See",
"      <a class=\"local\" href=\"#H350978455\">",
"       'Pretreatment evaluation'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      It is important to recognize that some symptoms in patients with chronic ulcerative colitis are not directly due to the underlying inflammatory process. Many patients have both inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/5/8279?source=see_link\">",
"       \"Irritable bowel syndrome in patients with inflammatory bowel disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/7/44152?source=see_link&amp;anchor=H3593887#H3593887\">",
"       \"Nutrition and dietary interventions in adults with inflammatory bowel disease\", section on 'Dietary interventions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who are noncompliant or incompletely compliant with therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/77\">",
"       77",
"      </a>",
"      ]. Compliance with medications and enemas in particular should be sought, as many patients have difficulty with retention of enemas. Such patients can be treated with topical steroid preparations in the form of foams, and steroid-containing suppositories can be useful in patients with severe rectal symptoms of urgency and tenesmus. (See",
"      <a class=\"local\" href=\"#H113301576\">",
"       'Ulcerative proctitis or proctosigmoiditis'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      Regardless of the extent of colonic involvement, some patients remain symptomatic despite optimal doses of oral 5-ASA drugs, topical therapy with either 5-ASA or steroids, and systemic glucocorticoids.",
"      <br/>",
"      <br/>",
"      Patients without a meaningful clinical response to glucocorticoids up to doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      &nbsp;40 to 60",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (or equivalent) within 30 days for oral therapy or 7 to 10 days for intravenous therapy are considered to have steroid-refractory disease. For patients with steroid-refractory ulcerative colitis, additional medical therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      as&nbsp;a short-term \"bridge\" to therapy with longer acting medications (AZA or 6-MP) or an anti-tumor necrosis factor (anti-TNF) agent should be considered. The management of patients with steroid-refractory ulcerative colitis is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24250?source=see_link&amp;anchor=H14#H14\">",
"       \"Approach to adults with steroid-refractory and steroid-dependent ulcerative colitis\", section on 'Steroid-refractory ulcerative colitis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1226797055\">",
"    <span class=\"h1\">",
"     SYMPTOMATIC TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concomitant symptomatic treatment for diarrhea and abdominal pain may be used for a short duration (7 to 10 days) only while waiting for anti-inflammatory medications to take effect in patients with mild ulcerative colitis symptoms and no signs of systemic toxicity. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients who have",
"      <strong>",
"       mild",
"      </strong>",
"      intermittent diarrhea",
"      <strong>",
"       without signs of systemic toxicity,",
"      </strong>",
"      antidiarrheal agents may be beneficial, particularly at night to decrease the frequency of nocturnal episodes (see",
"      <a class=\"local\" href=\"#H1226801754\">",
"       'Assessment of clinical severity'",
"      </a>",
"      above).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/53/16214?source=see_link\">",
"       Loperamide",
"      </a>",
"      is preferred because of its safety and efficacy [",
"      <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/78\">",
"       78",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In the author&rsquo;s experience, bulk agents such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/26/8614?source=see_link\">",
"       psyllium",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/28/29123?source=see_link\">",
"       methylcellulose",
"      </a>",
"      or pectin may also be helpful while avoiding the risk of precipitating toxic megacolon.",
"     </li>",
"     <li>",
"      Abdominal cramping in patients with",
"      <strong>",
"       mildly",
"      </strong>",
"      active",
"      <strong>",
"      </strong>",
"      ulcerative colitis",
"      <strong>",
"       without signs of systemic toxicity",
"      </strong>",
"      can be relieved by anticholinergic medications such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/4/14404?source=see_link\">",
"       propantheline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/6/27749?source=see_link\">",
"       dicyclomine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/9/29846?source=see_link\">",
"       hyoscyamine",
"      </a>",
"      sulfate. (See",
"      <a class=\"local\" href=\"#H1226801754\">",
"       'Assessment of clinical severity'",
"      </a>",
"      above.) However, systemic side effects are common since these agents do not selectively affect the intestine.",
"      <br/>",
"      <br/>",
"      Opiates should be avoided because they can mask the signs and symptoms of an acute abdomen, and their addiction potential. Nonsteroidal antiinflammatory drugs should be avoided because they can exacerbate IBD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110252836\">",
"    <span class=\"h1\">",
"     OTHER MANAGEMENT ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to consider routine health maintenance, including screening and prevention of other diseases as well as monitoring for side effects of therapy in patients with inflammatory bowel disease (IBD) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/79-81\">",
"     79-81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110256081\">",
"    <span class=\"h2\">",
"     Immunization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with IBD are at increased risk for infections due to their underlying disease, malnutrition, surgery, or immunosuppressive medications [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/82-84\">",
"     82-84",
"    </a>",
"    ]. Routine vaccination status should be reviewed at the time of diagnosis, and patients should be immunized in accordance with guidelines (",
"    <a class=\"graphic graphic_figure graphicRef82634 \" href=\"UTD.htm?36/52/37701\">",
"     figure 1",
"    </a>",
"    ). Regardless of immunosuppression, all patients should be vaccinated for influenza and pneumococcal infection. In patients on immunosuppressants, live vaccines (eg, MMR, varicella, zoster) are contraindicated (",
"    <a class=\"graphic graphic_figure graphicRef62130 \" href=\"UTD.htm?41/17/42263\">",
"     figure 2",
"    </a>",
"    ). If live vaccines are required, they should be administered 4 to 12 weeks prior to the initiation of immunosuppression. Patients should be screened for hepatitis B before initiating anti-TNF therapy, and individuals who are seronegative should be vaccinated for hepatitis B [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/85\">",
"     85",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/44/41670?source=see_link&amp;anchor=H10#H10\">",
"     \"Approach to immunizations in healthy adults\", section on 'Immunization schedule for healthy adults'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110256027\">",
"    <span class=\"h2\">",
"     Cancer screening",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110256055\">",
"    <span class=\"h3\">",
"     Colorectal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with IBD are at increased risk for colorectal cancer (CRC) and should undergo CRC screening with colonoscopy based on the extent and duration of their disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/86-94\">",
"     86-94",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25722?source=see_link&amp;anchor=H19#H19\">",
"     \"Colorectal cancer surveillance in inflammatory bowel disease\", section on 'Surveillance'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25722?source=see_link&amp;anchor=H25#H25\">",
"     \"Colorectal cancer surveillance in inflammatory bowel disease\", section on 'Recommendations of major societies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is unclear if 5-ASA medications confer a protective effect against CRC and dysplasia risk in patients with ulcerative colitis. While the reduction in CRC risk is biologically plausible by reduction of inflammation, the results of two meta-analyses have been conflicting. A 2005 meta-analysis, which largely included case-control studies, estimated that the risk of CRC was reduced by approximately 50 percent (0.51, 95% CI 0.37-0.69) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/95\">",
"     95",
"    </a>",
"    ]. However, the results of a 2012 meta-analysis varied based on the referral population included in the analysis. The results of pooled analysis of non-referral populations, although limited by heterogeneity, failed to demonstrate a protective effect of 5-ASAs (odds ratio [OR] 0.82, 95%, CI 0.54-1.26). Whereas a pooled analysis of nine clinic-based studies demonstrated a 42 percent decrease in CRC risk with 5-ASAs (OR 0.58, 95% CI 0.45-0.75). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25722?source=see_link\">",
"     \"Colorectal cancer surveillance in inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10846416\">",
"    <span class=\"h3\">",
"     Cervical cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of abnormal Pap smears is higher in women with IBD on corticosteroids and immunosuppressants [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/96\">",
"     96",
"    </a>",
"    ]. Compliance with cervical cancer screening is low in women with IBD [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/97\">",
"     97",
"    </a>",
"    ]. Screening for cervical cancer, in accordance with guidelines, should therefore be recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=see_link\">",
"     \"Screening for cervical cancer: Rationale and recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10846423\">",
"    <span class=\"h3\">",
"     Skin cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with IBD on",
"    <span class=\"nowrap\">",
"     6-MP/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"      azathioprine",
"     </a>",
"    </span>",
"    are at an increased risk of nonmelanoma skin cancer. Patients should be advised to avoid excessive sun exposure and use a high-strength sunscreen and sun protective measures [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41350?source=see_link&amp;anchor=H6#H6\">",
"     \"Skin and eye manifestations of inflammatory bowel disease\", section on 'Miscellaneous skin lesions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33447?source=see_link&amp;anchor=H9546106#H9546106\">",
"     \"Selection of sunscreen and sun-protective measures\", section on 'Selection of sunscreen products'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110256103\">",
"    <span class=\"h2\">",
"     Osteoporosis screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with IBD are at increased risk for bone loss [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/98\">",
"     98",
"    </a>",
"    ]. Screening for osteoporosis should be performed in all IBD patients who meet one of the following criteria: postmenopausal, ongoing corticosteroid treatment, cumulative prior use of corticosteroids exceeding three months, history of low-trauma fractures, or age over 60 years. Our approach is consistent with current guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IBD patients on glucocorticoids (any dose with an anticipated duration of &ge;3 months) should maintain a total calcium intake of 1200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and vitamin D&nbsp;intake of 800 international",
"    <span class=\"nowrap\">",
"     units/day",
"    </span>",
"    through either diet",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    supplements. Treatment with bisphosphonates in patients with IBD, based on age, gender, and the presence of existing osteoporosis, is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link&amp;anchor=H622797#H622797\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\", section on 'Candidates for pharmacologic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110256110\">",
"    <span class=\"h2\">",
"     Anxiety/depression screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many IBD patients suffer from anxiety and depression secondary to their disease process and should be screened for these conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/100-102\">",
"     100-102",
"    </a>",
"    ]. Patients with underlying anxiety and depression may benefit from other specific pharmacologic interventions. In addition, tricyclic antidepressants, even in low doses, can improve sleep quality while decreasing cramping and diarrhea due to their anticholinergic effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110256095\">",
"    <span class=\"h2\">",
"     Laboratory monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periodic laboratory monitoring is necessary to detect complications associated with IBD and side effects of medical therapy. Approximately 35 to 90 percent of adults with IBD are iron deficient. Other potential causes of anemia in patients with IBD include anemia of chronic disease, vitamin B12 deficiency,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    &nbsp;deficiency, or drug-induced anemia (eg, in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    or thiopurines). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/6/43113?source=see_link&amp;anchor=H14#H14\">",
"     \"Nutrient deficiencies in inflammatory bowel disease\", section on 'Iron'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with IBD, hematocrit should be measured every 6 to 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/31\">",
"     31",
"    </a>",
"    ]. In patients with anemia or those with low MCV, ferritin, transferrin saturation, and C-reactive protein (CRP) should also be checked. The CRP is important in the interpretation of the ferritin level, as ferritin is an acute phase reactant. Ferritin levels less than 100",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    are suggestive of iron deficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=see_link&amp;anchor=H13#H13\">",
"     \"Anemia of chronic disease (anemia of chronic inflammation)\", section on 'ACD with coexisting iron deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients on 5-ASA agents, serum creatinine should be measured at 6 and 12 months after initiation of therapy and then annually [",
"    <a class=\"abstract\" href=\"UTD.htm?21/36/22090/abstract/103\">",
"     103",
"    </a>",
"    ]. For patients on",
"    <span class=\"nowrap\">",
"     6-MP/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"      azathioprine",
"     </a>",
"     ,",
"    </span>",
"    weekly blood monitoring (ie, hemoglobin, white blood cell count, platelet count, liver blood tests [serum aminotransferases and total bilirubin], and amylase) should be performed for the first month or until the maintenance dose is reached. Monitoring should be continued for the duration of therapy and performed at least every three months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21592?source=see_link&amp;anchor=H517303942#H517303942\">",
"     \"Azathioprine and 6-mercaptopurine in inflammatory bowel disease\", section on 'Laboratory testing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24250?source=see_link&amp;anchor=H12#H12\">",
"     \"Approach to adults with steroid-refractory and steroid-dependent ulcerative colitis\", section on 'Cyclosporine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/17/42258?source=see_link\">",
"       \"Patient information: Ulcerative colitis in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/39/10869?source=see_link\">",
"       \"Patient information: Ulcerative colitis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/11/17586?source=see_link\">",
"       \"Patient information: Sulfasalazine and the 5-aminosalicylates (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ulcerative colitis is a chronic inflammatory condition characterized by relapsing and remitting episodes of inflammation that involves the rectum and may extend in a proximal and continuous fashion to involve other portions of the colon. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When a patient with ulcerative colitis presents with recurrent symptoms, some aspects of the initial evaluation, including laboratory studies and endoscopy, need to be repeated in order to exclude alternative",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      comorbid conditions as a cause for their symptoms, as well as to assess the current extent of disease involvement and disease severity in order to best guide treatment. (See",
"      <a class=\"local\" href=\"#H350978455\">",
"       'Pretreatment evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22754451\">",
"    <span class=\"h2\">",
"     Ulcerative proctitis or proctosigmoiditis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with mildly or moderately active proctitis or proctosigmoiditis, we recommend topical 5-aminosalicylic acid (5-ASA) to induce remission (",
"      <a class=\"graphic graphic_table graphicRef86774 \" href=\"UTD.htm?13/37/13918\">",
"       table 1",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Suppositories alone are effective in managing proctitis, while patients with proctosigmoiditis require enemas in addition to suppositories. (See",
"      <a class=\"local\" href=\"#H100504367\">",
"       'Initial approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alternative treatment approaches may be required for patients who cannot tolerate topical 5-ASA medications, topical therapy in general, or who do not respond to topical treatment with 5-ASA medications (",
"      <a class=\"graphic graphic_table graphicRef86774 \" href=\"UTD.htm?13/37/13918\">",
"       table 1",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients who cannot tolerate topical 5-ASA medications, we",
"      <span class=\"nowrap\">",
"       recommend/suggest",
"      </span>",
"      steroid foam preparations and steroid suppositories (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients unwell or unable to tolerate any topical medication, we recommend oral 5-ASA medications (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients who do not respond to topical 5-ASA medications, we suggest combination topical 5-ASA and steroid foam preparation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients who do not respond to topical medications, we recommend combination therapy with oral and topical 5-ASA agents and topical steroids (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For maintenance of remission in patients who have more than one relapse a year and in all patients with proctosigmoiditis, we recommend 5-ASA enemas (",
"      <a class=\"graphic graphic_table graphicRef86774 \" href=\"UTD.htm?13/37/13918\">",
"       table 1",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Patients who required oral 5-ASAs to achieve remission or who have multiple relapses on topical therapy should be continued on oral 5-ASAs to maintain remission. (See",
"      <a class=\"local\" href=\"#H1226801081\">",
"       'Maintenance therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22754459\">",
"    <span class=\"h2\">",
"     Left-sided colitis, extensive colitis, or pancolitis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with mildly or moderately active left-sided",
"      <span class=\"nowrap\">",
"       colitis/extensive/pancolitis,",
"      </span>",
"      we recommend combination therapy with oral 5-ASA medications, rectal 5-ASA or steroid suppositories, and 5-ASA or steroid enemas or foam preparations (",
"      <a class=\"graphic graphic_table graphicRef86774 \" href=\"UTD.htm?13/37/13918\">",
"       table 1",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H777082449\">",
"       'Initial approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who fail to respond to combination therapy with oral 5-ASA medications and topical 5-ASA and steroids, we recommend oral glucocorticoids (",
"      <a class=\"graphic graphic_table graphicRef86774 \" href=\"UTD.htm?13/37/13918\">",
"       table 1",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Subsequent approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend maintenance therapy with combination oral and topical 5-ASA therapy (",
"      <a class=\"graphic graphic_table graphicRef86774 \" href=\"UTD.htm?13/37/13918\">",
"       table 1",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). After an adequate clinical response",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      remission has been achieved, the dose of oral 5-ASA should be continued to maintain remission and topical 5-ASA therapy can be tapered to once a day. Glucocorticoids should be tapered after the patient has been stable for two to four weeks. (See",
"      <a class=\"local\" href=\"#H1226800906\">",
"       'Maintenance therapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Patients with persistent symptoms despite glucocorticoids or steroid-dependent ulcerative colitis should be carefully evaluated to assess medication compliance, rule out other concomitant diseases, and to determine the need for additional medical therapy. (See",
"      <a class=\"local\" href=\"#H1226796987\">",
"       'Management of persistent symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is important to consider health maintenance issues in patients with inflammatory bowel disease (IBD). This includes vaccination to prevent infections, screening for cancer and",
"      <span class=\"nowrap\">",
"       anxiety/depression,",
"      </span>",
"      prevention of and monitoring for bone loss, and laboratory monitoring for complications of IBD and medication side effects. (See",
"      <a class=\"local\" href=\"#H110252836\">",
"       'Other management issues'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/1\">",
"      Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19 Suppl A:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/2\">",
"      Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010; 105:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/3\">",
"      Langholz E, Munkholm P, Davidsen M, et al. Changes in extent of ulcerative colitis: a study on the course and prognostic factors. Scand J Gastroenterol 1996; 31:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/4\">",
"      Gower-Rousseau C, Dauchet L, Vernier-Massouille G, et al. The natural history of pediatric ulcerative colitis: a population-based cohort study. Am J Gastroenterol 2009; 104:2080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/5\">",
"      Rodgers AD, Cummins AG. CRP correlates with clinical score in ulcerative colitis but not in Crohn's disease. Dig Dis Sci 2007; 52:2063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/6\">",
"      Prantera C, Davoli M, Lorenzetti R, et al. Clinical and laboratory indicators of extent of ulcerative colitis. Serum C-reactive protein helps the most. J Clin Gastroenterol 1988; 10:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/7\">",
"      Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004; 10:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/8\">",
"      Schoepfer AM, Trummler M, Seeholzer P, et al. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis 2008; 14:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/9\">",
"      Beattie RM, Walker-Smith JA, Murch SH. Indications for investigation of chronic gastrointestinal symptoms. Arch Dis Child 1995; 73:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/10\">",
"      Shine B, Berghouse L, Jones JE, Landon J. C-reactive protein as an aid in the differentiation of functional and inflammatory bowel disorders. Clin Chim Acta 1985; 148:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/11\">",
"      Poullis AP, Zar S, Sundaram KK, et al. A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and diarrhoea-predominant functional bowel disorders. Eur J Gastroenterol Hepatol 2002; 14:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/12\">",
"      Hanauer SB. Inflammatory bowel disease. N Engl J Med 1996; 334:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/13\">",
"      Biddle WL, Greenberger NJ, Swan JT, et al. 5-Aminosalicylic acid enemas: effective agent in maintaining remission in left-sided ulcerative colitis. Gastroenterology 1988; 94:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/14\">",
"      Campieri M, Lanfranchi GA, Bazzocchi G, et al. Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas. Lancet 1981; 2:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/15\">",
"      Campieri M, De Franchis R, Bianchi Porro G, et al. Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial. Scand J Gastroenterol 1990; 25:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/16\">",
"      Friedman LS, Richter JM, Kirkham SE, et al. 5-Aminosalicylic acid enemas in refractory distal ulcerative colitis: a randomized, controlled trial. Am J Gastroenterol 1986; 81:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/17\">",
"      Marshall JK, Irvine EJ. Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis. Aliment Pharmacol Ther 1995; 9:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/18\">",
"      Kam L, Cohen H, Dooley C, et al. A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults. Am J Gastroenterol 1996; 91:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/19\">",
"      Gionchetti P, Ardizzone S, Benvenuti ME, et al. A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: a randomized controlled multicentre trial. Aliment Pharmacol Ther 1999; 13:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/20\">",
"      Malchow H, Gertz B, CLAFOAM Study group. A new mesalazine foam enema (Claversal Foam) compared with a standard liquid enema in patients with active distal ulcerative colitis. Aliment Pharmacol Ther 2002; 16:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/21\">",
"      Chapman NJ, Brown ML, Phillips SF, et al. Distribution of mesalamine enemas in patients with active distal ulcerative colitis. Mayo Clin Proc 1992; 67:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/22\">",
"      Farthing MJ, Rutland MD, Clark ML. Retrograde spread of hydrocortisone containing foam given intrarectally in ulcerative colitis. Br Med J 1979; 2:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/23\">",
"      Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut 1997; 40:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/24\">",
"      Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000; 95:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/25\">",
"      Lamet M, Ptak T, Dallaire C, et al. Efficacy and safety of mesalamine 1 g HS versus 500 mg BID suppositories in mild to moderate ulcerative proctitis: a multicenter randomized study. Inflamm Bowel Dis 2005; 11:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/26\">",
"      Andus T, Kocjan A, M&uuml;ser M, et al. Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. Inflamm Bowel Dis 2010; 16:1947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/27\">",
"      Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997; 92:1867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/28\">",
"      Sutherland LR. Topical treatment of ulcerative colitis. Med Clin North Am 1990; 74:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/29\">",
"      WATKINSON G. Treatment of ulcerative colitis with topical hydrocortisone hemisuccinate sodium; a controlled trial employing restricted sequential analysis. Br Med J 1958; 2:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/30\">",
"      TRUELOVE SC, HAMBLING MH. Treatment of ulcerative colitis with local hydrocortisone hemisuccinate sodium; a report on a controlled therapeutic trial. Br Med J 1958; 2:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/31\">",
"      Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011; 60:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/32\">",
"      Mulder CJ, Fockens P, Meijer JW, et al. Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. Eur J Gastroenterol Hepatol 1996; 8:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/33\">",
"      d'Albasio G, Pacini F, Camarri E, et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol 1997; 92:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/34\">",
"      Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/35\">",
"      Sninsky CA, Cort DH, Shanahan F, et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Ann Intern Med 1991; 115:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/36\">",
"      Mansfield JC, Giaffer MH, Cann PA, et al. A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis. Aliment Pharmacol Ther 2002; 16:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/37\">",
"      Green JR, Mansfield JC, Gibson JA, et al. A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. Aliment Pharmacol Ther 2002; 16:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/38\">",
"      Green JR, Lobo AJ, Holdsworth CD, et al. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group. Gastroenterology 1998; 114:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/39\">",
"      Levine DS, Riff DS, Pruitt R, et al. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol 2002; 97:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/40\">",
"      Pruitt R, Hanson J, Safdi M, et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. Am J Gastroenterol 2002; 97:3078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/41\">",
"      Dew MJ, Hughes P, Harries AD, et al. Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid. Br Med J (Clin Res Ed) 1982; 285:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/42\">",
"      Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2012; 10:CD000543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/43\">",
"      Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012; 10:CD000544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/44\">",
"      Hanauer SB, Sandborn WJ, Dallaire C, et al. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Can J Gastroenterol 2007; 21:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/45\">",
"      Sandborn WJ, Regula J, Feagan BG, et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology 2009; 137:1934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/46\">",
"      Carter MJ, Lobo AJ, Travis SP, IBD Section, British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53 Suppl 5:V1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/47\">",
"      d'Albasio G, Paoluzi P, Campieri M, et al. Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial. The Italian IBD Study Group. Am J Gastroenterol 1998; 93:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/48\">",
"      Marteau P, Crand J, Foucault M, Rambaud JC. Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study. Gut 1998; 42:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/49\">",
"      Hanauer S, Good LI, Goodman MW, et al. Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. Am J Gastroenterol 2000; 95:1749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/50\">",
"      Mantzaris GJ, Hatzis A, Petraki K, et al. Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis. Dis Colon Rectum 1994; 37:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/51\">",
"      Marshall JK, Thabane M, Steinhart AH, et al. Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012; 11:CD004118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/52\">",
"      Kane S. Medication adherence and the physician-patient relationship. Am J Gastroenterol 2002; 97:1853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/53\">",
"      Sutherland L, Roth D, Beck P, et al. Oral 5-aminosalicylic acid for maintaining remission in ulcerative colitis. Cochrane Database Syst Rev 2000; :CD000544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/54\">",
"      Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005; 54:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/55\">",
"      Kruis W, Brandes JW, Schreiber S, et al. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Aliment Pharmacol Ther 1998; 12:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/56\">",
"      D'Haens G, Sandborn WJ, Barrett K, et al. Once-daily MMX(&reg;) mesalamine for endoscopic maintenance of remission of ulcerative colitis. Am J Gastroenterol 2012; 107:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/57\">",
"      Kruis W, Kiudelis G, R&aacute;cz I, et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut 2009; 58:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/58\">",
"      Kruis W, Bar-Meir S, Feher J, et al. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clin Gastroenterol Hepatol 2003; 1:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/59\">",
"      Marakhouski Y, Fixa B, Holom&aacute;n J, et al. A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis. Aliment Pharmacol Ther 2005; 21:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/60\">",
"      Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Comparison of mesalazine and balsalazide in induction and maintenance of remission in patients with ulcerative colitis: a meta-analysis. Dig Dis Sci 2009; 54:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/61\">",
"      Lichtenstein GR, Ramsey D, Rubin DT. Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysis. Aliment Pharmacol Ther 2011; 33:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/62\">",
"      D'Arienzo A, Manguso F, Castiglione GN, et al. Beclomethasone dipropionate (3 mg) enemas combined with oral 5-ASA (2.4 g) in the treatment of ulcerative colitis not responsive to oral 5-ASA alone. Ital J Gastroenterol Hepatol 1998; 30:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/63\">",
"      Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006; :CD000543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/64\">",
"      Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 1997; 92:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/65\">",
"      Meyers S, Janowitz HD. Systemic corticosteroid therapy of ulcerative colitis. Gastroenterology 1985; 89:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/66\">",
"      Sandborn WJ, Travis S, Moro L, et al. Once-daily budesonide MMX&reg; extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology 2012; 143:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/67\">",
"      TRUELOVE SC, WATKINSON G, DRAPER G. Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis. Br Med J 1962; 2:1708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/68\">",
"      Gordon G, Pruitt RE, Ringold M, Sedghi S, et al. Once daily 1.5 g granulated mesalamine is effective and safe in maintenance of remission in mild to moderate UC (abstract). Am J Gastroenterol 2008; 103:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/69\">",
"      Lichtenstein GR, Merchant K, Shaw A, et al. Once daily 1.5 granulated mesalamine effectively maintains remission in patients with ulcerative colitis who switch from different 5-ASA formulations (abstract). Am J Gastroenterol 2008; 103(s1):s429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/70\">",
"      Dignass AU, Bokemeyer B, Adamek H, et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol 2009; 7:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/71\">",
"      Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 2008; 57:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/72\">",
"      Sandborn WJ, Korzenik J, Lashner B, et al. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology 2010; 138:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/73\">",
"      Ford AC, Achkar JP, Khan KJ, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2011; 106:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/74\">",
"      Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/75\">",
"      Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004; 99:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/76\">",
"      Stange EF, Travis SP, Vermeire S, et al. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J Crohns Colitis 2008; 2:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/77\">",
"      Khan N, Abbas AM, Bazzano LA, et al. Long-term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10-year retrospective cohort from the veterans affairs healthcare system. Aliment Pharmacol Ther 2012; 36:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/78\">",
"      Barrett KE, Dharmsathaphorn K. Pharmacological aspects of therapy in inflammatory bowel diseases: antidiarrheal agents. J Clin Gastroenterol 1988; 10:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/79\">",
"      Selby L, Kane S, Wilson J, et al. Receipt of preventive health services by IBD patients is significantly lower than by primary care patients. Inflamm Bowel Dis 2008; 14:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/80\">",
"      Sinclair JA, Wasan SK, Farraye FA. Health maintenance in the inflammatory bowel disease patient. Gastroenterol Clin North Am 2012; 41:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/81\">",
"      Wasan SK, Baker SE, Skolnik PR, Farraye FA. A practical guide to vaccinating the inflammatory bowel disease patient. Am J Gastroenterol 2010; 105:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/82\">",
"      Rahier JF, Yazdanpanah Y, Colombel JF, Travis S. The European (ECCO) Consensus on infection in IBD: what does it change for the clinician? Gut 2009; 58:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/83\">",
"      Long MD, Martin C, Sandler RS, Kappelman MD. Increased risk of pneumonia among patients with inflammatory bowel disease. Am J Gastroenterol 2013; 108:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/84\">",
"      Long MD, Martin C, Sandler RS, Kappelman MD. Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013; 37:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/85\">",
"      Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009; 3:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/86\">",
"      ROSENQVIST H, OHRLING H, LAGERCRANTZ R, EDLING N. Ulcerative colitis and carcinoma coli. Lancet 1959; 1:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/87\">",
"      Course and prognosis of ulcerative colitis: Part IV Carcinoma of the colon. Gut 1964; 5:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/88\">",
"      MACDOUGALL IP. THE CANCER RISK IN ULCERATIVE COLITIS. Lancet 1964; 2:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/89\">",
"      Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990; 323:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/90\">",
"      Weedon DD, Shorter RG, Ilstrup DM, et al. Crohn's disease and cancer. N Engl J Med 1973; 289:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/91\">",
"      Softley A, Clamp SE, Watkinson G, et al. The natural history of inflammatory bowel disease: has there been a change in the last 20 years? Scand J Gastroenterol Suppl 1988; 144:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/92\">",
"      Richards ME, Rickert RR, Nance FC. Crohn's disease-associated carcinoma. A poorly recognized complication of inflammatory bowel disease. Ann Surg 1989; 209:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/93\">",
"      Ekbom A, Helmick C, Zack M, Adami HO. Increased risk of large-bowel cancer in Crohn's disease with colonic involvement. Lancet 1990; 336:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/94\">",
"      Farraye FA, Odze RD, Eaden J, Itzkowitz SH. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010; 138:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/95\">",
"      Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005; 100:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/96\">",
"      Singh H, Demers AA, Nugent Z, et al. Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study. Gastroenterology 2009; 136:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/97\">",
"      Long MD, Porter CQ, Sandler RS, Kappelman MD. Suboptimal rates of cervical testing among women with inflammatory bowel disease. Clin Gastroenterol Hepatol 2009; 7:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/98\">",
"      Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003; 124:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/99\">",
"      American Gastroenterological Association medical position statement: guidelines on osteoporosis in gastrointestinal diseases. Gastroenterology 2003; 124:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/100\">",
"      North CS, Alpers DH, Helzer JE, et al. Do life events or depression exacerbate inflammatory bowel disease? A prospective study. Ann Intern Med 1991; 114:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/101\">",
"      Porcelli P, Leoci C, Guerra V. A prospective study of the relationship between disease activity and psychologic distress in patients with inflammatory bowel disease. Scand J Gastroenterol 1996; 31:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/102\">",
"      de Boer AG, Sprangers MA, Bartelsman JF, de Haes HC. Predictors of health care utilization in patients with inflammatory bowel disease: a longitudinal study. Eur J Gastroenterol Hepatol 1998; 10:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/36/22090/abstract/103\">",
"      Cunliffe RN, Scott BB. Review article: monitoring for drug side-effects in inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16:647.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4051 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-89.32.226.102-D86B8ADF8C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_36_22090=[""].join("\n");
var outline_f21_36_22090=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H350978455\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1226801230\">",
"      Definitions of disease extent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1226801754\">",
"      Assessment of clinical severity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1226801399\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Stool studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H350979203\">",
"      Colonoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H432583317\">",
"      TREATMENT OF MILDLY OR MODERATELY ACTIVE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H113301576\">",
"      Ulcerative proctitis or proctosigmoiditis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H100504367\">",
"      - Initial approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H777082426\">",
"      - Subsequent and alternative approaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1226801081\">",
"      - Maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Left-sided colitis, extensive colitis, and pancolitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H777082449\">",
"      - Initial approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Subsequent approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1226800906\">",
"      - Maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1226796987\">",
"      MANAGEMENT OF PERSISTENT SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1226797055\">",
"      SYMPTOMATIC TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H110252836\">",
"      OTHER MANAGEMENT ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H110256081\">",
"      Immunization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H110256027\">",
"      Cancer screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H110256055\">",
"      - Colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10846416\">",
"      - Cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10846423\">",
"      - Skin cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H110256103\">",
"      Osteoporosis screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H110256110\">",
"      Anxiety/depression screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H110256095\">",
"      Laboratory monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22754451\">",
"      Ulcerative proctitis or proctosigmoiditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22754459\">",
"      Left-sided colitis, extensive colitis, or pancolitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/4051\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4051|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/52/37701\" title=\"figure 1\">",
"      Vax schedule healthy adult",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/17/42263\" title=\"figure 2\">",
"      Vaccine schedule based on medical conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4051|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/37/13918\" title=\"table 1\">",
"      Medical therapy of active ulcerative colitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=related_link\">",
"      Anemia of chronic disease (anemia of chronic inflammation)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24250?source=related_link\">",
"      Approach to adults with steroid-refractory and steroid-dependent ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/44/41670?source=related_link\">",
"      Approach to immunizations in healthy adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32025?source=related_link\">",
"      Approach to the adult with acute diarrhea in developed countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25289?source=related_link\">",
"      Arthritis associated with gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21592?source=related_link\">",
"      Azathioprine and 6-mercaptopurine in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11386?source=related_link\">",
"      Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=related_link\">",
"      Clostridium difficile in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25722?source=related_link\">",
"      Colorectal cancer surveillance in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/35/26166?source=related_link\">",
"      Diagnosis of gonococcal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39624?source=related_link\">",
"      Diagnostic testing for syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14089?source=related_link\">",
"      Endoscopic diagnosis of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/12/28872?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22103?source=related_link\">",
"      Glucocorticoid withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/5/8279?source=related_link\">",
"      Irritable bowel syndrome in patients with inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3319?source=related_link\">",
"      Management of severe ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/6/43113?source=related_link\">",
"      Nutrient deficiencies in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/7/44152?source=related_link\">",
"      Nutrition and dietary interventions in adults with inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/11/17586?source=related_link\">",
"      Patient information: Sulfasalazine and the 5-aminosalicylates (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/39/10869?source=related_link\">",
"      Patient information: Ulcerative colitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/17/42258?source=related_link\">",
"      Patient information: Ulcerative colitis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=related_link\">",
"      Screening for cervical cancer: Rationale and recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33447?source=related_link\">",
"      Selection of sunscreen and sun-protective measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41350?source=related_link\">",
"      Skin and eye manifestations of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=related_link\">",
"      Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/30/18920?source=related_link\">",
"      Toxic megacolon",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_36_22091="Extrinsic causes shoulder pain";
var content_f21_36_22091=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55507&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55507&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Extrinsic causes of shoulder pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neurologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cervical nerve root compression (C5, C6)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Supraspinatus nerve compression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brachial plexus lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Herpes zoster",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spinal cord lesion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cervical spine disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Abdominal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatobiliary disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diaphragmatic irritation (eg, splenic injury, ruptured ectopic pregnancy, perforated viscus)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cardiovascular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myocardial ischemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Axillary vein thrombosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thoracic outlet syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Thoracic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Upper lobe pneumonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Apical lung tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary embolus",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_36_22091=[""].join("\n");
var outline_f21_36_22091=null;
var title_f21_36_22092="Extract stability";
var content_f21_36_22092=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F69332&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F69332&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Stability of major allergens in dilute solutions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Extract",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Diluent",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        1:125 v/v",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        1:625 v/v",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        3 months",
"       </td>",
"       <td class=\"subtitle2\">",
"        6 months",
"       </td>",
"       <td class=\"subtitle2\">",
"        12 months",
"       </td>",
"       <td class=\"subtitle2\">",
"        3 months",
"       </td>",
"       <td class=\"subtitle2\">",
"        6 months",
"       </td>",
"       <td class=\"subtitle2\">",
"        12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Grass",
"       </td>",
"       <td>",
"        HSA",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        51",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        54",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NSP",
"       </td>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Bermuda",
"       </td>",
"       <td>",
"        HSA",
"       </td>",
"       <td>",
"        73",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        43",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        51",
"       </td>",
"       <td>",
"        34",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NSP",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        53",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Birch",
"       </td>",
"       <td>",
"        HSA",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        49",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NSP",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        41",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        41",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        13",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Numbers represent percent of original potency.",
"    <div class=\"footnotes\">",
"     v/v: volume/volume; HSA: normal saline with 0.03 percent human serum albumin (HSA); NSP: normal saline phenol.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_36_22092=[""].join("\n");
var outline_f21_36_22092=null;
var title_f21_36_22093="Induction agents for lung transplant";
var content_f21_36_22093=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F74258&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F74258&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Agents for induction of immunosuppression following lung transplantation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mechanism of action",
"       </td>",
"       <td class=\"subtitle1\">",
"        Suggested dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Monitoring",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adverse&nbsp;effects",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Alemtuzumab (Campath-1H)",
"       </td>",
"       <td>",
"        Monoclonal rat antibody directed at CD52 on T cells and B cells, causing depletion of these lymphocytes",
"       </td>",
"       <td>",
"        <p>",
"         30 mg IV intra-operatively infused over two hours",
"        </p>",
"        <p>",
"         Induction protocols may&nbsp;vary by institution",
"        </p>",
"       </td>",
"       <td>",
"        Lymphocyte subsets",
"       </td>",
"       <td>",
"        <p>",
"         Lymphopenia:",
"         <br/>",
"         - T cells may remain depressed for up to&nbsp;three years",
"         <br/>",
"         - B cells may be depressed for several months",
"        </p>",
"        <p>",
"         May cause cytokine release syndrome, but milder than compared to muromonab (OKT3)",
"        </p>",
"       </td>",
"       <td>",
"        Limited experience in induction therapy",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Anti-thymocyte globulin",
"       </td>",
"       <td>",
"        Polyclonal antibody that causes nonspecific T cell depletion",
"       </td>",
"       <td>",
"        <p>",
"         Thymoglobulin&reg; (rabbit origin): 1.5 mg/kg over 6 hours, then two or three additional doses given 24 hours apart",
"        </p>",
"        <p>",
"         Atgam&reg; (horse origin): 7.5 to 15 mg/kg per day for&nbsp;three to&nbsp;five days post transplant",
"        </p>",
"        <p>",
"         Induction protocols&nbsp;may vary by institution",
"        </p>",
"       </td>",
"       <td>",
"        Lymphocytes subsets",
"       </td>",
"       <td>",
"        Leukopenia, cytokine release syndrome, infusion reactions, thrombocytopenia, glomerulonephritis serum sickness",
"       </td>",
"       <td>",
"        Premedication includes glucocorticoids (eg, methylprednisolone 125 mg intravenously), antihistamines (eg, diphenhydramine 50 mg orally or intravenously), and antipyretics (eg, acetaminophen 1 g orally) one hour prior to infusion",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Basiliximab",
"       </td>",
"       <td>",
"        Chimeric monoclonal antibody (25 percent mouse, 75 percent human antibody derived antibody) binds&nbsp;with high affinity to CD25 on T cells to inhibit IL-2 mediated T cell proliferation",
"       </td>",
"       <td>",
"        20 mg on the day of transplantation and again on post-op day four",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        Low rate of adverse effects. Rarely: hypersensitivity, cytokine release syndrome",
"       </td>",
"       <td>",
"        Most commonly used induction agent",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Daclizumab (withdrawn from US and other markets)",
"       </td>",
"       <td>",
"        Chimeric monoclonal antibody binds with high affinity to CD25 on T cells to inhibit IL-2 mediated proliferation of T cells",
"       </td>",
"       <td>",
"        1 mg/kg on day of transplant, then every two weeks for a total of five doses",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        Low rate of adverse effects. Rarely: hypersensitivity, cytokine release syndrome",
"       </td>",
"       <td>",
"        10 percent mouse, 90 percent human derived antibody",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Muromonab-CD3 (OKT3) (withdrawn from US and other markets)",
"       </td>",
"       <td>",
"        Mouse monoclonal antibody that binds to the T cell receptor-CD3 complex, causing depletion of T cells",
"       </td>",
"       <td>",
"        2.5 mg/day for patients weighing &lt;80 kg or 5 mg/day for patients &ge;80 kg, given for 7 to 14 days after transplant",
"       </td>",
"       <td>",
"        Lymphocyte subsets",
"       </td>",
"       <td>",
"        Cytokine release storm (eg, fevers, rigors, vomiting, diarrhea, hemodynamic instability, pulmonary edema)",
"       </td>",
"       <td>",
"        <p>",
"         Patients will develop neutralizing antibodies to OKT3, limiting prolonged use and necessitating use of alternative drug if future augmentation of immunosuppression is needed",
"        </p>",
"        <p>",
"         Premedication includes glucocorticoids (eg, methylprednisolone 125 mg intravenously), antihistamines (eg, diphenhydramine 50 mg orally or intravenously), and antipyretics (eg, acetaminophen 1 g orally) one hour prior to infusion",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The US Food and Drug Administration has not approved any medications specifically for lung transplantation, so the doses are suggested based on the experience of large lung transplantation centers.",
"     <br>",
"      &bull; Immunosuppressants may interact with BCG, live vaccines, and other agents that modulate the immune response, cause myelosuppression or agranulocytosis such as clozapine. For additional interactions, effects, and management suggestions, see Lexi-Interact&trade; drug interactions application included with UpToDate.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      Bhorade SM, Stern E. Immunosuppression for lung transplantation. Proc Am Thorac Soc 2009; 6:47.",
"      <br>",
"       Korom S, et al. Immunosuppressive therapy in lung transplantation: state of the art. Eur J Cardiothorac Surg 2009; 35:1045.",
"       <br>",
"        Floreth T, Bhorade SM. Current trends in immunosuppression for lung transplantation. Semin Respir Crit Care Med 2010; 31:172.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_36_22093=[""].join("\n");
var outline_f21_36_22093=null;
var title_f21_36_22094="Differential diagnosis of acute malignant hyperthermia";
var content_f21_36_22094=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F82570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F82570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of acute malignant hyperthermia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Hypercapnia",
"       </td>",
"       <td class=\"subtitle1\">",
"        Tachycardia",
"       </td>",
"       <td class=\"subtitle1\">",
"        Rigidity/myoclonus",
"       </td>",
"       <td class=\"subtitle1\">",
"        Metabolic acidosis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Rhabdomyolysis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Hyperthermia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Cardiorespiratory",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypoventilation",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sepsis",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +/-",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Neurologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypoxic encephalopathy",
"       </td>",
"       <td class=\"centered\">",
"        +/-",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +/-",
"       </td>",
"       <td class=\"centered\">",
"        +/-",
"       </td>",
"       <td class=\"centered\">",
"        +/-",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Meningitis",
"       </td>",
"       <td class=\"centered\">",
"        +/-",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +/-",
"       </td>",
"       <td class=\"centered\">",
"        +/-",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intracranial bleed",
"       </td>",
"       <td class=\"centered\">",
"        +/-",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +/-",
"       </td>",
"       <td class=\"centered\">",
"        +/-",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        +/-",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Traumatic brain injury",
"       </td>",
"       <td class=\"centered\">",
"        +/-",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +/-",
"       </td>",
"       <td class=\"centered\">",
"        +/-",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        +/-",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Endocrine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Thyrotoxicosis",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +/-",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pheochromocytoma",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        +/-",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Toxicologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serotonin syndrome",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        +/-",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Radiologic contrast neurotoxicity",
"       </td>",
"       <td class=\"centered\">",
"        +/-",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +/-",
"       </td>",
"       <td class=\"centered\">",
"        +/-",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anticholinergic syndrome",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +/-",
"       </td>",
"       <td class=\"centered\">",
"        +/-",
"       </td>",
"       <td class=\"centered\">",
"        +/-",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cocaine toxicity",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amphetamine toxicity",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alcohol withdrawal",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Salicylate toxicity",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Iatrogenic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Faulty temp probe",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Overheating",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Absorption of CO",
"        <sub>",
"         2",
"        </sub>",
"        during laparoscopy",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Miscellaneous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neuroleptic malignant syndrome",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        +/-",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Heatstroke",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Extrapyramidal syndrome",
"       </td>",
"       <td class=\"centered\">",
"        +/-",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     +: likely manifestation; +/-: possible manifestation; -: unlikely manifestation.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_36_22094=[""].join("\n");
var outline_f21_36_22094=null;
var title_f21_36_22095="Neurogenic dysfunction";
var content_f21_36_22095=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52890&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52890&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Patterns of neurogenic detrusor-sphincter dysfunction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 322px; background-image: url(data:image/gif;base64,R0lGODlhHAJCAcQAAP///wAAAMDAwEBAQICAgPDw8BAQENDQ0ODg4KCgoCAgIDAwMGBgYHBwcLCwsFBQUJCQkAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAAcAkIBAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYJoBwKGAgeDPwiHhoo+BY0CCI+VT4UEBAMDCgGen6CgC5uZiJYljBAED5uhrp8Gmw0EDgKnJJEJBAybBq+vmwwEEJO3LIyNBcYjkaudv9DRngsPBALKgAIQvNLdrwoDtJSACAkNA77e6p4DDQmJirm7rd6xA8IJ134FDg0L6wChLWjgANsdAZoCKgylgEGCcXcOQHiQbqFCAw8gwNNzwNyAbvY2oZMWS5wdBBA+/1ocJfKfxQEQIL4pkICiRXAiVS4cuBFOv2cXc45caICBgzoSbYYaUI2YvmOGVD1wCUrBg4dvUFKNBm5WrZ4qDDkgcK5itAUQDKqpqe4egXxPVyDLNGArNAUNZKY5wMCswHDWirGIpG2VzmhFj7r5CaqkA704Dow9HICnGgEPpDUkphZHpG1AfzGwdQZBA7+hMFqDfEOAObuuFiRAUwBCaGDuwOJAMFkzAdZiDpyGlVF3EImH8QLvkuB2VaPLe5Rj4PyTgtljBFBuXPxIP9iwCHT2gqCvQGtHkEdjYLwLTaqJnfAzzw77l+a/0LY3Irx6gOtgaPdLfE2Uk9krRY2XRf950FyloBHzocYOaeQRkA6BUzhwYAAGiMcFfq4oR4VwEgK4hYCvGEVFbeB1+OAUBTDwywAJvLiEhr88EJ0UDHpynY1PFEDAMy5iccB2AQygGBYJIDnAfkHKGGJaWfD1zZJWQICaAXktaOErHl4hZDoDUPghkRBUUUADKUJJhQBShkKAFQ6gRmOFdu6oxAGwFcmccwqYKYUDz5Q5BoiBSsGnKwzoaQUC2y3g5hEFbGidoO592RiWT0Dgip9ggAhKAzAeqACnYiSQTgNAEpFAbJgGaJcB9jVxwG20moGApZ4wAEWlrrBqhqafLODoEHV6EuYZa/o4aRBxemJAmmloGQr/qU2oem2rXQhw2wLcArGoKM9yAWlq5QLBZmXpeuGtJ9QiASwoAxxLnl2+LvFqY7GW0Sy5Sxzg15xsaAtLrZSqhK0b8+YLoV0Eu0HAUkrs+8kD4YaRLCzt5iBwVR3fGwrCRBTwT65yeBoAxkZsZQCqbGzcKxIWKyvHuNLaG5lZA2QsRowjU3pyyIf6Ai4R0RpAdBgff+LwEDUHQDLDWx1NRNMz07HuJ0vHYDKHXQfnywNDTMyxHVgHEO9xQdfx9ScDlLzV03PUbIDPNHykdB4f082DAI2FLTYogq9QQGhTx/G2zUJE6/ccZrMzBJt767Fv4jccfjbfogixtdp6LB5A/+EpOEDvHtGu3QPgUvfhaeU8RN76Hioz7gPrnpC9B9Zx/6C5j3ivAZ/OL2i+MB8f9b4DAqDozseGd/+gkwLBr1H77D3I3m8dCFT0OA4TU/9H99jnEGf0fZBv+w64BwAzHtND4v0fshM/mC/v5+GpAjsUUJHqe4gc+nagE+X14QCg2B4NajfAPgDlezWYmAH/0AnMxYCBgfDfJywoA+Z9QoF32JDzdACUiPnBYgboAf4G4akF6IAqJvTD1kaIg9q5MBDtqx4KEPgJ+8GhIvmTgen4N4gCeMKHJTBiDwXBQ0/wQCcAdOAngnjBiw0iThCUAZuOF4jMRDEGuLuhIIACQv8YgAKJb9haDG2woS/uwXTT2ME/ypiHV9FwBpHj4h/i5MYYNJGIgoBjknYAFNKtARQ7cOIjEJjCG/BREZFbIw1wN8E//DGRn3hEIXMAODEqQpE20AkdDwI3HUTyEYjMgQf/8whRcnKQleiE4Fw5CEqa8hOS9EMqcWBLRdCyNbBsZQBGmYJf4rCUOTjlJzP5Ssn58oOvrGQgPkJMFBgTEBa74wKdhkpmegYWwvRENVMAOGkCwhc6HIEaIYlLHfRSEGHEJCgFURE0koB5jexmDa04iA1x8AWrzGcgaqdNGlBlnHJYZQAwmU44dJKX4BxERQwJgIn2s506iJMe+2Axc87/4CP/zMPEsviCiiDUJxHVwYY2ugcNeoKiFgMkIDaUSzwGgKR6+EdIWYBFQWwIpzBAoSBiygMlijMQCqUoIxvaBg8yVQSCDIA91aDQk6bApeWToidYWoMNeRQPW5NpDv5RUz3ICKgueOBMreODOInvhGfsQVStugaF9nEGr2pg+o6qg5rRNQ3t2ykMFFpWOmAVrTEAiif3AL2nmqAThbWDjL46A6C8NXSWBUK0KCoGS00VBVGNbBxC+wM4cjY7L5UrKBDbBkv9VQVYvSweasZVHBzmtWTAmlh5kJnF5kGDte0qKO76BtkVVAfXo+wbmvgfx6JAfWD77VZwe1VfsLYN/x+xWg+wmtW6VcW5KbDUdc+QNuqqoGbaNexWRGsD1hH3DTKCnQ+Y21042O20JxDdeHNrlvfiIFrpVdxWlJsDlQlWDVI6MF5D4d9hte1qZmGZHARglv0aNHBzEF2AoeUJBZshwUWImoXdE636HscsxoqDiOXlMiqaIW2yRdpW6wBiI0QtxW3AWYf3ZJaXMazEI66B6ALA3jBcrzKf1WLuwGuFt3n4BlGbFhusBYone8wvwrrMbYJsgwJQRlJ1/TKTg+qsNyTLx0qg8FKSfAnKyFcJQz4VbT4HryeUmMjV8ouEmXCr9c15GvgFKGyy/LM7b3gJd35SGagMC/NC2S8myv8ObIoshHklCg2E2uqYbZqaZWUKNZQmgsycxuYjiOpim66BjicUBhRVxdE52JiOyoCiS0dBAH36jbmGEwowq4lXvYI1EGjiHJRVgVjFsnISXD2qVGcOi6U2Qo+I7GwbINtpwmbfnTnU4CW8yxU0qrYNTCMhBoj7Brv6hq6bbBtgBHoHR3Lau1f302hvd9v/WTcU+vMLT2fBYKlRURTeM6N5/w1JK6vRoPAt524VUNlDIHiv7A2EacemAQYPSwP8UxSKV3pIAzLKuZ+bEmgYKkAIT7jHB5MA+oQI4nw+n8Cj4ACZrzwIY4IGRjRCBG0oRd0jD0ICwAM3a5x7Ov6ZOK3/gS0KgtxcBPzwRzSUpCuQS0vkS6CJy9ESdKGnHG4N4IxntHGOblzlMi7PjzAE0xpdDOUuVEIDAqx+l2o4gHSYeEDSpdUlNfCFZ0aP+HeqgvG6QoDowGhHKSTB+Eyc4+u9jgnD2KKOUQiDFoyXhCo08XbNFN4NcJLQN5iSCadk3hC6mMfeGzNzNwjHLgtYe5Il44xeEyDjTkAJ0y1ykas8XQrzWT3vvbGA29dBAFIf/vDx4uK6vuYVls8EXE5fGMNUpx0FwQNCOq98nVcj216QCHW67w3sd11Ngye/NGKPFT+Qnfs3aUc+kDqWqaifGiYpIkK4QX5wvAX3rQYBZUF+/7EQduC3BlGRCawgFEJxefkAgLQhAGNBFwwoFJkQGOd3GdW3gBUYDNJnCstQAoWQerzQgZtQDcPgCCG4gizYgi74gjAYgzI4gzRYgzZ4gziYgzq4gzzYg18AgUh1CD44hLAlhDo4dN5kRNQgeTVYDmU3eujBg4eQgYbVD/D3H+HQfI/AGyNQMyPQPlpoCSwCEEVxgHawfdXhGDNIeevwAGHoBwwCSMz1haBgEH0Xgjn3EmboUGk3DfQQCqPhgtcGEJFmCTWzJGwlApGjPPsSam8kenBTF9KwZ8bgag3xDicgGRt3KSH4bSYniWcBhEyzWiNwAOPRDPahWFQIBts2EP+PcQI+tyV7+Ge9ki4ksmS3IDvW4RDG4Rp9yCEwFwdmowDdBgDotYpewCtFkS5N4grBCAcI4BKNMgNCIi2i+AV3Fogu4ADb8YxpUAA9ARM08CUxdkWAWD2emFpb6AsG8FqL8maAoIv1MgPMZmJ5kBneCCnX+AXX045dFi3luA//cGgy8DV65X4PNo6N8XtcIEjBRQPzl0EVAY8zEC2OKAeUA15fc1x6ABQUKQM1Q2ByMD1M9i4iSQfXQ1GNJQgeJGw8NIteEFXeCAD1s1fQBG91GAgwVFQVMZNn4CknCQNnFQhxEpQtUELupwm+hQNA8YZxEFc8sDUPaQcg9QMItFv/e9CUPdBRPrhOf4A7WHkDgmSUceALKzdPfbBLOCktPqhMCOlMf4NMgICWPECXe6CW8rRQgIBfbbSXKbUDXKmTw+Q7dqkHORmXccQHtaE322VSgZBAPUBTPgU6PmA6S5lTG9QDM9QHRoVny+MSAuUHXoWY6ohNrOQDH3GRbhBWGtmTfnA+Y9YcXLYGUVWMV0UVYckHkLWVHIKMj0KKOqATB4kHq5SPSTQIWxGMouOTmLZjOvAxqglfwPmPoBCda2AhG2FPnjKbcEBf5lYD6ciRfFBjreELZCkH3NUzqlY1vlkFEHE4JzdYOsGcaxA1hegCFlcZ7akFUkJonEaQB9Rj//42GLr4kTJULF5jFvvoBVHzH58HWzjSa/u5BetibEH1DN9ZCWrWGA+qAjX3KQt6ItOpC4aADULCANQwApFjm9pXInaneU/oCpRoCd/GJc/CbxzilHyThi/aCG6XHww5BvHmCUvimACAO/nkP4q2DECjfGi2gqJSEtMnFrUnLQNaCdXopNZZB00CSFUlAsxFIUFaV/jWDQpwpctQc5DIHfQ5B+WxpjqHppUAEVFlEMNFgygBebDQejLYEZxngTw3gzSxe59ydn06DwYkDNmHgwjxeDlRDZhIhD1YGBX4f5J6qZiaqZq6qZzaqZ76qaAaqqI6qqRaqqZ6qqiaqqq6qv+s2qqu+qqwGquyOqu0Wqu2equ4mqu6uqu82qsmUA6loAVHMpVewA+ZsKhdsAlbwAifpayK0g4jEhc0MKxTQK1RAHCeKQXlBKbQuhehcZ5MUJhTMDFbCgDimmbBFAXUBEzg+gPbGgW+YAtzNyeFoAz1eqTXAAFUEgmJYAsSkQnwwKwIQSEHALBQhwhzhx0tNAn8CgACG4UAULAQmwWZMSeD6rDFwKwYywhR6AimCKy0wAyplwggiyUTmAj1igAIYKxvgQ3nGgXkek8ZWwz1qguUYLMicETDoAwNSxoSm52qIHn/anxQpwuS57EFULIi8K5SsK4joLEaW7O6hrPlhBD/2MGs4AhVwwAREqtwCLG1Igu2SKu0R5quTrBVyLqu6yotkgM4CtAJAMAJIzEnE+OY+9MJaQI4FTEn1bmtdQtNr7IAFbQFH+F7KopnMfu3R8UOw2QhnDBI5PO4NBkLnRA3ohO3SUJk5XQyyvCyUBCzh0u3eKY30gKancshbfsfcHu3oGM6sRALcQsOvkCvFRE3jIsQlDtITKuugxm6NDm6qMshpqu37TQxCwC7vWUA/sgm4IBnlaES/lq75pq5uPu4cbO7TvA5LKO2g3lEGsQI/+EIlDB3gzRSv2tuvalBkaCfQFm2veO3NwUAFWtE/EO/WxBVYJa4iBu/5kuk10AJ//zgRCOlDPIKAAG8UGyCMWuCuatRAATcCbbguU8Auoq4v3MCUpozGxA8vStrlm5boumLTh9BLQVMvnFDVg7Lt+7zvwYMR+5LBU5bwaJ7wVKTwQAAwZ20vvwzMQ+ACKZzvZUxvYmQtZRwABULACg8d9NbC0nbwk6EvU4AJ9KIubawtnpJTUxLLHETs1ULS1isu2D8vuVrwe0jwU9gGiqxwxb8u3OyraCUaZkElnMCx04Uw1TMrZBpxk1AwWzcx9xbxd17xcP0ru9KTZGzAEehxdNbAm8cGi88BXasvzQMyJT8rgLsmaBbxxdjiha5yCTQyIgExUywJD98x1YsArL0rv9XWQhjPCd2hEA39A+sDMS0vLStzMZX2Qj3ywyXPMN9bEeeXFHu48lzdyAfcxROhI8k4LTze8pawMeSbMqD6cyyrMpBjMSjc6QEMDT/McvCLBOgtEJPbLZPEMlr/MdUvK1GlEKg6ymkss4iYA6dkBErQ75zYpafrJfCjMwLJcpLUBmzoFPyC9DxOr2rwErWHChsssVJ8iWz8Q/6GsTbuq25bAi3HLNk5RqXCckNcdC+8jogJ7rh4AuzEc7usy802QCG0Ank4wAo7bqzwD/MTGSZFsH6jAXhIxISwSEhLc2UPL3agNDBBNEtJL/EMES5vNAAwLxkQTYm7dLj3K7S87z/ygrSu4nOX7wAcMK/ntk9LyMjpCIbCHFTntLDqbnU+dYATq3P+IPS/qwEm1gZ2NFnDMALiTANSYKy3YrWZwqt4aO8BJNu9Ryx0Gqt66IR0Noks6HYBmweGLEFSJhvPJs85zAbf90hIuCsxgjYyuoALoHIm90hzurZubPUS0rXdh23Uh1iQmGKlH0n55AIsW3aiSASeU3YCyPYs2Z1DyDb+datIIfZmq0qoh031ioFjqqsXpYklU3bzh3bR6J3N6UMjL20JyMsNpEgy90Od0KTnSDcjMjZxr3XX6DHvjuDfOyr6h0F5i3DNJje6x3f8j3f9F3f9n3fYjCwL4CzHKVv/y3A333l3wm73/4tBpnwAvr9ggPuAgDePyWKB/BdTL2LPBPeAnZsWxX+1iZw4WGgxxGOA2xSrlig4SXA4TfAQG2K09n64KUIgknk4swgrV+ADC/+IgfQE4awERxOGCSggigQCediJkxbCDJRCMbRsDWOBaDECD1B47AYK2zHArgj4lcw5FFu5PkF419oLwI41qEpBzHbNHvTZ6W9rjZECcbLjmOqA8vNlmnOIZRgxQqTs9YR5xWO1my5of7YSTICAKMm5IO0OLNB5itzx2f+u8cL51egSD3V5hzSx3puC277DFoYCTJC5VagzlQx6EBBNmZeLJQw6UQqA+3tYPd8N/+wPNCDnibUdJW1UegShGvZ2gXbmcK/WyaZQSpWnAAqE8/KcMR23EIO4NnCfOOPrrcHPruyDuhxkxnX0AnAsupU7Oplfeuyjul1uVCeMieZ4QC1rsQx6wvGnkJu+6ETpMsm8OFosK3OrjnRHrGsPkzUXujlPlm4cAjtAcx2QK56Sw8AICXtYOdjTTC93Mf3MQ2ByMWD5MyK1CTpMMnLPMy23DtfLMY3ZMdunCQjsdXMLfCZvFDRbAWaPAqQtS+xZwv87sWDHMaM7E0koO5nkPG9MEwA3yWG7JlR/ci2DJckIDAGsOafq7n5doEGnBCsdPMED/JrHCpDYc9+vvCBTOf/xijXl37HI/ARS1LIKy/GFJ/hg6QsF7iyRi/TjYvzSu/LIr9QH3F56OHwOiv0XW/RtdzjRlgCMG8GGX+BvyEkaUzFH//Cu0sYWu7nyhuiTBDug2kaNEmyj97qzVXtIc+giiFLIyXr8W7TUj8xpFL1wV4ZteAr4s5Ij6xECVDTPT5IR1wbBcv4KeT41AP5S18FTlTWyuDSpY/Ko4P44w745PxcCREOQG8E7I5nqm98+DTtj0/vLN8CKjMLBS6MeEboKQQ9s/Hp04DmsU/ro/K7cKMMDL9Q5GMAKHzhW0PuFyLpwbQvb+v1lnsYRnwwhg7qfXz34aqXnxPRn0AqXHz+/7wPAgMwkmUpBGkqmK37wrE8x6hYDGpwPKqRAHIsiGqBANiQAREtp2PRotIpdXoQHEgIAbRVwFbD4upXUBgRAoRDNvo9z8qnrmsb3Xbxr2977P+PlMEJvnABHiIm0uiNMHqBKUZKTlJWWrakEVxucnZ6foKGio6SlpqWbB2drrK2ur7CxsrO0tba3uLm6u7y9vr+AgcLDxMXGx8jJysvMzc7P0NHS09TV1tfY2drb3N3e3+Dh4uPk5ebn6Onq6+zt7u/w8fLz9PX29/j5+vv8/f7/wMMKHAgwYIGDyJMqHAhw4YOH0KMSK2MAFX68FTEx2UjHXxXOMJxV6BPAicKSP+gUEHiwIABDwhYHIfAYskUTACkSbFgZUsGmshdIUCgpQIdRo0qaCkUErktEAg8aHl0agADLRsQcNDRm4MBBgLsHJFAB0qyI1Km0DKgQYI+2SA4uZlzCYm5N4moHMGSrVtqAqAuoKpjQcuWgQXrfLnV2gEIDJwgTloYsuCkWUNSa/wTAN60Z80qyQvAAWi0AWJG01y3yGqbremiUXEXdDQHDQ7rSIpVa18YVxwQaDCgqNEFDRxkHnrUqs8EhhZxEToAtwoFDBJgbuaAeICyKlSZ5tnSwGu5PlYaYICcGYSvAU6OIC06vNjCD8qTaCCbRAIFx5MVkEAPgzEAwWJ/COD/GHUBPICddgy4l4ICimUHyAEJCFccBKgV04d8K5BQRB8ZxcEFBECMwIAK98WWAnnHkKQDHAfsF4gZ0P3VBWQNkKCihMUEOKCEx1VISQG2ccegg8Y4AKEP13FYyV/ULbAhMQVAUJRFEW7GFCIIADfAZrjdNBMwCBCggAFwIKDDekhE6ceFwr0ZIQNaFHnLAU7qZCUpCECAW3px6lJAmtU10NsnQerwwJu+IMBlj2DBFIoOKAKgIgOE0kKjCpgGNoCfnniawptebaqLAJApMOoqgHI3wIG2IOBjVYm6EiCrmPaCG3wAIJAnJ0dCOIgOm+kSIYvACrtJkL+WGgCvs6yq/wIDs64igK2y6lKrbNO+gkAD7ikAriwFYMWfbM2WMlcA2LZSK6ZzLQuLrafVUm1Vld5Sq3sDKPpKAbY+AG8rARJXbi3tVRWScZyewjBsAGApCwFf/VqAAvxa7N6djZhbysAuEsBuLOiq0IDJpEg8AMSy9GdTwKeMZS0v/XWhnwIGg6KfCsjeYqgBFuUAMCsOePwyLQgMaMCjrBxw2AI8zyJ0CkC3Imgw0UKQa4Rh/fLhD6aM/B7VtghAnMqtMGxA18Mg4IQRqxRgkadrAyNkAG+LbBFpBpQcTJJnTxL11cegDJbSl5Tt8jFIV/V0KFGvyd/M3Q5Y7ygHGLBASK7+wv9SCjySIsBXBhCu6umXO3sY38cg4DopnOukTAKe8xeyJQl4rAwBYAPQ1ic1475M7CnofgntqDfj48ehJIk1Mp4mL0mblzozlgGsJ1Lz88wUMGD1hX81d/YpfE/qus3Qjvzw1q4MjNjcA+K9ND5KbkmkYMU/jP2hjCV9vtPBizwxFtI1w2eusYSnBOgMFW2vEwUITPGiUbPXVeJIJaAfMYi3OD8gwC0fFIaPKjiJAnxFc9HIgQL654ceVI4aeEldGHqAwGn8zoVjCAwGo8EABuiwCjkwoTQ0xqBN4IWDyYBgEKfwoQE0EXaUmAsQtTHCKGhPicnwVP4Ssb8eFjEwDkT/BAqrE0VixA1fkbhe7bBBuTO6oIzSw+F74CiDHtzkGimh4R0gw8di8A59kkibi654jLnMUQxp+FU2ipJIBKXAkEuc2CT6M8ZouEuSM2jPI59hqxgCoozjg8ZYGKkITXHjen90gx2HwZ0bKqKVwiij+w5RSm8UZZRUuJ4mJ3nJeoylYP1IAwO0eMe9eYMIKgSEMr1BowIiImqgy0YvYXC7aV6jALIkQQFSsE00ekYROdBlNALTRUWmjB+2AuM8UAA8bgRmlS/w5jf000kqQIad2PgCIrhzzmwa0wVpgOU2VHTPKaDAlNsgTR4BEaGAMuMBxEGEjLoRvqJAUwwq0uc1/waqCIaCg0YK9cNjivIN7sizEVFRwEixQRsxCAEcSUhEJsIRTn74kR/cgWgJYvqNmSKipuC46T5yWlQVpNSn3gDqIYT6DaLqw6hRReoflNqNYCqCCL+8BlT9AByofEOqYziSUA4qDR1UEwD2BIdTD8FUbrhTES/VxkMtdB5vzLUKWgVHD8i5iKqAA6uJQKk3GDDRQ6C1G0wrSkut8B5wfIWnMIjsNzaqCCERVBv8PARu/AqNEB6Cst0QqSQs6w3RIoIIVUprOfQjKtaOQ0WZvYZsJUGaxlbjtpGo2zd4u9tvohG4SgBlNsoo2Rh8JaXGyIFZ4aGfa/UjB6lKRGCa2/+MNDSUppTERkqEiwroYoON0poE02ALDNMolwR/M++ZQHTCr3hWGYGZbShz8k5qCIm4h/DWEbHhq0jkYJnTKJol0qBfGTaMEjU7XEd/JonOBOCfzlBgfGVAPWwQYWiXCIyAoUE7jgICMhnNzAJaOIlYZSNt2W1qVY4LDE+B+BAwtsYEt2u9r0CxGtlhrwlSUkVqxESblMjBgZ1Buw5HAi8VFgaRvdsCDNF4AT++BAFirIwJbpWMFHRy1YpCREv4yMW8gKCYq8ASLgtMamh+wZmfUeMATLkS+/uyMg7g5TW7AIJL7gX+JoexMteCMllWBO3ofIwkDdpCqzNy+fD8Ah//7TkXb460GPbnovTS4kOGJp8PeByLBW96jYEZ2zICGepL+Ii+w7BzVTBNhTfz78rqOvVuybSMkOiH1rF0At6M0ThHy8Bn5jsGwxQA6DCEr8XcLEbcgOcAYJugxiZuRIcWUC8IQNsEwnZ1tohjXUtAzm3GYJpNsg2D/+hFDcOQ2LdPiKv4iFsYc6E0IiAXgF7/omzMi9dhjCYMdsfiMAqQcC1o6V5W0HJqZ4qQhk+R7KpYeRYSi3MrLjY6c0dCAFI7tiLcpepZ0KQ6HAeEApHJC4vMZdinIOR76A1A4igc5E0LnKqcEO9PuyeGAbpFtYimBozPYC6/soMtbqdzNUUc/xQSKxfQyZAlCbmcE/oyQAM8TYmupKzpUyD3ZkrJMVhw53lskIXoMKUzbMsCAdzBFIlOZvGqFJPsfNqY1sdwuxURfBRoCrvVpRQS7iBZFBbRW92p0AWDJ1qCFuEObj/NndWyAlC+ivoo9PWedztcQD74+i4WPN4RsKXvcUgAhMD2IWPzwl1duE7TEaD5ZS3YcbvQ1mAgMHIpHOB3OgCvMMQVIf/knbya/5Yw9uQiNoloWOpN7AiSwu1P6AtaRRC9CSwC4UGk5/mgYNSTbL+JxjwgQkoqfCWaJH4xab8Frm9AkiDPbKGQ4Pp6eYkDjg2VorShmw5mdgP4psACOoBiAP8amkhUAMwI9iBDkIjfErDFjfzBF2AIZcDdkmgH+xVHgbSdnITJAr7WMwgJ2HTGr/xFlfUBRtAEATwGpkQI39hcu+kC4OVHjSCBUCSA3WwEykGFvwHAE5AAcdxcnUFA+E2FUiwFRxhhdASHVCzHA3hfNbieYU0FYfhEVhyhET5FDi6gTRBA+nXKbdzbpCwQTsigkGwGZJShzYgFujEDknxeEKTTCJghCcRh831KD+4fTmDeZwHHAywIYvihtWUF9fXCF6CgBPphZIiJ8FCTReAGAgnJ88yhGwoS6K3INQRLiNxhJGpiJqKhYgnAVwnHZIjiVQiFVpAfLyBhDo7iZEz/oXPc3jEkiHBgyiamwLLYBUps4Sm2wl88Rh9IChxy4iQigYFIRDH6j1A0SH4UBgL9hYG8YjNcoaMoY0tgSgJUmZcYYzZq4zZyYzd64zeCYziK4ziSYzmK4yWaozdQxD58xDNqg+gc3HCIiTtyFxfoIpDYhldMhWUEXzgACgP0oU1AyTtoUCDw4AjYSTsNRZL4gJj0Y2DpzSEyyEMWV6AchWQwJFigXTpYTR8Q1gi4CX9w4TJoSxYShiHC2Ugmw9tJ5EVS3pWxJBM6YAkQYn7RXDlYGpzJoYush3hhH4PcY76wynUoygGwoYSoJDGwnGAYxh/So/y4xwJQoAwgDE+a/4MRuYgWREksvkYEjUPiwJkSHcC41GJQwoK7VAdRuoAAkF4Wkpo3+MzOiMF2MBg5pER66BDDPeWZHMZ0vVpOeGVlHQXvzQDWGcVLktDoPKDzhMOjNADFRQHLUaQ07M++jYHhBCY3oKXsGZ4EIuYv5ETUXdA37NUhDMxnAsmWmeaomaUpmEYbolOnWVEtpVZVCOIuJJx3JQhcJpiW9dc2cEdm2p0OrNg0qEjghYF0dYO7cBy5FZkTHlw0Rec1fAhs/kEm7VMkSYKntCYp4IYLIlcdbgMRFOcfoJI2bEskcAd4EgNp3BcixBM3gF/DJYICJV4zjFPhPJY2+FMkxB42tP+VIqxVPzwRN3yF6HUVNeTVH5TKiElDgGoXe6YDWpTnNCQoYnWHNizoH2zoMxATJZjWaEnCf25DfEqC/m1DRSkCWrxnNCQUJeAfN7Tlu0QCZnFDDySdE4FFiYpnfVYiNiTXiO7nNghJhYaBrUym7QypOKmbNijQtJlmhKCmLiwScBmRhB6D5yVpDQwHLjVp9/QmNe1eIohYd25fUSDnFLCQmXqnMD4gZrDpKMgH5dEOlhrDvdznHtyLna5aWYYSke3lLtAI3wiZGKSNrlkDpLkVjqnj+Z2R4RRBnIIC8cgTIQlnKpVA+FUYwZBDqsGRfUmqKLQPyeiQoRjFpbpR0lT/AX+hXjmcnjFRBp8ug8+85RTEDJyFauUtINXRT5MsR6DiJsFM5R7UBPrkqsMFJy5qhfVliHcAZTmwHK/SwFj64JZ6WEZWBf0ZoTWipOKMgwDojXEYiBEGB3XE3TmUzRemyB2GJBwOXDrcalUkohHuYXDe5FeiZUueqqw2g+S1pPupg7f0wXeSQCPiCTuYn0QaQDIGLJ/oK6muAyE+hij6xEy6Q0wcy06GYTxcyFCMIgnCA/cd4sJOaTrmShIOwJs8hSKaLDQkiMeKIgGwbMvSbM3a7M3ibM7q7M7ybM/67M8CbdAK7dASbdEa7dEibdIq7dIybdM67dNCbdRK7blY/+MWXoJwKFFLzB4NEkpJlKwJeK0JaC0WDcDXhoFmNKEL7EUnrG0JYG0UtC0q3mAovK0xjOqXToJVycDYBo0EwgCEThHe7mCG0kDYtkLJ0eha2hglvJXe+sZa+ELGgoLjxga/StBXdI2haEKAyCybVESO6MWNXMEZcO4aiG3ifpXd0OAZPAfnLsnoWuNt0oAynYED7AQfUAwYZII1dsFXIQdZde5KlCKwVMRIzGCVqUKAegbnbmTpZkEq6IVQ5B8WoInZppsCHAEPsMBzGIIN/AWm5F7wjuCoMO8RGMIBjMQVtkHjoq5Q+M3w4i6wPMWbwC7nrRwPZa8ZxK7wZkUjzP8vSpgBBGAblqAdH1QvMEJB6lKMptwIoMgsLQgWNxXFmophhLBATAnB/gwH4SJwpiyBAUSQzjDX4FLMBNeRG+Yc+aVBlYwIXSSBgVEVBcWTDbCmByPVClvFDhIGiChvd0yQVfCPBptUTREBSyETCvyiJSCx1WIiSHYHEjuYCKsbWDgBC4yqCNjEu8jjV2gC+7KAinhFBMnwuySB6XROfxHZ8b2CT6Vxgt0LF4AwhzlxVP7LcDlYTIExCF/BE3COAojRLAToWnnUh/aAJmDwuxAT657uJ+okadxJCmSB8aaFIH/hOBlRUs5ATipMGdPFhxKTOx3BTAgZITEy9nJG7jH/CBhkbyGLIdBM8njphzXiKhK0cjetSRl9Af+QJycICul4Rlq4Uy6fBCRTzPMCAA+oW3UBiyaYihmEMnYpQUMJgSOPRkp660wkQXzmAHJYclFgMj4lbje/y20dge1pc4QNbghF0vUogee86DQ3sk4KVWAcAT1bjLru5PZ2srrV1CFzQXUAjRBspiQySBakRUwlgT87HFy4xxa48D538RLQEl7C4wq0lVClKz8L7kEbxRYCdCvPlBBwspF2TwGO1y8/MWxwdC2i756ScAmEE0uKgBdv5kQDURJ4Rj/TKOWWAhvvNCLjbU5PcYaidDQ7sRv+hVGIgFAdxTef7Qnnbg8g/wdp3EdN6fQF0ygBEnM+K9NGtAGGoCkJS3U134dCX4HsrqXDkPFDL7W6UTXFOAbmFjIOvEtpVu4IKBOaaLQrd0chz61W70Am0EhYBMYezzRs2CN59cFaFXUS2HIaomle19SBwnSGipRhG3VP1XUqc0Ekx/XeJMFXnIF+dI1ZZyAp+DRWJ4hOkoBoqxUyFTUJJ0GbkIcQdHVntzJCRthGxGkPbMy4ZAVYaBw6W7W69YBxJFdwcIGWaHZFgLBzBCEASGVSP3J3uOdwc/NPswBzh8LFvITOHPPoENgnB4ZzOAq4Sksh06Vzw9lQJPVPdPUI93A1L4BWYIVyE5JeawIPqf+WUc/2kq7oEggFZaeQj7Qz7d3JdBNTfKubzgTHfXiGSAmAa2V2PkfKDyRIwZx3XyXBcyGNhik0d/d0+QCBP++PT8iKh4PwEcQ2ML+H7t1JBj93hnPGRIpLKgegUysScQjT07VKfQBB2LLaDwGM7erE07wtMr84AAghXgYBE/j427wt1rZJniYCesOdKjg45JZE+AEOsJiEJgx5Lx7zgBiB4dL1WpRt8Kx5TzGBkYOFA8B5fbM5EJAbg2Qv5K7tWEypv9QiFPAO4GgtSxRgFTU5EKW5LKIBRhnyTWw5j8Qt6BmNkm9MGi352qJL+UDBlANMla/CZAABp2eBkhtBpgv/NxwywdhqLRIXRRUl+YBsDMU4QRYcyhKg9TaMxa2Xg2EBRK5Lw1ttI/wthDT+g7C76OJObbIr+7Iz+84aOzI8uysccBhMu/o9cMVZLiBEewlsuy/sr39+XbXPAOiWw4XybS9caKTPgOFCEkkXArIDeylcKLvTQN2GwYVe6C7wtB9YVby/AOD+whb0Qfz2GHigBtG9NPH2wU3JwS+QCFCVAWokNsAT7wx8xMScdQtk4MUzwUeUhbuXAok4FR7A6XPs+9hpAVPkO00+xyskdsEXwkyObgug/FkwRb9j/MZjIwCvpa6PFWTcR2fMTUJ5G3Fkt9wctQ3rJGSIAKgdq4sb/zE6H4tpMEEgpQCE0UHRtFFsU8YNdJYSRP16dD1BO02FrwLUGz16uctP/J+7mEAWq6utfExamFM184hn/J8rtE8EEb2pIHXwPNTxXL0T85oTS8gR4LzX1yGr1WJum86lgb3R10IPFIyAiBSWHFFC+erAUXgONAAhIUdaEIEmSLWnYAGNiAARfBwrQL2vpr5wz8TvevMzmbevXgtmeD7ov7Tox/ku94AZFIUwu36N1/cuO0A5s7UrtD4Yj8ztg4GnEL+cGwEPdQTyyAfmk77Ud8deqYhBb3+c264rgPBI7KjmrzBS0z64oje2xSjy4IVYnAErJz6Tv4sRJRsQNEZuR//WM4E9CDhMMADmiabqyrYuGgTFSQSEGQMCqfN7OQgIALVbLrgYKGyAHDGgGCx4r6r16sr9eqUtoEAIxgS1BqqoCg7RzmPAwW2SBgbhdhuE3x9LHxULGIgTELeFBoDAMOUGd6Km4qSGpMSUUxBgAGCwMAiQJwgauGMwIBYn5ylUBkP4ZNTqlEAXc/N4shVTWicwQtKA4OqldvcXaowVM2NyqOXXxfPYUEkYxEBwPeRUM3BNkHAMDtj8TG4y8uAwRRZgRsOUEj3d+Yhr041ADCTEhYAJAeEsnMAT4+IcWtJgB7U3KGyxMqGuWrdsrUaM+Ibq08CNOxR0u7Hl0sJ17Tr/uUKFKkGABQlG1Np3iwete2DEKAhGZVjAjTxPPAjwQIADAgegFAD4oFDAIBAc1DmACukMB9+SISiqANiBGz27osrXgxOCPAXUFTWQgMxWdgWUmWDqNADUGBBUEpI2QABeAD9vHD0AFq9eEjs4qSznNVRBQ2xFFuhHCOACB7xSOQDGSgDATFIBUEXpIIaMTpIpM0gcahciM4V5AU0l4Gxaoj8hFFgyFxahVS5ho9jS9wuErVD7ZULz9KzSEqgFFhDzGmCMBcDA4hHNzqQ00RAAbC+RoE6MpM0HLqayiEBoKEuGhBd9AIH4IY6wt/tuaVGQEs+xAw5YVi486LdTecgQ/wKWfGPg18p2mHgmWgrYoWWCgwF05wQAS5ymnWiZGIjFAX08qFAMCkD1yHsxxLfIhSbloOAmTDgUR3/w/RQDhWgIIJ4BQ4AFIjj4QGVCAbFhMQxmKhgpgFuAKSmAAEoG2VyUM+CzgpVFRgmPHVMeQORvU5qAD30uSJkCmlR6xaQJYC7JJZlHsmKkW19oGUiba14BGJE/YMkCngAAZucKdQZS5gmJBmrmno62QOOjkhoY6aSWXooSpo56oWmnnvLZ5KeiHkPoqKaWF+epzRkZpqquvgprrLLOSmuttt6Ka6667sprr77+Cmywwg5LbLHGHotsssouy2yz5R0wAAMjnP9YYR3UepLXAxAMcN8AMzRgbavOQsqNARQCkMAS5zYwgAgtDQAVtN2liwlG496L772jNDBFUtKoZ+4gSSjU1kre2eDUh/muEAMDP2USWlBToAjFAAlIY4Y0DkQswMQLfwxysWDVcU17mV6k0jckE2ByyATpxlcA1gTxEn393KTATT/N/I7LPv98K1i5lAJvpjs88IABMwxdirggt7FQEqV841AQKr0ktcVAb801rGCp4yYwGWrYMEQwxQc01AdzZaRvJtgVADD/btl13XZ7CtYBdUixz9g1nL032D+rHWASM8L0xd5FTmE4V3c/DvmarN5JZAEJYGNCqnc2ajnmQMdWmepQ6s1Q6glPoiC6A4VGznrrrr8Oe+yyz0577bbfjnvuuu/Oe+++/w588MIPT3zxxh+PfPLKL898884/D3300k9PffXWX4999tpvz3333n8PfvjRhwAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The large circles represent the detrusor and the small circles the urinary sphincter. Dotted lines represent normal function, thin lines decreased function (hypo- or areflexia), and thick lines increased function (hyperreflexia).",
"    <strong>",
"     Suprapontine lesions",
"    </strong>",
"    typically result in detrusor hyper-reflexia (uninhibited contractions) with normal sphincter function.",
"    <strong>",
"     Suprasacral lesions",
"    </strong>",
"    typically result in both detrusor and sphincter hyperreflexia, with detrusor-sphincter dyssynergia.",
"    <strong>",
"     Lumbosacral lesions",
"    </strong>",
"    may result in several patterns, including (1) detrusor hyperreflexia with sphincter hyporeflexia/areflexia, or (2) impaired detrusor contractility with sphincter hyperreflexia.",
"    <strong>",
"     Complete subsacral conus lesions",
"    </strong>",
"    typically result in both detrusor and sphincter hyporeflexia.",
"    <strong>",
"     Subsacral cauda equina",
"    </strong>",
"    and",
"    <strong>",
"     peripheral nerves lesions",
"    </strong>",
"    result in detrusor hyporeflexia with intact sphincter function if the pelvic nerve plexus is damaged but the pudendal nerve is intact, and in normal detrusor function with sphincter hyporeflexia if the pudendal nerve is damaged but the pelvic nerve is intact. In rare instances,",
"    <strong>",
"     epiconal lesions",
"    </strong>",
"    may result in normal detrusor function with sphincter hyperreflexia, but impaired detrusor function with sphincter hyperreflexia is most common.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wyndaele, JJ, Castro, D, Madersbacher, H, et al. Neurologic Urinary and Fecal Incontinence, In: Incontinence, 2nd ed, Abrams, P, Cardozo, L, Khoury, S, Wien, A, (Eds), Health Publications Ltd, Plymouth, UK 2002. p.697-753. Copyright &copy;2002 International Consultation on Incontinence.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_36_22095=[""].join("\n");
var outline_f21_36_22095=null;
